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Abstract 
Nanomaterials with different surface designs and biophysical properties are being developed to 
improve the efficacy of hydrophobic drugs. To date, these improvements have not overcome the 
complexity of biological and physical barriers via different delivery routes, however, nanoemulsions 
(NEs), in particular tailorable nanocarrier emulsions (TNEs), are emerging as promising drug carriers. 
The novel oil-in-water NEs are stabilised with chemically-engineered biosurfactants (AM1) that 
allow top-down sequential addition and modification with a chemically-related 4-helix bundle 
protein, DAMP4, which can be fused to various biomolecules. In this project, the feasibility of using 
TNEs for diagnostic/therapeutic applications via different delivery routes was investigated. The 
initially stages of the work were to evaluate the encapsulation and retention capacity of hydrophobic 
compounds within the oil core of TNEs with varying surface properties. Polyethylene glycol (PEG), 
an important pharmaceutical tool, was chemically conjugated to DAMP4 and influenced cargo 
retention within the oil core. In collaboration with Professor Tarl Prow, tuning the TNE surface 
charge, which was found to be indirectly related to PEG density, allowed TNEs to coat elongated 
microparticles via electrostatic interactions, creating a promising tool for topical drug delivery. Co-
functionalising TNEs with antibody fragments showed receptor-specific targeting in vitro, however, 
in vivo active targeting was not achieved following intravenous administration. Biodistribution 
studies suggested rapid clearance via the renal route with some liver involvement, however ex vivo 
studies involving cytokines, serum and urine analyses demonstrated TNE safety for drug delivery 
applications. This work suggests that the structure-function relationship of the TNEs interface has a 
strong influence on their interactions with the surrounding environment, therefore deeper 
understanding of the structure of TNE interface and how it relates to functional performance was 
needed. Tuning the amount and type of PEG displayed on TNEs showed that the molecular weight 
of PEG has considerable impact on the surface charge of the emulsion. Also, targeting moieties 
presented on TNE surfaces were equally accessible to their receptors even when the PEG layer created 
differences in interfacial thicknesses determined by X-ray reflectometry that showed a role in 
reducing non-specific targeting. These findings suggest that precise and controlled bioconjugation of 
functional moieties to DAMP4 is needed in the design and characterisation of sophisticated interfaces. 
Genetic engineering of DAMP4 with cysteine residues produced variants with conserved structure, 
stability, and surface activity that can be specifically conjugated to PEG via maleimide-thiol reaction 
with nearly 100% yield and showed with molecular precision how interfacial activities of 
biosurfactants can be affected by the number and mass of their conjugates. Consequently, the ability 
of DAMP4 variants with multiple PEG conjugates to impart colloidal stability on peptide-stabilised 
emulsions was reduced. These findings contribute to the design and modification of biosurfactants 
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increasingly used in industrial processes, nutritional and pharmaceutical formulations. This research 
investigated the challenges facing the surface design of TNEs and their interactions, helped to better 
understand the physicochemical properties regarding ligand accessibility and receptor-binding 
performance; and provided tools to further explore functional interface design and better understand 
the relationship between genetic and chemical modifications of polypeptides and their function.	
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1 Chapter 1: Project Overview 
1.1 Background 
Advances in biotechnology have led to the development of various promising diagnostic and 
therapeutic small molecules. However, a large number of these molecules are not being exploited 
successfully due to several disadvantages including toxicity, hydrophobicity and, therefore, 
insufficient bioavailability levels (De Jong and Borm, 2008). It has been estimated that approximately 
40% of newly discovered therapeutic agents are eliminated from the drug development pipeline 
because of poor aqueous solubility. Also, 90% of the active pharmaceutical ingredients (APIs) in the 
discovery and development stages feature poor solubility (Loftsson and Brewster, 2010). Various 
strategies have been developed to overcome the drawbacks of these lipophilic drugs for the treatment 
of diseases such as cancer. These include the synthesis of different isoforms of APIs to enhance 
solubility and the development of drug delivery nanocarriers (Devalapally et al., 2007). 
Nanotechnology is a rapidly growing multidisciplinary field that has been applied to the formulation 
of nanoscale pharmaceutical carriers to improve therapeutic outcomes. It is defined by The Royal 
Society and Royal Academy of Engineering  as ‘the study of phenomena and manipulation of 
materials at atomic, molecular, and macromolecular scales, where the properties differ significantly 
from those at a larger scale; and “nanotechnologies” are the design, characterisation, production, and 
application of structures, devices, and systems by controlling shape and size at the nanometer scale’ 
(Dowling, 2006). It involves the application, characterisation and engineering of synthetic particles 
and structures ranging from 1 to 500 nanometres in one or more dimensions (Devalapally et al., 2007). 
The application of nanotechnology to the medical or pharmaceutical field is known as nanomedicine. 
The motivating concepts of nanomedicine are to enhance drug safety, solubility, bioavailability and 
specificity (Jeevanandam et al., 2016); to have a positive impact on clinical diagnosis and treatment 
of disease (Evers, 2017). 
Various nanotechnologies are considered very promising in diagnosis and treatment, particularly for 
cancer, and some are currently undergoing clinical development. These include nanoparticle (NP) 
platforms such as polymer-based NPs including dendrimers; inorganic materials-based platforms 
such as carbon nanotubes and quantum dots; and lipid-based NPs such as liposomes and 
nanoemulsions (NEs) (Shi et al., 2016) (Table 1.1). Nanotechnology-based drug delivery has the 
potential to overcome the limitations of traditional chemotherapeutic drugs (Cho et al., 2008). Even 
though chemotherapy can kill cancer cells, it has several serious disadvantages. These include poor 
selectivity, the emergence of multi-drug resistance (MDR), limited bioavailability, and the 
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consequent administration of high drug doses that can lead to cytotoxicity in normal body tissues 
(Szakacs et al., 2006, Cho et al., 2008). MDR can be developed through different mechanisms 
including the increase in drug efflux and drug evasion via apoptosis (Gillet and Gottesman, 2010). 
Because of these disadvantages the development of various NPs for cancer nanomedicine is urgently 
needed in order to deliver anticancer drugs efficiently, selectively and safely to the diseased tissues. 
Achieving this goal has become increasingly realistic with the rapidly growing number of 
nanodiagnostics and nanotherapeutics, both in clinical studies and the pharmaceutical market. Key 
benefits of such platforms include biocompatibility, prolonging circulation time and improving drug 
localisation via targeting. 
It is believed that the market for nanomedicines will have a growing share in cancer therapeutics over 
the next few decades (Scheinberg et al., 2010, Peer et al., 2007, Kim et al., 2010). However, the 
development of nanomedicines is showing slow progress, which is attributed to the complexity of the 
nanomaterials’ structures and, therefore, their specific analytical requirements. Also, it is difficult to 
control batch-to-batch variability in manufacturing, which is problematic in meeting regulatory 
requirements (Ragelle et al., 2017). The difficulty of obtaining superior therapeutic benefits over 
existing approved nanomedicines or API is another major challenge. Recently, it has been estimated 
that only 0.7% of injected NPs can reach their target site. This almost results in 99% off-target drug 
delivery, which increases cytotoxicity risks (Wilhelm et al., 2016). The development cost is also high 
and considered a burden for clinical translation of NPs due to the need for high number of NPs per 
an injected dose, therefore, cost management of NPs synthesis is also required (Min et al., 2015). In 
addition, high injected volumes of NPs may cause technical difficulties for patient use (Wilhelm et 
al., 2016). These issues indicate that patients are not benefiting from the ‘magic bullet’ idea to date, 
but this does not mean that these issues cannot be overcome. Therefore, our thinking should be 
deviated from just targeting, and be focused on exploring new means to accelerate clinical translation 
of NPs efficiently (Lammers et al., 2016). Also, more fundamental understanding is required into the 
assembly of NPs and their interactions with biological environments. This includes understanding the 
target disease, choosing safe and effective materials, exploring methods of surface modifications and 
routes of administration.  
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Table 1.1. Nanomaterials classes, subclasses, properties, products and their applications. 
  
Nanomaterial 
classes and 
subclasses 
Size Shape Toxicity 
Examples of 
approved 
nanomedicines 
Product 
Application 
Approval 
year 
Inorganic NPs  
Carbon 
nanotubes 
1-100 (Kaushik 
et al., 2017) 
Cylindrical 
with open or 
close ends 
(Kaushik et 
al., 2017) 
Variable based 
on geometry and 
surface 
chemistry (De 
Volder et al., 
2013)  
No approved 
products 
- - 
Silica NPs 
<500 (Argyo et 
al., 2014) 
Amorphous 
(Murugadoss 
et al., 2017) 
Variable based 
on size and 
dosage(Kim et 
al., 2015, 
Murugadoss et 
al., 2017) 
No approved 
products 
- - 
Gold NPs 
10-100 (Yeh et 
al., 2012) 
Spheres, 
cages and 
rods (Kaushik 
et al., 2017) 
Low or no 
toxicity (Connor 
et al., 2005) 
No approved 
products 
- - 
Quantum dots 
2-20 (Kaushik 
et al., 2017) 
Spherical or 
ellipsoid 
(Kaushik et 
al., 2017) 
Toxicity is a 
main challenge 
in drug delivery 
(Volkov, 2015) 
No approved 
products 
- - 
Polymeric NPs  
Dendrimers 
1-13 (Cheng et 
al., 2008b, 
Müller et al., 
2007, 
Dobrovolskaia 
et al., 2012) 
Highly-
branched tree-
like structures 
(Sikwal et al., 
2017) 
Variable toxicity 
based on 
structure (Cheng 
et al., 2008a) 
No approved 
products 
- - 
Micelles  
10-100 (Ahmad 
et al., 2014b, 
Yokoyama, 
2014) 
block 
(Spherical) or 
random 
copolymers 
(Jones and 
Leroux, 1999) 
Low toxicity 
(Movassaghian 
et al., 2015)  
 EstrasorbTM 
(Novavax) 
(Simon, 2006) 
Menopausal 
therapy 
(Simon, 2006) 
2003 
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Magnetic NPs  
Sliver NPs 
10-100 (Marin 
et al., 2015) 
spheres, 
cubes, rods 
(Helmlinger et 
al., 2016) 
Variable 
toxicities based 
on size and 
synthesis 
method (Wei et 
al., 2015) 
No approved 
products 
- - 
Iron oxide NPs 
1-100 (Laurent 
et al., 2008) 
Spheres 
(Mahmoudi et 
al., 2011) 
Variable toxicity 
based on coating 
Nanotherm® 
(MagForce) 
(Magforce, 2018) 
Solid tumours 
(Bobo et al., 
2016, 
Magforce, 
2018) 
2010 
(Bobo et 
al., 2016) 
Lipid-based NPs  
Liposomes 
Nanosize range 
(Malam et al., 
2009) 
Sphere 
(Malam et al., 
2009) 
Low or no 
significant 
toxicity 
(Bozzuto and 
Molinari, 2015) 
Doxil® (Janssen) 
(Barenholz, 
2012b) 
Kaposi’s 
Sarcoma  
1995  
 
DaunoXome® 
(Galen) (Forssen, 
1997) 
Kaposi’s 
Sarcoma 
1996 
 
AmBisome® 
(Gilead Sciences) 
(Stone et al., 
2016) 
Fungal or 
protozoal 
infections  
1997 
 
Marqibo® 
(Spectrum 
pharmaceuticals) 
(Silverman and 
Deitcher, 2013) 
Acute 
lymphoblastic 
leukaemia   
2012 
Nanoemulsions 
20-500 (Gupta 
et al., 2016) 
Sphere (Ganta 
et al., 2014b) 
Low or no 
toxicity 
(Borthakur et 
al., 2016) 
Intralipid® (Baxter 
healthcare) 
(Hippalgaonkar et 
al., 2010) 
Nutritional 
therapy 
1962 
Diprivan® 
(AstraZeneca) 
(Chidambaran et 
al., 2015) 
Anaesthesia  1989 
Restasis® 
(Allergan) (Ames 
and Galor, 2015) 
Dry eye 
syndrome 
2003 
Durezol® (Alcon 
pharmaceuticals) 
(Smith et al., 
2010) 
Eye 
inflammation 
and uveitis 
2008 
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1.2 Lipid-based drug nanocarriers 
Lipid-based nanocarriers include liposomes, emulsions and solid lipid NPs, and they have a promising 
future in meeting the ideal requirements (Lederer and Parascandola, 1998) for a drug delivery system. 
These requirements include primarily protection of the drug from harsh environments, such as pH 
(Chanana et al., 2013) and enzymatic degradation (Soenen et al., 2015); increasing the safety profile 
of these lipophilic drugs in order to reduce their undesirable side effects; and the potential to introduce 
tissue specificity by cell receptor targeting. In this section, I will discuss only soft lipid carriers, 
including liposomes and emulsions.    
1.2.1 Liposomes 
Liposomes are spherical NPs that comprise a lipid bilayer enclosing a central aqueous phase. They 
have been extensively studied in vivo and show remarkable biocompatibility and biodegradability, as 
well as low immunogenicity (Torchilin, 2005). However, liposomes can be easily removed from the 
blood circulation by opsonisation. Thus, additional surface coating molecules, such as polyethylene 
glycol (PEG), are required for the liposomal carriers to extend their serum half-life and enable them 
to evade the immune system (Hauser-Kawaguchi and Luyt, 2015). Nevertheless, liposomes possess 
a distinctive feature, the capacity to encapsulate both hydrophobic and hydrophilic drugs in the lipid-
bilayers and the aqueous core, respectively (Hauser-Kawaguchi and Luyt, 2015). Currently, several 
liposomal formulations of different anti-cancer drugs have been approved for human use (Table 1.1). 
In cancer therapy, Doxil (PEGylated form) (Safra et al., 2000) and Mycoet (non-PEGylated form) 
(O'Shaughnessy, 2003, Swenson et al., 2001), which are liposomal  formulations of the anthracycline 
doxorubicin, are approved for treating metastatic breast cancer. It was found that Doxil improved the 
drug accumulation of doxorubicin 10-fold compared to administration of the drug alone (Rosenthal 
et al., 2002). Currently, numerous liposomal formulations are in preclinical development and are 
being evaluated in clinical trials. 
1.2.2 Nanoemulsions as drug delivery systems       
NEs, heterogeneous systems in which one liquid is dispersed as nanosized droplets within another 
liquid, have evolved as robust carriers for the delivery of a wide range of hydrophobic drugs (Ganta 
et al., 2014b). NEs are non-equilibrium, kinetically stable systems that feature small droplet sizes 
typically ranging from 20 to 500 nm (Gupta et al., 2016). NEs are characterised by advantageous 
features, including ease of production, high loading capacities, long-term stability, increased 
bioavailability and protection and controlled release of cargos, all of which make them promising 
carriers for use in nanomedicine (Talegaonkar and Negi, 2015). The presence of commercialised NEs 
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in various applications (Table 1.2) demonstrates their suitability and their long history of safety in 
pharmaceutical applications. 
Both oil-in-water (O/W) and bicontinuous water-in-oil-in-water (W/O/W) NEs are suitable for the 
delivery of hydrophobic compounds in aqueous environments. NEs have four main components: the 
dispersed phase, continuous phase, surfactant and co-surfactant. The selection of the oil type 
determines the solubility of the encapsulated drug and, therefore, the loading capacity. Surfactants 
reduce the interfacial tension between liquid phases imparting thermodynamic stability, and they can 
be anionic, cationic, non-ionic or zwitterionic. In the last few years, NEs have shown promising 
results as preclinical cancer theranostics (Ganta et al., 2014a). For instance, a recent study has shown 
a synthesis of a theranostic NE platform that involves the use of vitamin E and D-α-tocopheryl-
PEG1000-succinate as an oil core and surfactant, respectively. This platform was applied to co-
deliver an imaging probe (sulforhodamine B) and paclitaxel for cancer imaging and therapy (Yang et 
al., 2014). Another study also showed that NEs hold promise for use as a theranostic platform, where 
a targeted docetaxel-loaded NE was applied to ovarian cancer using folate as a targeting moiety and 
gadolinium for magnetic resonance imaging (MRI) (Ganta et al., 2016). 
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Table 1.2. Pharmaceutical NE formulations on the current market (Mansoor and Sandip, 2006, 
Lovelyn and Attama, 2011). 
 
 
 
 
 
  
Active agent Indication Brand name Company 
Propofol Anaesthetic Diprivan® Astra Zeneca 
Dexamethasone 
palmitate 
Steroid Limethason® 
Mitsubishi 
Pharmaceuticals 
Palmitate alprostadil Vasodilator platelet inhibitor Liple® 
Mitsubishi 
Pharmaceuticals 
Flurbiprofen axetil NSAID Ropion Kaken Pharmaceuticals 
Vitamins A, D, E or K Parenteral nutrition Vitalipid® Fresenius Kabi 
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1.2.2.1 Tailorable nanocarrier emulsions 
Tailorable nanocarrier emulsions (TNEs) were recently invented by the Middelberg group at the 
Australian Institute for Bioengineering and Nanotechnology (AIBN) and have shown promising 
results in the selective delivery of antigens (Zeng et al., 2013). TNEs are easily formulated by the 
assembly of protein-based surfactants in a bottom-up fashion followed by the top-down sequential 
addition of reagents. The core of TNEs is made from a pharmaceutical-grade oil, Miglyol 812, which 
is classed as a generally recognised as safe (GRAS) substance by the US Food and Drug 
Administration (FDA) (Dexter et al., 2006). It is stabilised by a 21-residue surface active peptide 
called AM1 (Ac-MKQLADSLHQLARQVSRLEHA-CONH2) (Malcolm et al., 2006) (Figure 1.1). 
The design of AM1 was based on an amphipathic peptide Lac21 which adsorbs at fluid-fluid 
interfaces (Fairman et al., 1995). The difference between AM1 and Lac21 is only in the insertion of 
two histidines residues at positions 9 and 20. These histidines give AM1 its metal binding properties 
that allow the cross-linking between AM1 molecules at the oil-water interface, and facilitates the 
formation of stable foams and emulsions (Dexter et al., 2006). AM1 molecules adsorb at the oil-water 
interface where the hydrophobic residues (positions 1, 4, 8, 11, 15 and 18) oriented toward the oil 
phase (Figure 1.1). AM1 has also switchable properties allows easy reversible destabilisation of 
emulsions through pH change or chelating effects (Dexter et al., 2006, Malcolm et al., 2006).  
DAMP4, a recently reported protein-based biosurfactant that shows chemical similarity to AM1 
(Dwyer et al., 2013) spontaneously integrates into the oil-water interface of TNEs, which have already 
been stabilised by AM1. Genetic or chemical conjugation of bioactive moieties to DAMP4 for 
subsequent TNE surface integration enables decoupling of the physical stabilisation and biological 
functionalities of the TNEs (Sainsbury et al., 2014) (Figure 1.2). That is, it separates emulsification 
from functionalisation, which is unique among NEs. In this way, DAMP4 allows for the display of a 
wide range of molecules on the surface and the engineering of sophisticated surfaces at the oil-water 
interface (Zeng et al., 2013). For example, DAMP4 was chemically conjugated to PEG (Zeng et al., 
2013), a non-immunogenic and non-toxic hydrophilic polymer that is widely applied in 
pharmaceutics for shielding from immune system detection (Harris and Chess, 2003). The importance 
of PEG for decorating and applying drug delivery systems will be discussed in the next paragraphs. 
The TNEs were then also functionalised by fusing DAMP4 to a monoclonal antibody (anti-Clec9A), 
targeting the Clec9A receptor on the dendritic cells (DCs) (Zeng et al., 2013). Functionalising the 
TNEs with anti-Clec9A antibody enables the specific targeting of the DCs subset in in vivo studies. 
Immunotherapeutic TNEs remain under development for various diseases, including cancer 
(Sainsbury et al., 2014). However, because of their versatile features, such as ease of production, high 
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drug loading capacities, cargo protection and cell-selective targeting, they show remarkable potential 
as carriers for hydrophobic compounds. 
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  Figure 1.1. Schematic representation of AM1 peptide. The hydrophobic chains of AM1 are 
presented in green. The metal binding properties of AM1 via histidine molecules are shown in 
yellow. 
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Figure 1.2. Diagrammatic depiction of how TNEs are fabricated. This shows the addition of 
the PEGylated DAMP4 to the AM1-stabilised TNEs to stabilise the emulsion and impart 
hydrodynamic stability (Sainsbury et al., 2014). AM1 shown in red, DAMP4 shown in blue 
and PEG shown in white. 
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1.3 Bioconjugation 
Since the pioneering studies done by Ringsdorf (Ringsdorf, 1975), bioconjugation chemistry has 
become a central element in pharmaceutical applications as well as fundamental research (Veronese 
and Morpurgo, 1999). It is defined as ‘the covalent derivatisation of biomolecules’ (Kalia and Raines, 
2010), and it has been the basis of most stabilisation mechanisms against physiological processes, 
including enzymatic degradation (Fee and Van Alstine, 2006), immunogenicity (Jokerst et al., 2011) 
and clearance (Monfardini and Veronese, 1998). Therefore, bioconjugation of polymers to 
biomolecules can improve their properties and, thus, their pharmacokinetic profile (Lu et al., 2002). 
Bioconjugation is widely used in various applications, including biochemical assays (Newman and 
Zhang, 2008), discovery of ligands (Rup and O'Hara, 2007) and diagnostics which, in turn, include 
in vivo imaging (Parker, 1990, Wester and Schottelius, 2007), industrial applications (Wong and 
Whitesides, 1994) and PEGylation (Harris and Chess, 2003, Zalipsky, 1995). Bioconjugates can be 
attached to their biomolecules either through conjugation to natural amino acids (which will be 
discussed in this work) or incorporated unnatural amino acids. The most widely used method for 
protein conjugation is the nucleophile to electrophile attacks where cysteine is the most robust 
available nucleophile as a natural amino acid, although cysteines are rarely present in most proteins 
(Veronese and Morpurgo, 1999). The reaction of maleimide to thiol groups of cysteines is a common 
example for thioether formation (Figure 1.3f). A more commonly applied approach is protein 
conjugation of the amino groups in lysines by N-hydroxysuccinimides (NHS-chemistry) (Kalia and 
Raines, 2010). Primary amines of proteins can also react with conjugates having carboxylic groups 
(Figure 1.3c). The presence of amino groups in most proteins reduces the opportunity for site-
specificity conjugations (Veronese and Morpurgo, 1999). Site-specific bioconjugation of proteins can 
occur through the incorporation of functional groups such as the sulfhydryl group or other reactions 
such as copper-catalysed azide-alkyne cyclo-addition (Kakwere et al., 2010). 
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  Figure 1.3. List of amino and thiol functional reactive groups.a. Reaction of primary amines 
with N-succinimidyl activated ester leads to amide formation. b. Reaction of primary amines 
with pentafluorophenyl activated ester leads to amide formation. c. Reaction of primary 
amines with carboxylic acid in the presence of N,N’-dicyclohexyl carbodiimide (DCC) or 
carbodiimide (1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) leads 
to amide formation. d. Reaction of pyridyl disulphide with sulfhydryl group (thiol) leads to 
disulphide formation. e. Michael addition of alkene to thiol leads to thioether formation. f.  
Reaction of maleimide to thiol leads to thioether formation. g. Michael addition of vinyl 
sulphone to thiol lead to formation of thioether group (Cobo et al., 2014). 
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1.3.1 PEGylation   
PEG is the most common FDA-approved polymer used for stabilising colloidal nanocarriers in 
pharmaceutical applications (Gref et al., 2000). It has been reported that PEG can affect the surface 
charge, size and hydrophilicity of drug delivery systems. Circulation time is considered an important 
benchmark in the evaluation of drug delivery systems, including emulsions, via the intravenous (IV) 
route. The half-life of drug delivery systems in blood circulation is usually short due to the rapid 
clearance by macrophages via the opsonisation mechanism (Juliano, 1988). Hence, coating with 
hydrophilic polymers, such as PEG and poloxamines, is crucial to extend their half-life in the 
bloodstream and improve therapeutic efficacy (Allen and Martin, 2004). That is, PEG coating can 
reduce protein adsorption (opsonisation) (Owens and Peppas, 2006) onto the interface, which 
prolongs circulation half-life by avoiding phagocytosis. Successful PEG presentation can also 
minimise aggregation by improving colloidal and steric stability (Moore et al., 2015). In contrast, it 
has been reported that IV-administered PEG-labelled formulations can induce immune response or 
opsonisation. The complement system as well can be activated through injected PEG-conjugates or 
formulations which can result in hypersensitivity reactions (Knop et al., 2010). Even though there are 
a few concerns surrounding the use of PEG, it is still considered the gold standard polymer for use in 
drug delivery.    
Controlling the surface properties (size, surface charge and hydrophilicity) of an NE system is 
essential to enable modification and synthesis of a promising drug delivery system for various 
biological applications (Ganta et al., 2014b). The density of PEG coating is also crucial to any direct 
drug delivery system for a particular route of delivery. PEG density also relates to targeting efficiency 
for both passive and active targeting (Xu et al., 2015). PEG also might have a positive or negative 
impact on the function of conjugated molecules, such as antibodies and surfactants. Therefore, 
studying the application of PEG molecules on surface-modified emulsions is an important area of 
research as it provides insight into the future direction for the medical applications of NEs. For 
example, tuning a biophysical property, such as the surface charge, can affect the interaction of NPs 
with cells in several ways, including the minimisation of non-specific binding. It can also affect 
interfacial thickness, stiffness and activity of co-displayed molecules by varying parameters, such as 
size, PEG length or orientation (D’souza and Shegokar, 2016). Due to the importance of PEG and 
these possible impacts on the interface of an emulsion system, this research project investigated and 
characterised the TNEs’ interface using the designer biosurfactant, DAMP4, which allows 
functionalisation with molecules such as PEG. In addition, due to the importance of DAMP4 in 
imparting stability and functionality to TNEs, the impact of PEG on DAMP4 activity was 
investigated.  
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1.4 Thesis aims  
The overall aim of this thesis is to further refine the nanocarrier emulsions previously developed by 
the Middelberg group at the University of Queensland. This aim is addressed by tuning the platform 
to suit different applications based on the biophysical properties of the oil-water interface.  The 
structural elements of the interface consist of the ensemble of molecules at the surface including 
AM1, coordinated metal ions and DAMP4 as well as bioconjugated moieties such as PEG and 
targeting ligands. Together, these determine functional properties of TNEs. Investigation of the 
structure-function relationship of the interface will be achieved through the following three 
objectives:  
1- To broadly explore the suitability of TNEs in diagnostic and therapeutic applications 
employing different routes of administration. 
2- To gain insight into the interfacial structure-function of the polyethylene glycol-decorated 
peptide-stabilised Nanocarrier emulsions, and  
3- To gain better control over the interface of the TNEs through genetic engineering of DAMP4 
for precise bioconjugation of DAMP4 and interfacial activities. 
 
To achieve the first aim of this project, I evaluated the feasibility of using TNEs for 
diagnostic/therapeutic applications via the IV and topical (skin) routes. This includes the 
encapsulation and retention capacity of hydrophobic compounds within the oil core of TNEs based 
on variable DAMP4-PEG densities on TNE interfaces. Control over the surface charge of TNEs was 
harnessed for electrostatic interactions to form a hybrid system with a promising technology called 
silica elongated microparticles (EMPs) developed by Professor Tarl Prow at the Translational 
Research Institute (TRI). 
The application of TNEs as a targeted drug delivery system was also evaluated by developing a 
DAMP4-scFv fusion protein. The integration of this fusion into the TNE interface was evaluated, and 
the scFv-labelled TNEs were applied to cancer cells for in vitro targeting studies. Targeted and un-
targeted TNEs were tested for in vivo studies in tumour mouse models.  
The second aim was addressed by exploring the interfacial structure-function relationship of the 
polyethylene glycol-decorated peptide-stabilised nanocarrier emulsions, which have profound 
influence on biodistribution, stability and efficiency of functional surface properties such as active 
targeting. Surface modification of drug delivery systems is commonly applied to improve their 
stability and further biological applications. PEG is an FDA-approved hydrophilic polymer widely 
applied to fabricate nanomaterial surfaces to achieve better pharmacokinetics. Therefore, 
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understanding the molecular characteristics of the PEG layer offers insight into the structure-function 
relationship for the development of soft nanomaterials more broadly.  
The third aim involved studying the impact of covalent modification on genetically engineered 
DAMP4 variants. DAMP4 variants were evaluated for structural and functional alterations following 
the introduction of cysteine residues. The variants allow for more accurate design and analyses of the 
TNE interface. They provide more precise information on the structure of biosurfactants following 
the covalent attachment of PEG, and how this can affect their functional properties including 
interfacial activity, stabilisation of emulsions and presentation of biomolecules.  
1.5 Thesis organisation 
Chapter 2 - Comprises a literature review (publication manuscript) under the title of 
‘Nanoemulsions: promising drug delivery systems for medical applications’. The review addresses 
the basic science of NE formulations as it relates to the medical application and route of 
administration. It summarizes the dispersion and stabilisation of O/W emulsions and discusses their 
physical properties in terms of pharmacological performance. Then, it critically examines the uses of 
NEs in the treatment and prevention of disease by route of administration. Finally, we comment on 
the potential for the functionalisation of NEs by both bottom-up and top-down self-assembly 
mechanisms to formulate sophisticated NEs for specific applications. 
Chapter 3 - Investigates the use of TNEs as a drug delivery and imaging tool for topical and IV route 
applications. This work was to elucidate the possible biological challenges that might be faced during 
topical and IV administration. A hydrophobic fluorescent dye, 1,1′-dioctadecyl-3,3,3′3′-
tetramethylindocarbocyanine perchlorate (DiI) used to evaluate the interfacial properties of TNEs 
including the capacity of cargo retention and physical and colloidal stability. These tuneable 
properties were explored for coating a promising EMPs for human skin applications and stabilising 
TNEs for IV delivery.      
Chapter 4 - Presents a fundamental insight into the interfacial structure-function of the polyethylene 
glycol-decorated TNEs. This chapter relates physio-chemical properties of TNEs as a tuneable model 
interface to ligand accessibility and receptor-binding performance. PEG-mediated surface shielding 
is commonly used to impart anti-fouling and immune-evading characteristics on interfaces and NPs. 
This chapter uses the precise control over the surface decoration of TNEs to study the interfacial 
properties of a PEG-modified oil-water interface, and examines how the physical properties of 
different PEG layers influence the accessibility of a co-decorated single-chain fragment antibody.  
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Chapter 5 - Reports the development of a second generation of the protein biosurfactant, DAMP4, 
to enable precise and efficient bioconjugation of PEG and, therefore, more controlled investigation 
of the impact of DAMP4 adsorption on interfacial activity.	The second-generation biosurfactants 
(cysteine variants of DAMP4) were engineered using rational amino acid substitution, and their 
structure, stability and interfacial activity were studied and compared to the parent molecule. The 
mass and number of bioconjugated PEG molecules to the cysteine variants were evaluated for their 
impact on the interfacial activity of DAMP4 and the overall stability of the TNEs interface. 
Chapter 6 - Provides a summary of all the thesis findings and relates these to the future directions of 
research.    
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2 Chapter 2: Literature Review: Nanoemulsion: a Promising Drug Delivery 
System for Medical Applications  
The following literature review manuscript will be submitted to the Journal of Nanomedicine, 
Future medicine:   
 
Hossam. H Tayeb1, 2, Frank Sainsbury1* 
1 The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, 
QLD 4072, Australia. 
2 King Abdul Abdul-Aziz University, Faculty of Applied Medical Sciences, Jeddah, Kingdom of 
Saudi Arabia.   
 
Abstract 
Emulsions are heterogeneous systems of two immiscible liquids stabilised by emulsifiers or 
surfactants.  Nanoscale oil-in-water emulsions (NEs) show great potential in a broad range of medical 
applications because of their attractive characteristics for drug delivery. These include enhanced drug 
solubility, the use of generally recognised as safe ingredients (GRAS), ease of production and high 
loading capacity. NEs have been explored as therapeutic delivery vehicles for hydrophobic 
compounds via various routes of administration including via the skin, ocular, nasal cavity, 
respiratory tract, and ingestion and via injections. In some cases, NEs provide opportunities to 
improve drug delivery via alternative administration routes. However, deep understanding of the 
fundamental processes of NE manufacturing and functionalisation, and how they relate to the choice 
of administration route and pharmacological profile is still limited. These challenges remain to be 
overcome to ease the transition of NEs from laboratories to patients use. Here we review the diversity 
of medical applications for NEs and how that governs their formulation, route of administration, and 
the emergence of increasing sophistication in NE design for specific applications. 
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2.1 Introduction 
NEs, also known in the literature as ultrafine emulsions, mini-emulsions and submicron emulsions, 
are heterogeneous systems in which one liquid (dispersed phase) is dispersed as nanosized droplets 
in another liquid (continuous phase) (Solans and Solé, 2012, Ganta et al., 2014b, McClements, 2011, 
Lu et al., 2012). The droplet size range of NEs is between 20-500 nm (Gupta et al., 2016).  NE types 
are based on the class of the dispersed and continuous phases, for example, oil-in-water (O/W), water-
in-oil (W/O) and double emulsions (W/O/W or O/W/O) (Figure 2.1). NEs can be relatively easily 
fabricated with biocompatible and biodegradable ingredients involving FDA-approved oils. They are 
non-equilibrium (thermodynamically unstable) and kinetically stable systems (Solans et al., 2005, 
McClements and Jafari, 2018). Therefore, they require energy input (high or low energy methods) 
for their formation (Tadros et al., 2004) and surfactants or emulsifiers to impart colloidal stability. 
Surfactants and co-surfactants used to stabilise NEs can be lipid-based molecules (Gianella et al., 
2013) or peptides/proteins (Malcolm et al., 2006, Dwyer et al., 2013) both of which show a degree of 
compatibility for human use. Surfactants reduce the interfacial tension (IFT), surface energy (δA) per 
unit area (A), between the dispersed and continuous phases, providing thermodynamic instability 
which leads to an increase in the shelf-life stability (Mason, 1999). Surfactants can also act to stabilise 
NEs through repulsive electrostatic forces (Mason et al., 2006) 
Our review addresses the basic science of NEs formulation as it relates to the medical application and 
route of administration. We summarize the dispersion and stabilisation of O/W emulsions and discuss 
their physical properties in terms of pharmacological performance. We then critically examine the 
uses of NEs in the treatment and prevention of disease by route of administration. Finally, we 
comment on the potential for the functionalisation of NEs by both bottom-up and top-down self-
assembly mechanisms to formulate sophisticated NEs for specific applications.  
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Figure 2.1. Types of emulsion based on the dispersed phase. 
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2.2 Preparation methods of nanoemulsions 
NEs are synthesised by various techniques that fall under one of two energy input paradigms; high-
shear forces (e.g. ultrasonication) and low-shear forces (e.g. phase inversion temperature (PIT) (Fryd 
and Mason, 2012, Talegaonkar and Negi, 2015, Gupta et al., 2016). The high energy methods involve 
the use of mechanical devices to exert shearing forces to split the dispersed phase into fine droplets 
(Musa et al., 2013). Sonication devices are mostly used in research laboratories; however, rotator-
stator and high-pressure devices are usually used in industry (Solans et al., 2005, Kentish et al., 2008). 
The low energy methods leverage the internal chemical potential of the system to formulate NEs 
(Komaiko and McClements, 2016). The production of NEs using high-energy approaches is 
determined by the formulation composition and the required energy input. There are two major 
mechanical-shearing methods using high energy, ultrasonication and homogenisation (Figure 2.2). 
The ultrasonication method applies high-frequency sound waves to two immiscible liquids. These 
generated shearing forces break up the dispersed phase into small droplets in the presence of a 
surfactant that prevents droplet coalescence or flocculation by reducing the IFT (Maa and Hsu, 1999). 
Homogenisation involves the application of very high pressures on the formulation mixture which is 
then pumped via a restrictive valve. This generates high shearing force resulting in the formation of 
small droplets of the dispersed phase (Tadros et al., 2004, Quintanilla-Carvajal et al., 2010, 
Håkansson and Rayner, 2018).   
The low energy methods utilise the chemical potential of the system internal components to formulate 
dispersions. Low energy emulsification and condensation methods use the phase transitions that take 
place in response to temperature and composition changes (Gupta et al., 2016, Usón et al., 2004). The 
phase inversion temperature (PIT) method, first reported by Shinoda and Saito (Shinoda and Saito, 
1968), is one of these methods widely applied in industry. 
2.3 Nanoemulsion-destabilising mechanisms  
In the absence of the following mechanisms: flocculation, creaming, cracking and Ostwald ripening, 
NEs are generally known as a stable platform. The most common destabilisation mechanism is 
Ostwald ripening (Delmas et al., 2011, Kabalnov, 2001). It is defined as the growth of the dispersed 
phase larger droplets at the expense of the smaller droplet (Figure 2.3). In other words, Ostwald 
ripening is the process by which smaller droplets of the dispersed phase (higher Laplace pressure) 
migrate via the continuous phase into large droplets that have lower Laplace pressure (Mason et al., 
2006).  
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Figure 2.2. The common techniques used for the formulation of NEs. 
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Figure 2.3. The destabilising mechanisms of the NEs. The continuous phase and the dispersed phase 
are in (blue) and (yellow) respectively. 
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Laplace pressure differential allows for mass transfer from smaller to larger droplets. The solubility 
of the dispersed phase (e.g. oil) in the continuous phase plays a major role in the ostwald ripening 
phenomena (Rahn-Chique et al., 2012, Lifshitz and Slyozov, 1961), which can be suppressed by 
selecting two phases that are highly immiscible where the dispersed-phase droplets have very low 
solubility in the continuous phase.  
Flocculation or coagulation occur when two or more droplets join and form dispersed larger clumps 
or floccules due to attractive forces. These floccules move in the solution as a single object (Figure 
2.3). The DLVO theory suggests that when the repulsive minimum between two droplets is low, these 
droplets tend to form floccules or clumps (Rahn-Chique et al., 2012). Floating of these clumps is 
known as creaming; therefore, flocculation might lead to creaming (Jaiswal et al., 2014, Rahn-Chique 
et al., 2012). This floating (buoyancy) occurs because of an upward exerted force by the fluid because 
the pressure under the floating droplet is greater than the pressure on the top of the droplet. This 
buoyant force controls the degree of freedom of a particular system when it dominates thermal 
fluctuations and Brownian motion. In the case where the dispersed phase is less dense than the 
continuous phase, it leads to floating of the droplets (creaming) (Mewis and Wagner, 2012). In the 
case where the dispersed phase is denser than the continuous phase, it leads to sedimentation (Figure 
2.3). These floating droplets form a thick (concentrated) layer of the dispersed phase. A cracked NE 
is characterised by the separation of the dispersed phase from the continuous phase where the NE 
cannot be reverted to its normal condition. However, creamed NE can be reconstituted by mixing 
(Jaiswal et al., 2014). 
2.4 Nanoemulsion stabilisers 
Long shelf-life and stability in various environments are important requirements for the use of  NEs 
in medical applications (McClements and Gumus, 2016). Surfactants or emulsifiers are surface-active 
molecules that can maintain the kinetic stability of NEs by reducing IFT between the dispersed and 
continuous phases. Stabilisers can be ionic, non-ionic surfactants, polymers or solids. Polymers and 
non-ionic surfactants can help to prevent destabilisation of NE through steric hindrance. Ionic 
surfactants (charged surfactants) can also prevent instability of NEs via electrostatic repulsion (Otto 
and du Plessis, 2015). Currently used stabilisers are either chemically-synthesised (Spans, Tweens or 
Cremophors) (Kralova and Sjöblom, 2009, Kaur et al., 2016) or bio-sourced (egg lecithin, whey 
protein, caseinate and microbial) (Dickinson, 1986, Dickinson, 1994, Rodrigues et al., 2006). Some 
of these surfactants are associated with toxicity concerns, therefore considering selection criteria that 
include surfactant source, concentration and safety profile is important for the formulation of stable 
NEs.  For example, the stabilisation of NE systems usually requires high concentration of surfactants 
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and co-surfactants, and this may cause irritation and toxicity in oral and topical drug delivery 
applications. The selection of surfactants based on chemical properties is also another important 
aspect in the formulation of NEs for drug delivery. For instance, it has been reported that non-ionic 
synthetic surfactants show less toxicity when compared to ionic surfactants, which can damage 
biological membranes (Azeem et al., 2009). In addition, non-ionic surfactants tend to have better in 
vivo stability in comparison with their ionic counterparts (Kawakami et al., 2002). Although non-
ionic surfactants such as Cremophor have been marketed as part of paclitaxel formulation (Taxol), 
this formulation still have a considerable level of toxicity (Kaur et al., 2016). In addition to toxicity, 
chemically synthesised surfactants are not biodegradable and non-renewable, whereas biosurfactants 
are gaining interest as stabilisers in food and medical applications due to their biocompatibility, 
biodegradability and sustainability. Even though biosurfactants are less toxic than chemically-
synthesised surfactants, some of these can still provoke adverse reactions such as egg lecithin. 
Biosurfactants can be classified as low molecular weight (peptides, proteins and glycolipids) or high 
molecular weight (proteins, lipoproteins and polysaccharides) compounds (Marchant and Banat, 
2012, Rodrigues et al., 2006). Lipid-based surfactants have been used to stabilise multifunctional NE 
in drug delivery applications (Gianella et al., 2013). Glycolipids extracted from microorganisms were 
studied extensively as surfactants with antimicrobial activity (Gerard et al., 1997). They were also 
applied for stabilising NE for drug delivery applications such as analgesia (Ahmad et al., 2014a). 
Proteins have a safety profile history in both food and pharmaceutical applications. Peptide and 
polypeptide surfactants are promising amphiphilic molecules for stimuli-responsive and self-
assembly systems (Dexter et al., 2006, Malcolm et al., 2009). They can be conjugated to a wide range 
of molecules to stabilise and functionalise NEs for a particular application (Zeng et al., 2013, 
Sainsbury et al., 2014). These conjugates include polymers such as PEG that is commonly used in 
drug delivery to achieve immune shielding and in vivo stability through steric hindrance. Thus 
protein-based surfactants can potentially be utilised to functionalise NEs for a wide range of medical 
applications. 
2.5 Nanoemulsions in medical applications 
The emergence of high-throughput screening methods and combinatorial chemistry has facilitated the 
design of potent therapeutics. However, most of these promising therapeutic agents show poor 
aqueous solubility. It is estimated that approximately 40% of newly discovered therapeutic agents are 
eliminated from the drug development pipeline because of poor aqueous solubility (Ganta et al., 
2014b). NEs have evolved as a robust carrier for the delivery of a wide range of hydrophobic drugs. 
Their attractive features, including ease of production, enhanced loading capacities, long-term 
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stability, increased bioavailability and protection and controlled release of cargos, make them 
promising carriers for use in nanomedicine (Fryd and Mason, 2012). NEs have been broadly applied 
to a broad range of applications including food industry (Silva et al., 2012, McClements and Rao, 
2011), cosmetics (Sonneville-Aubrun et al., 2004) and medicine(Jaiswal et al., 2014, Singh et al., 
2017).  They have been applied via different administration routes and they are applied as dried 
(powdered) formulations, aerosols, ingestible and injections (Figure 2.4). NEs have been widely 
applied to improve pharmacokinetics and bioavailability of water-insoluble drugs. 
Our review addresses the fundamentals of O/W NE formulation as it relates to drug delivery 
applications. The physiochemical properties of NE formulations including charge, size and the type 
of oil or surfactants are important for successful medical application. Therefore, studying and relating 
the physiology of both application and indication is essential for integrating desired properties into 
bespoke NE formulations.  
2.5.1 Topical applications 
Skin provides a layer of protection for the human body against the surrounding environment. 
However, it is also considered as an administration route for topical drug delivery. The skin is a multi-
layered organ (Cosco et al., 2008). The stratum corneum (SC), the outer layer, is composed of the 
epidermis, dermis and subcutaneous tissues. The lipid matrix of the SC comprises keratinocytes, 
cholesterol, fatty acids and ceramides (Morrow et al., 2007). This lipid matrix provides a barrier 
against environmental factors such as radiation.  
Drug application to the skin offers various advantages including the non-invasive administration of 
medicines either locally or systemically (Barry, 2004). However, this requires diffusion of a drug to 
the dermis layer, which presents a challenge in topical drug delivery due to the presence of a 
protection layer, the epidermis. The inherent properties of O/W emulsions can enhance the absorption 
of lipophilic drugs when applied topically to the skin. Firstly, the encapsulation of lipophilic drugs 
within the NEs oil core can improve their bioavailability. Also, the use components (surfactants and 
co-stabilisers) within the interface can enhance penetration activity of the SC layer (Rhee et al., 2001). 
The small size and the low-surface tension of NEs might also improve the permeation rate of the 
encapsulated drug (Talegaonkar and Negi, 2015). A large number of studies have been published on 
NEs for topical skin drug delivery (Mou et al., 2008, Salim et al., 2016) and various NE candidates 
have entered clinical trials (Table 2.1). NE have shown improved bioavailability and pharmacological 
effect of various water-insoluble compounds. For example, Quercetin is a flavonoid that has potential 
chemo-protective effects including antioxidation and wound healing. However, it has also low 
bioavailability because of poor aqueous solubility and low skin absorption and penetration 
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al., 2016). The enhancement of quercetin permeation through the skin was demonstrated when loaded 
into the lipid core of positively-charged NEs formulated using spontaneous emulsification (Fasolo et 
al., 2009). 
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Figure 2.4. Drug delivery applications of nanoemulsions. It illustrates the medical 
application of NEs based on the routes of administration. These include the nasal, ocular and 
oral cavities, injections and topical applications. 
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This indicates the importance of tuning the biophysical properties to improve drug permeation where 
the positively charged interface of NEs enhance the interaction with the negatively-charged epithelial 
cells. However, the composition of these NEs include the use egg-lecithin as emulsifier (Fasolo et al., 
2009). Egg lecithin is not approved by FDA for medicinal use because of safety concerns, and 
therefore, biocompatible, FDA-approved, or generally recognised as safe (GRAS) surfactants should 
be considered to enhance the translation of NE formulations to the clinic. 
Skin layers can be targeted through various drug delivery approaches. For example, the treatment of 
psoriasis requires drug delivery to keratinocytes (epidermis) and deeper layers involving 
angiogenesis. Formulations for the treatment of psoriasis showed higher bioavailability of paclitaxel 
at the respective skin layers with minimal leakage to the blood stream when they loaded paclitaxel 
into NE formulation (Khandavilli and Panchagnula, 2007). The surfactant, labrasol (Hu et al., 2001), 
known as skin penetration enhancer, was used to improve drug permeation to the required site of 
action (Khandavilli and Panchagnula, 2007). NE formulations have been developed for poorly soluble 
compounds with a range of therapeutic effects including anti-proliferative (Pham et al., 2016), anti-
microbial (Savi et al., 2005, Kelmann et al., 2016), and antioxidation (Kuo et al., 2008).  
Skin drug delivery also offers great opportunities for water-insoluble drugs that show low availability 
when taken via other routes of administration. To avoid systemic delivery and its side effects for 
breast cancer therapy, local or intraductal drug delivery to mammary tissues using topical application 
of cationic NEs loaded with C6 ceramide was recently reported. This study showed that NEs can 
prolong the drug localisation within the mammary tissues compared to IV delivery of the API in 
solution (Migotto et al., 2018). Also, it provides convenient non-invasive systemic drug delivery via 
systemic escape. Allowing systematic escape of encapsulated drugs through dermal layers without 
accumulation in these layers is known as transdermal delivery. NE properties can be harnessed to 
disrupt the stratum corneum (barrier), increase thermodynamic activity against skin or flux using 
penetration enhancers as alternative promising approaches to systemic delivery of hydrophobic drugs 
(Aqil et al., 2016). For example, the transdermal delivery of indomethacin, an anti-inflammatory drug, 
using NE facilitated skin permeation via surfactants and co-surfactants that penetration enhancing 
capabilities (Williams and Barry, 2004). This suggests that the transdermal route can be an alternative 
non-invasive IV route. Here we suggest the use of biocompatible surfactants to ease the formulation 
and fabrication of NEs for topical delivery, and also to facilitate the approval of NEs candidates for 
patient use. Understanding of drug absorption mechanisms through the skin layers in accordance with 
the composition, formulation, fabrication and the biophysical properties of NEs is crucial to accelerate 
the progress in topical therapy. 
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Ocular drug delivery via the cornea is a type of topical applications of NEs, for which there are 
particular formulation considerations. These include the refractive index, transparency and viscosity. 
To control these elements, the type and concentration of the dispersed phase (oil) should be chosen 
carefully. O/W cationic NEs carrying antisense oligonucleotides have been developed to prevent 
neovascularisation and treat retinopathy (Hagigit et al., 2012). The benefit of using NE in this context 
was to prevent degradation of the antisense oligonucleotides and improve their ability to cross the 
cellular membranes. The delivered oligonucleotides targeted the tyrosine kinase vascular endothelial 
growth factor receptor-2, which is responsible for angiogenesis (Hagigit et al., 2012). In addition, 
NEs have also been used to improve the delivery efficiency of other APIs for ophthalmic diseases 
including lutein (Lim et al., 2016) and loteprednol etabonate (Patel et al., 2016).  
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Table 2.1. Examples of NEs in clinical trials for skin applications (Singh et al., 2017). 
* Active pharmaceutical ingredient 
  
Disease 
(application) 
Encapsulated 
API* 
Clinical trial 
stage 
Formulation Sponsor 
Clinical trials, 
gov identifier 
Osteoarthritis Diclofenac 
II 
(completed) 
3%-Diclofenac-
NE Cream 
Pharmos NCT00484120 
Women 
(menopause) 
libido 
Testosterone 
II (not 
complete) 
Testosterone 
NE 
(Biolipid/B2) 
University Potiguar NCT02445716 
Multiple 
actinic 
keratosis 
Aminolevulinic 
acid 
VI 
(completed) 
BF-200 ALA 
cream 
Joint Authority for 
Päijät-Häme Social and 
Health Care 
NCT01966120 
Lentigo 
maligna 
5-
aminolevulinic 
acid 
VI (not 
complete) 
NE as light 
sensitising 
cream 
Joint Authority for 
Päijät-Häme Social and 
Health Care 
NCT02685592 
Basal cell 
carcinoma 
Aminolevulinic 
Acid 
II (not 
complete) 
BF-200 ALA 
NE 
Joint Authority for 
Päijät-Häme Social and 
Health Care 
NCT02367547 
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2.5.2 Ingestible nanoemulsions  
The oral route is considered a viable and promising option for the delivery of hydrophobic drugs 
(Strickley, 2004). This is because orally-administered drugs can be conveniently self-administered 
and do not require intervention by healthcare professionals (Sastry et al., 2000). In contrast, the drug 
administration via the oral route faces many obstacles, including the pH changes and the presence of 
digestive enzymes within the gastrointestinal route that can degrade ingested drugs. Other contents 
of the gastrointestinal tract such as fat and proteins released from food can also interact with orally-
administered drugs (Kong and Singh, 2008). Therefore, protecting the ingested drugs from 
endogenous factors as well as minimising their side effects are primary concerns for orally 
administered therapeutics.  
In addition to improving solubility, NE formulations can also increase absorption and efficacy of 
orally-administered drugs by prolonging residence in the gastrointestinal tract (Rubinstein et al., 
1991) and initiation of the intestinal lymphatic transport pathway (Kotta et al., 2012). The intestinal 
lymphatic pathway can be stimulated via increasing the association of lipophilic drugs to 
chylomicrons (Subramanian and Ghosal, 2004, Dahan and Hoffman, 2005), resulting in avoidance of 
the first-path metabolism by the liver. Furthermore, NE formulation can also improve reproducibility 
of systemic drug delivery via the oral route (Tirnaksiz et al., 2010). NEs are proven to protect 
hydrophobic compounds when encapsulated in the oil phase from hydrolysis and degradation (Khani 
et al., 2016, Sun et al., 2012). In contrast, utilising the high surface area of NEs, in comparison to 
coarse emulsions and suspensions, can enhance drug absorption by increasing lipid digestion and 
drug release (Nicolaos et al., 2003). 
Improving the efficacy of administered drugs is one of the major aims of drug delivery. An example 
of that was shown in an in vivo study of orally-administered curcumin-loaded NEs that showed an 
improved anti-inflammatory effect of curcumin when compared to curcumin in a surfactant solution 
(Young et al., 2014, Wang et al., 2008). Another example is the Primaquine-loaded NEs, which 
showed better antimalarial activity when administered orally using 25% lower dose when compared 
to free primaquine (Singh and Vingkar, 2008). Orally-administered NEs have been intensively 
investigated as well for systemic delivery via the oral route in various medical applications (Tiwari 
et al., 2006, Tang et al., 2012, Borhade et al., 2012). However, as discussed, there are many 
considerations to improve drug delivery via the digestive system that need to be overcome for clinical 
success via this route.  
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2.5.3 Aerosolised nanoemulsions  
Aerosolised therapeutics and diagnostics using colloidal nanocarriers for respiratory diseases are a 
promising alternative for non-invasive drug delivery (Courrier et al., 2002, Azarmi et al., 2008). The 
pulmonary delivery route provides a large surface area for drug absorption, low enzymatic activity, 
thin epithelial barrier, accessible vasculature and avoidance of the first-path metabolism (Azarmi et 
al., 2008, Patton and Byron, 2007, Gaspar et al., 2008). During last 20 years, many nanocarriers have 
been developed for different respiratory diseases including liposomes, solid NPs and emulsions, and 
some have obtained clinical approval to reach the pharmaceutical market. Showing the potential of 
lipid-based NPs to act as surfactants in the lung, the liposomal formulation, Alveofact®, was approved 
in 1980 as a synthetic lung surfactant. It is mainly used to prevent or treat respiratory distress 
syndrome in premature babies who were born with immature lungs (Beija et al., 2012). 
The type and characteristics of a pulmonary drug delivery device are important elements for the 
delivery and, therefore, NE formulations for this route of administration. Examples of these are active 
breath inhalers (dry powder inhalers) (Islam and Gladki, 2008) or passive breath nebulisers 
(Groneberg et al., 2003). Active breath inhalers depend on patient inspiratory force (Virchow, 2004) 
and the internal turbulence of the device (Kruger et al., 2014). Nebulisers are based on the breakdown 
mechanism of any pre-filled formulation such as the air-blast atomisation (Martin and Finlay, 2015). 
All these devices are selected for compatibility with particle drug formulations based on a number of 
factors including their pore size. The optimal pore size is defined by the biophysical characteristics, 
particle/droplet size, of any given formulation (Groneberg et al., 2003). 
There are relatively few published studies demonstrating NEs for drug delivery via the pulmonary 
route (Table 2.2). Because NEs act as solutions with a large fine particle fraction (FPF), they show 
high aerosolisation performance after nebulisation when compared to suspensions (Amani et al., 
2010). For example, the emulsification of budesonide NE showed a significant improvement in the 
aerosolisation capacity when compared with the commercially available suspension-based 
budesonide, PulmecortRespules® (Amani et al., 2010).   
Amphotericin B (AmB) is an antifungal antibiotic applied for both local and systemic fungal 
infections such as Aspergillosis, a life-threatening infection (Tomee and van der Werf, 2001, Soubani 
and Chandrasekar, 2002) caused by the inhalation of Aspergillus conidia. However, AmB possesses 
poor aqueous solubility which limits its therapeutic window (Brajtburg et al., 1990). Two AmB NE 
formulations, intralipid® and clinoleic®, are commercially available products for the treatment of 
aspergillosis. Both intralipid® and clinoleic® have high encapsulation efficiencies, however, the 
clinoleic® formulation was shown to have higher drug deposition (over 80%) when compared to 
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Intralipid (57%). This is due to the fact that clinoleic® NEs have higher FPF than the Intralipid® NEs 
(Nasr et al., 2012). 
Ibuprofen O/W NE mists have also been synthesised as an inhalable formulation for asthma and other 
inflammatory diseases (Nesamony et al., 2014). NEs were also prepared as a carrier for 
oligonucleotides through electrostatic interactions. These carriers were used to protect against 
Mycobacterium tuberculosis (pulmonary immunisation). The pulmonary immunisation was achieved 
via the delivery of DNA to the lungs using cationic submicron emulsions (Bivas-Benita et al., 2004). 
Cyclosporine A (CsA)-loaded NEs were also prepared as dry formulation (lipid-based powder) using 
the spray-drying technique. These emulsions can be rehydrated to form the original O/W emulsion 
formulation (Onoue et al., 2012). CsA plays a role as an anti-inflammatory (asthma and other 
respiratory inflammations), anti-fungal and anti-parasitic drug. It is not commonly used in clinics 
because of its poor solubility and limited oral bioavailability (Beauchesne et al., 2007). However, 
CsA dry emulsions combined with a lactose carrier and obtained a remarkable 4,500-fold 
improvement in the dissolution behaviour of CsA resulting in a dispersion suitable for inhalation 
therapy (Onoue et al., 2012). 
Drug delivery via the intranasal route is also considered desirable because it is painless and non-
invasive, and can be used to administer drugs either locally (paranasal sinuses) or systemically. This 
route provides an opportunity for NE formulations that have excellent aerosolisation capacity. The 
nasal route is mainly utilised for the local treatment of nasal aliments and paranasal sinuses, including 
the sinusitis, nasal congestion and infections (Pardeshi and Belgamwar, 2013). However, to date, 
there are no approved NEs for local delivery of drugs such as corticosteroids or antihistamines to treat 
these indications. There are some examples of intranasal NE for local delivery including vaccination 
by the delivery of an influenza vaccine to mucosal immune cells (Das et al., 2012), and small molecule 
delivery for psychological and neurological disorders (Boche and Pokharkar, 2017, Kumar and Jain, 
2017, Mahajan et al., 2014, Pandey et al., 2015). 
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Table 2.2. Examples of the diversity of APIs delivered by aerosolised NEs. 
  
Encapsulated API Encapsulated API Finding Reference 
Fungal infections Amphotericin B 
Nebulisation 
(Higher drug efficacy 
than chitosan-coated 
AmB liposomes 
(Nasr et al., 
2012) 
Inflammatory diseases and asthma 
Budesonide 
Nebulisation 
(better aerosol 
outputs and FPF 
values compared to 
suspensions 
(Amani et al., 
2010) 
Ibuprofen 
Nebulisation 
(biocompatible and 
sterile Ibuprofen 
pulmonary delivery.  
(Nesamony et 
al., 2014) 
Transplantation Cyclosporine A 
Dry-powdered 
inhaler (lower 
systemic exposure 
compared to drug 
only) 
(Onoue et al., 
2012) 
Gene delivery DNA 
Nebulisation (Not 
toxic to cells and 
protect DNA) 
(Bivas-Benita et 
al., 2004) 
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On the other hand, there are a number of formulations developed for systemic delivery via the nose. 
For example, aerosolised NE formulations have been developed for the treatment of migraine 
(Zolmitriptan) (Abdou et al., 2017) and immunisation (inactivated respiratory syncytial virus) 
(O'Konek et al., 2015). 
Nasal systemic delivery offers many advantages including rapid absorption and the avoidance of the 
first-path metabolism. NEs can improve the delivery of hydrophobic drugs via the nasal mucosa, 
improving their bioavailability when compared with drug solutions or suspensions. Nasally-
administered drugs have shown an improved systemic bioavailability (Comfort et al., 2015). For 
example, nitrendipine, a highly lipophilic calcium channel blocker used for hypertension treatment, 
bioavailability was improved in a NE formulation and delivered through the nasal cavity (Jain and 
Patravale, 2009). Avoiding the blood brain barrier and the first-path metabolism through the nasal 
route is another alternative strategy for the treatment of central nervous system disorders (Kumar et 
al., 2008), to minimise invasiveness, bioavailability issues and undesired side effects. Therefore, NE 
use in the systemic delivery of hydrophobic drugs through the nasal route can be a promising way of 
overcoming some of the hurdles of IV injections. 
2.5.4 Injectable nanoemulsions   
2.5.4.1 Nutrition therapy 
By the 17th century, the first trial of IV administration of olive oil to a dog at 1 g olive oil/kg as a 
nutritional supply was conducted by William Courten and resulted in embolism and death because 
injecting a pure oil into the circulation is fatal. In 1962, the first safe lipid-based IV nutritional NE, 
Intralipid®, was approved in Europe (Hippalgaonkar et al., 2010). Intralipid® is still marketed and 
used for calories, and essential fatty acids supply for nutrition-deficient and ill patients. It is composed 
of made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerine, and water for 
Injection. Even though Intralipid® was approved and marketed for clinical use, hypersensitivity has 
been observed in a small number of patients, who are allergic to egg yolk, egg whites and soybean 
protein (Rotenberg et al., 1991).  
NEs have since been investigated for use in various parenteral applications. Cancer diagnosis and 
therapy are major targets for the use of drug delivery systems in general and the improved parenteral 
administration of lipophilic materials. 
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2.5.4.2 Cancer therapy 
The tumour microenvironment contains a diversity of biochemical conditions and cell types. Tumour 
progression into malignancy is promoted by the components of its particular microenvironment. 
There are critical differences between the growth of tumours and normal tissues, depending on 
various parameters, such as vascular abnormalities and angiogenesis, oxygenation and perfusion, 
which can potentially be harnessed for the development of drug delivery systems (Jaiswal et al., 
2014). Drug delivery to tumours can be either through passive or active targeting (Figure 2.5) which 
will be discussed in the coming sections. 
2.5.4.2.1 Passive targeting 
Targeting cancer cells can be achieved by passive targeting via the enhanced permeability and 
retention (EPR) effect, where the size of the delivery system is crucial (Kumar Bishwajit and Md. 
Lutful, 2014). Conditions with EPR effect occur due to unrestricted angiogenesis that leads to the 
development of poor tumour vasculature, deficiency of pericytes and abnormal basement membranes, 
thus increasing vascular permeability (Maeda et al., 2000) (Figure 2.5). Drug delivery systems should 
be between 10 and 100 nm to achieve optimum levels of the accumulation of the therapeutic agent at 
the tumour mass (Danhier et al., 2010).  
Particles sizes less than 10 nm can be cleared by the reticuloendothelial system (RES), whereas 
particles larger than 100 nm can be engulfed by immune cells (Caron et al., 2013). Engineering of 
colloidal carriers with neutral or negative charges can help to evade the immune system (Ganta et al., 
2014b). Coating NEs with hydrophilic polymers, such as PEG (Ikeda and Nagasaki, 2012, Harris and 
Chess, 2003) and poloxamines, modifies their surface properties (charge and size), extends their 
serum half-life and can improve their therapeutic efficacy (Allen and Martin, 2004). Thus, the size, 
surface charge and hydrophilicity of NEs are important parameters that can be modified to tune the 
effectiveness of drug delivery to cancer cells by passive targeting (Ganta et al., 2014b). 
There are a number of reports of NEs for passively targeting cancer (Ragelle et al., 2012, 
Venkateshwarlu et al., 2010, Desai et al., 2008). Ganta et al. studied the delivery of chlorambucil 
using NEs for adenocarcinoma where the effect of PEGylation on circulation was investigated. The 
PEGylated NEs in this study showed longer circulation and higher accumulation of the drug in the 
colon-38 adenocarcinoma tumours (Ganta et al., 2010). TOCOSOL™ is an example of the use of 
NEs to achieve better accumulation and efficacy of a chemotherapeutic at the tumour site that reached 
the clinic. 
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The tumour suppression of colon adenocarcinoma was higher using this NE formulation, however, 
this formulation was discontinued because it did not meet phase 3 efficacy targets (Insight, 2017). 
Controlling the interface of the NE systems is crucial to obtain the optimum stability against the 
surrounding biological environment and determine biodistribution. Ideally, PEG density, and other 
surface biophysical properties can be precisely tuned. 
2.5.4.2.2 Active targeting  
Active targeting of NEs can be achieved by surface modification with targeting ligands, such as 
antibodies (Ansell et al., 2000), aptamers (Wu et al., 2015, Aaldering et al., 2015) and small molecules 
(Kue et al., 2016) specific to cell surface receptors in cancer tissues. Distinct from passive targeting, 
therapeutics can theoretically be delivered to their target with high specificity, thereby minimising 
interaction with healthy tissues. 
Moreover, internalisation and endocytosis can be facilitated by active targeting in cases where 
endocytic receptors are targeted, delivering payloads intracellularly where their cytotoxic effects are 
executed. For optimum selectivity of the tumour-related receptors, it is crucial to select receptors that 
are overexpressed in cancer cell lines but not in normal tissue. For example, folate, transferrin and 
the epidermal growth factor receptor (EGFR) are overexpressed in several types of cancers, such as 
ovarian and breast cancers (Milane et al., 2010). Targeting moieties that can be conjugated to NEs to 
target a specific antigenic site include vitamins, aptamers, sugars, peptides, antibodies and synthetic 
polymers, (Zeng et al., 2013, Tayeb et al., 2017, Talekar et al., 2012, Mulik et al., 2010). Monoclonal 
antibodies and their derived fragments are commonly used for active tumour targeting due to their 
exquisite specificity, high affinity and, in the case of Fab fragments and scFv antibodies, their small 
size (Ahmad et al., 2012). 
Many studies of NEs have been published on the active targeting of cancer to deliver a broad range 
of water-insoluble drugs, including the exploration of this concept as a way of overcoming multidrug 
resistance (Meng et al., 2016). For example, NEs loaded with aclacinomycin A and externally 
functionalised with folate for targeting human nasopharyngeal tumour cells showed better efficacy 
of the loaded drug compared to an untargeted formulation (Ohguchi et al., 2008).   
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Figure 2.5. Targeting strategies of drug delivery systems. 
63 
 
2.5.5 Other parenteral applications of nanoemulsions 
NE can be applied to overcome challenges of a particular route or delivery through alternative routes. 
Parenteral delivery of NEs has been developed to treat health problems including sepsis (curcumin) 
(Shukla et al., 2014), hypertension (Clevidipine, Cleviprex®) (Cleviprex, 2018) and erectile 
dysfunction (Alprostadil, Liple®) (Ganta et al., 2014b, Hörmann and Zimmer, 2016) to protect API 
from degradation, and minimise their side effects. IV-administered NEs have also been applied and 
improved the bioavailability of an anti-convulsing (anti-epileptic) agent, Carbamazepine (CBZ), 
when compared to oral administration (Kelmann et al., 2007). In addition, NEs have been utilised to 
facilitate the IV administration of drugs for patients having upper gastrointestinal tract complications 
(such as ulcers) and difficulties in taking oral therapies (Araújo et al., 2011).  
2.5.6 Nanoemulsions in biomedical imaging 
Non-invasive diagnostic imaging is one of the important future applications of nanomedicine.  In 
2002, the word “theranostic” first appeared in the literature by Funkhouser, and it is defined as the 
integration of diagnostics and therapeutics in a particular delivery system (Chen and Wong, 2014). 
Before the initiation of any treatment plan for complex pathologies such as cancer or cardiovascular 
disease, it is beneficial to conduct diagnostic imaging to reveal the location, cellular phenotype and 
the heterogeneity of the affected tissue (McCarthy, 2009, Sumer and Gao, 2008, Warenius, 2009). 
Thus, rather than the development of two individual systems for each process, theranostics can offer 
both diagnostic and therapeutic tools in one package that have the potential to overcome the 
biodistribution and selectivity issues of traditional imaging modalities and cancer therapies. NEs have 
the potential to be harnessed for localising imaging and drug delivery to the site of action that will 
eliminate the unwanted side effects of some hydrophobic drugs. 
 
In MRI imaging, perfluorocarbons (PFCs) are considered highly promising intracellular MRI tracers, 
however, they are highly hydrophobic (Krafft and Riess, 2007). NEs developed to improve the 
delivery of PFCs to allow for monitoring and imaging of specific cell types or pathologies of diseases 
such as cancer and atherosclerosis (Balducci et al., 2013, Kislukhin et al., 2016, Lanza et al., 2010). 
They have also been developed as targeted imaging tools using metallic MRI contrast agents. For 
example, ScFv-functionalised NEs loaded with iron oxide particles have been used to image 
atherosclerosis (Prévot et al., 2017). Theranostic NEs with folate-targeting have been developed to 
deliver docetaxel to ovarian cancer cells (Ganta et al., 2015). The surface of these NEs was 
functionalised with gadolinium as an imaging agent, and their diagnostic efficiencies were compared 
favourably to a clinically-relevant MRI contrast agent, Magnevist® (Ganta et al., 2015), This showed 
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that the NEs formulation was less toxic than cisplatin in the treatment of ovarian cancer model in 
mice. 
 
NEs have also been used as platforms for fluorescence-based imaging. Vascular inflammation was 
targeted, treated and visualised using a P-selectin-targeted NE loaded with dexamethasone to treat 
inflammation, and rhodamine as a molecular imaging agent (Simion et al., 2016). This approach has 
also been used for the simultaneous monitoring and treatment of inflammation by celecoxib delivery 
(Patel et al., 2015), and for cancer theragnosis by paclitaxel delivery (Yang et al., 2014). Furthermore, 
careful NE design has allowed the combination of imaging modalities within a single particle, for 
example, integrin-targeted paramagnetic and fluorescent NEs designed to target human umbilical 
vein endothelial cells (HUVEC) cells (Hak et al., 2012). 
2.5.7 Emulsions for vaccine applications 
Historically, emulsions have been used as effective adjuvants for vaccine formulations in both human 
and animals (Table 2.3). Paraffin W/O emulsions including inactivated mycobacterial cells is known 
as Freund’s complete adjuvant (FCA) and a non-bacterial form of these emulsions, Freund’s adjuvant 
(FIA), have been used as immunopotentiators in animals (Hilleman, 1966) and human vaccines (Salk 
et al., 1951, Edelman, 1980). However, the w/o formulation is generally reactogenic due to the 
presence of high content of oil (Allison and Byars, 1986). W/O emulsions have also been applied as 
adjuvants for human immunodeficiency virus and malaria, but they also showed undesired local 
reactions (Aucouturier et al., 2002).  In the 1980s, Syntax Adjuvant Formulation (SAF), was used as 
the first squalane O/W emulsion with an antigen (Allison, 1999). As a less toxic replacement for 
mineral oils, SAF is also able to induce a robust cell-mediated response (Lidgate and Byars, 1995), 
however, SAF is associated with muramyl dipeptide (MPL) analogue and discontinued because it had 
evoked reactogenicity (Allison, 1999) as well as muscular irritation (Lidgate and Byars, 1995). 
Squalene/squalane emulsions are considered non-toxic adjuvants of growing interest (Allison, 1999). 
One of the most widely used squalane emulsion adjuvants is the MF59®, which shows higher potency 
in triggering the cell-mediate immune response when it is compared to aluminum-based adjuvants. 
MF59 was first licensed as Fluad® in 1997 and is currently approved in US, Canada and various 
European countries for human use. It is an O/W emulsion that is prepared with 5% v/v squalene in 
citrate buffer (Ott et al., 1995, O’Hagan and Podda, 2008). MF59 is considered safe and contributes 
to a potent trivalent (2 subtype A and one B) vaccine against influenza mainly for over 65 years-old 
patients (O’Hagan and Podda, 2008).  
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Squalene emulsions and those of its hydrogenated form, squalane, have also been developed as 
immunotherapeutic and immunostimulant adjuvant. The DETOX® formulation is composed of a 
bacterial cell wall and monophosphoryl lipid A (MPL) dissolved in squalane and Tween 8 (Baldridge 
and Ward, 1997). It showed potent adjuvanting activity against melanoma cell lines as a cancer 
immunotherapy, however, reactogenicity and granulomas have also been observed at the injection 
site (Ott and Van Nest, 2007). Despite that, DETOX® was licensed for the treatment of melanoma as 
Melacine®.  
Other examples of squalene-based emulsions as adjuvants include the Ribi adjuvant system (RAS) 
(Table 2.4) (Gomez et al., 1998) and the so-called stable emulsion (SE) (Leesman, 2003). The 
addition of MPL to SE resulted in a potent vaccine adjuvant for the prevention of leishmaniasis (Reed 
et al., 2009). Other prominent examples are the SB62 and its two-fold diluted form, AS03. AS03 was 
approved as a constituent of prepandrix®, the pandemic flu vaccine (Reed et al., 2009). AS03 was 
also a component of other vaccines including the Arepanrix® for the prevention of influenza caused 
by H1N1, and H5N1 pre-pandemic vaccines. AS02 is formulated by adding immune-stimulatory 
agents such as MPL and triterpenoid saponin molecules (QS21) to AS03 (Fox, 2009) and has been 
tested as an effective adjuvant for vaccines against malaria (Cohen and Druilhe, 2002), HIV, hepatitis 
B and tuberculosis (Reed et al., 2009). However, the development of AS02 vaccines was discontinued 
due to the presence of undesirable reactogenicity at the injection site (Table 2.3) (Roestenberg et al., 
2008, Garçon and Di Pasquale, 2017). Using emulsions as adjuvant systems are of growing interest 
for various prophylactic and therapeutic vaccines. Balancing the immunogenic benefits with the 
safety profile of any formulation is a major concern in vaccine development. Selecting the right 
antigen or adjuvant and the emulsion composition directly affects the benefit-risk scale. Therefore, 
rational selection of the oil composition, the adjuvants, surfactants, particles size for a particular 
disease could provide more efficient vaccines against pandemic diseases such as influenza.  
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Table 2.3. List squalene O/W emulsions as vaccine adjuvants. 
  
Adjuvant name  Application (disease) References 
MF59® 
(Novartis) 
 Influenza 
(Ott et al., 1995, 
O’Hagan and 
Podda, 2008, 
Mosca et al., 
2008, Pellegrini 
et al., 2009)  
AS03 
(GSK) 
 
H5N1 (pre-pandemic) and H1N1 (pandemic) 
influenza 
(Fox, 2009, 
Garçon et al., 
2012, Schwarz et 
al., 2009) 
AS02 
(GSK) 
 Malaria, HIV and tuberculosis (discontinued) 
(Roestenberg et 
al., 2008, Garçon 
and Di Pasquale, 
2017) 
MPL® SE ( Monophosphoryl lipid A-Stable 
emulsion) 
(Infectious Disease Research Institute, IDRI) 
 Leishmaniasis 
 (Leesman, 2003, 
Fox et al., 2008) 
AF03 
(Sanofi) 
 Pandemic H1N1 influenza 
 (Klucker et al., 
2012) 
DETOX® (MPL in squalane)  
(Corixa corporation) 
 Melanoma (Melacine®) 
(Sosman and 
Sondak, 2003) 
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Table 2.4. Examples of squalene O/W emulsion under investigation 
Adjuvant name Application (disease) References 
Thermo-reversible O/W emulsions (E6020 in 
AF03) 
Immunostimulants 
(Klucker et al., 
2007, Haensler et 
al., 2015) 
RAS 
(Synthetic trehalose dicorynomycolate, 
bacterial cell wall skeleton, and MPL) 
Immunostimulants (Sigma-Aldrich) for 
research 
(Gomez et al., 1998, 
Sjolander et al., 
1996) 
ESA 
Abil®-Care (polysiloxan polymer 
dimethicone copolyol) 
Veterinary vaccine 
(Suli et al., 2004, 
Benı́šek et al., 
2004) 
Baldridge (Monophosphoryl lipid A) Immunostimulants 
(Baldridge and 
Crane, 1999) 
Hjorth1 and Hjorth2 Veterinary vaccine (Allison, 1999) 
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2.6 The future of nanoemulsions in nanomedicine through top-down assembly  
Nanosized formulations can be fabricated using bottom-up, top-down or both approaches 
(McClements, 2015). Bottom-up assembly is characteristic of most approaches to add functionality 
to NE interfaces, where functional moieties are covalently linked to one or more emulsifiers. 
However, this restricts the tuneability of NE interfaces due to the need to maintain compatibility with 
stable emulsification (Sainsbury et al., 2014). In contrast, top-down approaches to modifying NEs 
has traditionally relied on the rather unspecific adsorption of functional layers by electrostatic 
deposition. While this approach separates functionality from the need to impart stability during 
emulsification, it does not result in controlled deposition or the rational presentation of functional 
groups (Sainsbury et al., 2014). Recently, a novel peptide-stabilised NE system has been developed 
that decouples emulsification from controlled surface modification. Characterised by the spontaneous 
and step-wise addition of functional moieties linked to a designer protein biosurfactant (Zeng et al., 
2013), this platform allows the rational generation of sophisticated interfaces (Tayeb et al., 2017). 
Such interfaces will provide valuable insight into the interaction of NEs with their environment, and 
will aid in the functional design of NEs tailored to specific applications and routes of administration. 
2.7 Conclusion and future directions 
The continued progress in NE development shows great promise in nanomedicine and is expected to 
attract greater attention as a versatile platform for drug delivery, molecular imaging and vaccine 
formulation. Oral delivery was the inspiration for the development of therapeutic emulsions, however, 
they were first clinically applied as injectable formulations. NE have enjoyed most success as vehicles 
for delivery of APIs to various epithelial or mucosal surfaces. With the use of clinically approved 
ingredients and the success of injectable formulations such as vaccine adjuvants, the potential of NEs 
to improve solubility, bioavailability and pharmacokinetics of hydrophobic compounds they have a 
bright future in IV applications. In addition, NE formulations can improve the therapeutic efficacy of 
APIs via alternative routes of administration in many situations, as highlighted in this review. 
Amenable to the incorporation of multiple functionalities, either loaded in the oil core or presented 
on the surface, they have also demonstrated great potential in molecular imaging and theranostics. 
The further development of NE technologies will require a deep understanding of the relationship 
between NE formulation science and the various physical, chemical and physiological challenges 
associated with various pathologies and routes of administration. To facilitate the translation of 
candidate NEs from research laboratories to the pharmaceutical market, numerous considerations 
must be met. These include careful selection of components, including the oil phase and emulsifiers 
with regards to safety concerns including hypersensitivity (Galho et al., 2016, Khandavilli and 
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Panchagnula, 2007). Therefore, formulating NEs with biocompatible surfactants and FDA-approved 
excipients is a pre-requisite for any future pharmaceutical application. In addition, formulation 
challenges including ease of synthesis at large scale, storage and stability must be addressed with the 
application in mind. The continued research on approaches to create ever more sophisticated NEs 
with controlled interfacial structure will lead to increasing opportunity for clinical translation of NEs 
for a wide range of indications. 
2.8 Acknowledgment 
H.H.T. acknowledges the financial support (Scholarship) from King Abdul Aziz University, Ministry 
of Higher Education, Saudi Arabia. The preparation of this manuscript did not involve any writing 
assistance.  
 
  
70 
 
3 Chapter 3: Exploring the Use of Nanocarrier Emulsions in Drug Delivery 
3.1 Introduction 
Nanoscience in medical research focuses on the potential role of drug nanocarriers to improve the 
therapeutic outcomes of hydrophobic drugs. The application of nanotechnology that involves 
multidisciplinary sciences including physics, chemistry and biology in medicine is known as 
nanomedicine (Webster, 2006). According to the European Science Foundation, nanomedicine aims 
at “ensuring the comprehensive monitoring, control, construction, repair, defence and improvement 
of all human biological systems, working from the molecular level using engineered devices and 
nanostructures, ultimately to achieve medical benefit.”(Anderson, 2005).   
Nanocarriers, such as liposomes, have evolved as successful vehicles for solubilising hydrophobic 
drugs whilst also prolonging their circulation time and accumulation at target sites due to the EPR 
effect (Torchilin, 2005, Northfelt et al., 1998, Safra et al., 2000). Doxil® was the first successful 
liposomal formulation approved by FDA for the treatment of Kaposi’s sarcoma (Barenholz, 2012a). 
Nanocarriers have also been applied to a broad range of diseases including fungal infections, multiple 
sclerosis and late-stage renal conditions (Zhang et al., 2008). Most of these applications have led to 
improvements in patient safety and have possibly contributed to lower morbidity rates (Gradishar et 
al., 2005), however these improvements are still considered minor when compared to the benefits of 
traditional formulations (O'Brien et al., 2004).  
Nanocarriers face many biological barriers including opsonisation, phagocytosis (Gustafson et al., 
2015) and off-target delivery (Wilhelm et al., 2016) that limits optimum bioavailability and 
functionality. The complexity of these barriers varies with different routes of administration (IV, oral, 
skin, etc.), disease type (cancer, infections) and condition (stage of disease) (Blanco et al., 2015). 
Nanocarriers designed with targeting (Wang and Thanou, 2010, Lammers et al., 2016), stimuli-
responsive (Lopes et al., 2013) or controlled release functionalities (Mura et al., 2013) fail to 
overcome most of these barriers resulting in minimal therapeutic impact. The clinical translation of 
nanocarriers could be improved by addressing and overcoming these biological barriers through the 
rational and informed design of a particular drug delivery system (Blanco et al., 2015).  
Nanocarriers offer a variety of possible advantages when compared to free drugs such as drug 
protection, enhanced drug solubility and cellular targeting (De Jong and Borm, 2008). However, 
ensuring biocompatibility in their design is probably going to be the key to transforming nanocarriers 
into nanomedicine platforms (Farokhzad and Langer, 2009). Well-defined characteristics, simple 
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surface functionalisation, specific cellular uptake, aqueous solubility and colloidal stability are other 
important considerations in the design of effective nanocarriers. Developing sophisticated nanocarrier 
design is challenging and may not be compatible with a specific route of administration and disease. 
This design challenge may be addressed through the development of nanocarrier screening techniques 
for specific applications or by exploring different routes of administration (Peer et al., 2007).  
The aim of this chapter is to explore TNEs as a carrier of lipophilic compounds via topical (skin) and 
IV routes to elucidate the possible biological challenges that might be faced during topical and IV 
administration. A lipophilic fluorescent dye, DiI (Li et al., 2008) was used as a model drug to evaluate 
the properties of TNEs including the capacity of cargo retention and physical and colloidal stability. 
Encapsulation of DiI within the oil core (miglyol 812), which is a material generally recognised as 
safe (GRAS) by FDA, was investigated after varying the density of PEGylated DAMP4 integrated 
on the interface of AM1-stabilised TNEs. DAMP4 (Middelberg and Dimitrijev-Dwyer, 2011), was 
chemically-conjugated to PEG and integrated onto the TNE interface to impart colloidal and 
functional stability.  
TNEs were assembled in a bottom-up fashion via the top-down sequential addition of reagents. The 
bottom-up approach starts with the individual components leading to the formulation of TNEs. These 
components include the surfactant (AM1), coordinated metal ions, and the oil and water phases. In 
contrast, the top-down modification comprises the sequential addition of functional moieties, such as 
PEG, bioconjugated to DAMP4, which promotes self-assembly at the oil-water interface.  Varying 
the PEG density onto the TNE interface using spontaneous integration of DAMP4 facilitated control 
over TNE surface properties like surface charge. This surface optimisation enabled TNEs to be 
combined with a EMPs (Raphael et al., 2013) technology via electrostatic interactions subsequently 
translating TNEs into a promising drug delivery system for topical applications. The EMPs facilitated 
physical targeting, allowed penetration through the dermal-epidermal junction and maximised the 
bioavailability of payloads into the epidermis (Raphael et al., 2014). The coating efficiency of EMPs 
with TNEs was also studied with respect to the density of the PEG layer, electrostatic interactions 
and the method of coating. To investigate the release profile in vivo, a human-safe dye, 6-
carboxyfluorescein (CFC), was loaded into the TNE oil core before being applied to human skin. 
To explore TNEs in IV applications, a DAMP4-single chain variable fragment (scFv) fusion protein 
was genetically engineered and expressed in mammalian cells to impart surface targeting 
functionalities. Receptor and cell-based studies evaluated the potential use of emulsions in parenteral 
drug delivery systems encapsulating DiI as a model drug. As a pilot study to test the feasibility of in 
vivo targeting, scFv-functionalised and DiI-labelled TNEs were administered intravenously in a 
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breast cancer animal model. Rapid clearance of TNEs prompted an investigation of biodistribution 
through the analysis of urine, serum and cytokines immediately post-injection and at short time 
intervals thereafter. These studies provided important information regarding biocompatibility and 
safety, targeting and the possibility of using TNEs as an IV formulation. This information directed 
further studies towards understanding the fundamentals of the TNE interface that impact the structure-
function relationship of TNEs. These studies are discussed in chapter 4. 
3.2 Experimental section 
3.2.1 DAMP4 expression, purification and quantification 
DAMP4, a protein biosurfactant, sequence (MD(PSMKQLADSLHQLARQ VSRLEHAD)4) was 
expressed in E-coli, and purified as previously published (Middelberg and Dimitrijev-Dwyer, 2011). 
DAMP4 purified using chromatography in three steps; immobilised metal affinity chromatography 
harnessing the presence of eight histidine molecules, ion exchange chromatography taking advantage 
of the neutral charge of DAMP4 at pH 7.0 and reversed phase (RP) HPLC. These combined 
techniques were sufficient for the removal of endotoxins from the expressed protein samples. 
Endotoxin levels of DAMP4 were evaluated using the LAL-based endosafe PTS™ (www.criver.com). 
The collected RP-HPLC fractions of DAMP4 were lyophilised, quantified using analytical HPLC and 
stored at ˗ 80°C.   
3.2.2 Preparation of tailorable nanocarrier emulsions 
The custom synthesis of AM1 (Ac-MKQLADSLHQLARQVSRLEHA-CONH2) peptide, with a 
molar mass of 2473 Da and ≥ 95% purity, was performed by Genscript (www.genscript.com). 
Lyophilised AM1 was dissolved using 25 mM 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) containing 800 µM ZnCl2, to a final concentration of 400 µM. DiI, 1,1′-dioctadecyl-3,3,3′3′-
tetramethylindocarbocyanine perchlorate (www.thermofisher.com), stock was prepared by 
dissolving DiI powder in 100% ethanol at a final concentration of 10 mg/ml. This stock was diluted 
in Miglyol 812, the oil core of TNEs (AXO Industry SA, www.axoindustry.com) to a final 
concentration of 1 mg/ml. Miglyol 812, also known as caprylic/capric triglyceride, is a neutral and 
clear medium chain triglyceride excipient. Miglyol 812 is a derivative of saturated coconut oil and 
comprises 6 to 12 carbon (C) chain fatty acids (Sellers et al., 2005). Miglyol 812 is composed of 50-
65% caprylic acid (C8) and 30-45% capric acid (C10) (Cremer, March 2013). DiI-labelled Miglyol 
812 was added to the AM1 solution to a final oil composition of 2% v/v. This mixture was sonicated 
in an Eppendrof tube by the Branson Sonifier 450 Ultrasonicator (www.emersonindustrial.com) using 
four 45 s bursts. Emulsions with a polydispersity index 0.2 or below were accepted for subsequent 
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surface modification. PEGylated DAMP4 products were integrated drop-by-drop onto the AM1-
stabilised emulsions (P0) with vigorous stirring at a 1:1 volumetric ratio. To prepare TNEs with 
different DAMP4-PEG densities, a one-step of addition of different concentrations of PEGylated 
DAMP4 to P0 was performed and included 2 µM (P1), 4 µM (P2), 10 µM (P5), 20 µM (P10), 40 µM 
(P20) and 400 µM (P200).  
3.2.3 Preparation of targeted and un-targeted TNEs 
To prepare untargeted TNEs, 40 µM PEG-DAMP4 was used as an initial addition to the AM1-
stabilised emulsions to obtain the P20-TNEs. Subsequent addition of PEGylated DAMP4 (400 µM) 
to the P20-TNEs formulated the P200-P20-TNEs (untargeted). Targeted TNEs, prepared by 
sequential addition using the same technique, were made by mixing 40 µM PEG-DAMP4 with P0 
emulsions, followed by 2 µM scFv-DAMP4 fusion and 400 µM. PEG-DAMP4. Size measurements 
with associated polydispersity indices and ζ-potentials were measured using a Malvern Zetasizer 
Nano ZS (www.malvern.com). All samples were diluted to 1:100 in Milli-Q water with ζ-potential 
measurements made using an electrophoretic cell (www.malvern.com). 
3.2.4 Cargo retention within the TNE oil core 
Cargo retention within the TNEs was assessed after surface modifications were made to the TNE 
interface by integrating various concentrations of PEGylated DAMP4 to AM-TNEs. A standard curve 
was established, using two-fold serial dilutions of DiI-labelled P20-TNEs (0.25 µg/ml DiI 
concentration), to estimate the difference between the fluorescence of DiI in hydrophilic (H2O) and 
hydrophobic (miglyol 812) media. Fluorescence was measured at excitation and emission 
wavelengths 535 and 570 nm respectively using the infinite® M200 Pro plate reader 
(www.thermofisher.com). Retention of DiI was evaluated by measuring the decrease in fluorescence 
from the TNE oil core. Cargo retention was investigated in the P0, P1, P2, P5, P10, P20 and P200 
TNEs. Measurements were performed in triplicate for 13 days in water. Size of the same TNEs was 
also measured in a Malvern Zetasizer Nano ZS (www.malvern.com) using a 1:100 final dilution in 
milli-Q water. Size measurements were collected within 24 hours and at the final point of cargo 
retention at 13 days. 
3.2.5 Stability of TNEs in different storage conditions  
P0, P20, P50, P100 and P200 TNEs, prepared using the method detailed in section (3.2.2), were stored 
for one week at 4 different temperatures including 25 °C (room temperature), 4 °C (fridge), -20 °C 
(freezer) and -80 °C (freezer). The stored TNEs were diluted 1:100 in milli-Q water before dynamic 
light scattering (Malvern Zetasizer Nano ZS) was used to investigate TNE size. 
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3.2.6 Coating efficiency of EMPs by TNEs  
P20 and P200 DiI-encapsulated TNEs were prepared as described in section 1.2.1. The hydrodynamic 
radius of the TNEs was determined using dynamic light scattering (Malvern Zetasizer Nano ZS). 50 
µl of each P20 and P200 DiI-loaded TNEs was added to 25 mg powdered EMPs. Four different 
methods were used to coat EMPs with TNEs including wet coating (W), freeze-dry coating (F), 
alginate cross-linking plus freeze-dry coating (AF), and alginate cross-linking (A). Wet coating was 
conducted by adding EMPs to the TNE formulation for 4-5 hours. Freeze-dry coating was performed 
by vigorously vortexing TNEs with EMPs in an Eppendorf tube with the resulting suspension 
incubated for 24 hours at 4 °C. Excess supernatant was removed before freeze-drying was performed 
under a vacuum at -80 °C for 4-5 hours. TNEs were also added to alginate coated-EMPs, that were 
generously supplied by Miko Yamada, either with (AF) or without freeze drying (A). Average size 
of the DiI-encapsulated P20 and P200 TNEs was collected before coating the EMPs and following 
each coating method. The coating efficiency of each method was estimated by comparing the 
percentage of coated TNEs with the percentage of uncoated TNEs (supernatant) following 
resuspension of the TNEs-EMPs mixture in milli-Q water. 
3.2.7 Release profile of 6-carboxyfluorescein (CFC)-encapsulated TNEs 
The release profile of CFC-loaded P20 TNEs (25 µg/ml dye concentration) was measured in Costar® 
96-well black polystyrene plates using the Infinite® M200 Pro plate reader (www.thermofisher.com) 
following the release of CFC from the TNEs oil core through dialysis membranes. Fluorescence of 
the released CFC was measured using excitation and emissions wavelengths of 492 and 530 nm 
respectively. Samples of the dye molecules released into the hydrophilic medium were collected at 
the following time points; 0, 6, 18, 24, 48 and 72 hours. 
3.2.8 Expression and purification of DAMP4-antibody fusions 
A synthetic gene encoding a scFv, based on an immunoglobulin light chain signal peptide, was fused 
to DAMP4 via a Gly4Ser linker and codon optimised for expression in chinese hamster ovary (CHO) 
cells. The gene was transferred into the pcDNA 3.1 (+) mammalian expression plasmid 
(www.thermofisher.com) for transient expression before 2 µg DNA/mL was transfected into 3x106 
cells/ml. DNA was complexed with polyethylenimine-Pro (www.polyplus-transfection.com) in Opti-
Pro serum-free medium (www.thermofisher.com) using a DNA (µg) to PEI (µl) ratio of 1:4 for 15 
minutes prior to transfecting suspension-adapted CHO cells. The transfected cells were cultured in 
chemically defined CHO medium (CDCHO; www.thermofisher.com) at 37 °C, 7.5% CO2, 70% 
humidity with shaking at 130 rpm for 6 hours, before feeding with 7.5% CD CHO Efficient Feed A 
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(www.thermofisher.com), 7.5% CD-CHO Efficient Feed B (www.thermofisher.com) and 0.4% anti-
clumping agent (www.thermofisher.com). The viability of the cells was evaluated by trypan blue 
staining from day 7 with cell culturing stopped when viability ≤ 50%. 
After transfection, the cells were pelleted by centrifugation and the supernatant was filtered through 
a 0.22 µm membrane (www.sartorius.com). The scFv-DAMP4 was purified from the supernatant 
utilising a 5 ml Protein-L column (www.gehealthcare.com.au) and eluted from the column using 100 
mM glycine pH 3.0. Elution fractions were buffer exchanged into phosphate buffered saline (PBS) 
pH 7.4 using the HiPrep 26/10 column (www.gehealthcare.com.au). The final product was filtered 
through a 0.22 µm membrane before concentration was determined by measuring absorbance at 280 
nm. The fusion was further analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE) and size exclusion high-performance liquid chromatography (SEC-HPLC) using a TSK 
gel G3000SW column (www.tosoh.com). The respiratory syncytial virus (RSV1)-DAMP4 fusion 
was synthesised using a gene encoding RSV antibody that was fused to DAMP4. The expression and 
purification protocol of the RSV-DAMP4 fusion is similar to that used for the scFv fusion.  
3.2.9 Epidermal growth factor receptor (EGFR) binding plate assays  
Enzyme-Linked immunosorbent assays (ELISA) were performed for DAMP4-RSV1 and scFv-
DAMP4 fusion proteins. Maxisorp plate wells were coated overnight with 100 μl 1 μg/ml antigen 
(EGFR-hfc). EGFR-fc was expressed in CHO cells and purified using protein A. After coating, the 
solution was decanted and the EGFR-hfc-coated wells were blocked with 2% (w/v) non-fat dry milk 
solution in PBST (PBS, 0.05 v/v % tween 20) for 1 hour. Blocking solution was decanted and each 
DAMP4 fusion (DAMP4-RSV1 and scFv-DAMP4) was diluted in PBS and added to the wells at 20 
μg/ml for 2 hours at room temperature. Incubated wells were washed three times with 200 μl PBST 
before Anti-His-Horseradish Peroxidase (http://www.miltenyibiotec.com), diluted 1/2000, was added 
and incubated for 1 hour. Three washes with 200 μl PBST were performed before 100 μl 3,3′,5,5′-
tetramethylbenzidine liquid substrate (https://www.sigmaaldrich.com) was added and incubated for 
5-15 minutes to facilitate colour development. 100 μl 2 M sulphuric acid was added to stop the 
reaction before absorbance was measured at 450 nm using a SpectraMax-M4 plate reader. 
3.2.10 Solid state EGFR binding assay 
Targeted and untargeted TNEs were prepared using sequential addition as per section 3.2.3. Firstly, 
40 µM PEG-DAMP4 was integrated onto AM1-stabilised emulsions before 2 µM scFv-DAMP4 
fusion was added to the P20-TNEs. Lastly, 400 µM PEG-DAMP4 was applied following the addition 
of the scFv-DAMP4 fusion. Untargeted TNEs were also formulated with the same technique, 
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however the second addition was RSV-DAMP4 rather than scFv-DAMP4. The human EGFR, diluted 
in PBS to a final concentration of 5 µg/mL (www.sinobiological.com), was immobilised onto 96-well 
black polystyrene plates (www.corning.com) at room temperature for 4 hours. The immobilised 
EGFR was blocked using 2% (w/v) non-fat dry milk powder in PBS for 1 hour. TNE formulations 
were diluted to 0.05% oil, and incubated for 30 minutes at room temperature. Two PBS washes, 
containing 0.05% Tween-20 were used to remove unbound TNEs. A final PBS wash was used before 
adding PBS to the wells and measuring fluorescence in the infinite® M200 Pro plate reader 
(www.thermofisher.com) using emission and excitation wavelengths of 535 and 570 nm, 
respectively.  
3.2.11 Flow cytometry 
Targeted and un-targeted TNEs, prepared as per section 3.2.3, were diluted to a final oil concentration 
of 0.03125%. Prepared TNEs were incubated for 1 hour at 4 °C with the MDA-MB-468 (breast cancer 
cell line, generously supplied by Dr Christopher Howard) cell suspensions (1.5 x 106 cells/ml) in PBS 
containing 10% foetal calf serum (FCS) at 1:1 ratio for binding. Three wash steps were conducted to 
remove weakly bound TNEs. Flow cytometry measurements were set to 20000 events using BD 
Accuri C6 Flow Cytometer System (BD Biosciences). Cell gating and a full analysis were performed 
using Flowing software v2.5.1. Overnight dialysed and un-dialysed, targeted and un-targeted TNEs 
were compared for binding to MDA-MB-468 cell suspensions (1.5 x 106 cells/ml) in PBS containing 
10% FCS at a 1:1 ratio. 
3.2.12 In vivo targeting and biodistribution studies  
The targeting and biodistribution studies were performed in compliance with the Australian National 
Health and Medical Research Council guidelines for the care and use of laboratory animals, and with 
the approval of the EnGeneIC Animal Ethics Committee under ethics application number: 
AIBN/400/13/ARC/NHMRC.  
For the targeting study, 7 female Balb/C athymic nude mice 6 weeks of age were obtained from the 
Laboratory of Animal Services at the University of Adelaide, South Australia. 100 µl (4 x 107 
cells/ml) of MDA-MB-468 cells in serum-free RPMI were injected in the mammary pad of 6 female 
Balb/C athymic nude mice. The mice were divided into three groups as follows: 3 mice were treated 
with targeted TNEs (200 µl, 0.25% oil); 3 mice were treated with un-targeted TNEs (200 µl, 0.25% 
oil); and one control mouse was not injected. The TNEs were injected when the tumour mass reached 
4 mm2. Molecular imaging of the mice was taken at 5 and 24 hours post-injection of TNEs using 
Carestream (www.carestream.com) and In-Vivo Xtreme (www.bruker.com).  
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For the biodistribution study, 12 female Balb/C athymic nude mice 6 weeks of age were obtained 
from the Laboratory of Animal Services at the University of Adelaide, South Australia. The mice 
were divided into two groups as follows: 10 mice were treated with un-targeted TNEs (200 µl, 1% 
oil); and two control mice were not injected. Molecular imaging of the mice was performed using 
Carestream (www.carestream.com) and In-Vivo Xtreme (www.bruker.com). 
3.2.12.1 Ex vivo biodistribution and cytokine analysis of TNEs  
Ex vivo analysis of TNEs was performed using two mice at each time point (30, 60, 90 and 120 
minutes and 24 hours). The analysis included body organs (liver, kidney, heart, gut and lung), blood 
and urine. Blood samples were collected through cardiac puncture with serum isolated via 
centrifugation. Blood and urine samples were evaluated for the presence of DiI-loaded untargeted 
TNEs using the infinite® M200 Pro plate reader (www.thermofisher.com) 
(www.lifesciences.tecan.com) at emission and excitation wavelengths of 535 and 570 nm, 
respectively.  
Cytokines were analysed by Sullivan Nicolaides Pathology using the Milliplex assay 
(www.merckmillipore.com) with kit number; MPMCYTOMAG-70K-06 (Mouse 
Cytokine/Chemokine Panel, 6-plex (IL2, IL-4, IL-6, IL-10, IFN-gamma and TNF-alpha). Cytokines 
were measured in blood samples collected from two mice at each time point (30, 60, 90 and 120 
minutes and 24 hours). The control samples were collected after 4 and 24 hours using subcutaneous 
injections of OVA albumin-TNEs (Zeng et al., 2013). 
3.2.13 DiI retention in simulated plasma fluid  
DiI-labelled TNEs (P0, P5, P10, P20 and P200), prepared as per section 3.2.3, were evaluated for dye 
retention over time in a simulated body fluid (Marques et al., 2011). The ionic concentration of the 
simulated body fluid composition was as follows: 4.2 mM HCO3-, 5 mM K+, 148.8 mM Cl-, 142 mM 
Na+, 2.5 mM Ca+2, 1.5 mM Mg+2, 1 mM HPO4-2, 0.5 mM SO4-2, 50 mM tris(hydroxymethyl) 
aminomethane and 45 mM hydrochloric acid. 
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3.3 Results  
TNEs are O/W emulsions stabilised by the peptide surfactant AM1 (Malcolm et al., 2006) and 
incorporating the protein DAMP4 that is used to tune the interface and allow the addition of various 
functionalities to the system. PEGylation is one of the most common techniques used to provide 
proteins and NPs with stability (Roberts et al., 2002, Ikeda and Nagasaki, 2012). Chemical 
conjugation between DAMP4 and an NHS ester-labelled 5 kDa PEG, allowed PEG presentation onto 
the TNE interface to impart colloidal stability and allow investigations into surface properties. 
3.3.1 Surface properties and cargo retention of the tailorable nanocarrier emulsions  
Controlling the surface charge of nanomaterials is an important element of drug delivery. In this 
study, the surface charge of TNEs was controlled by the integration of different PEG densities onto 
the TNE interface. DiI-labelled AM1, P20 and P200 TNEs were utilised to determine the effect of 
different PEG densities on surface charge. AM1 (P0), P20 and P200 TNEs were formulated with 
average sizes of 173.9 ± 2.4, 175.1 ± 1.7 and 179.2 ± 4.2 nm respectively. Increasing DAMP4-PEG 
density on AM1-TNEs reduced their surface charge from 52.5 ± 1.1 to 47.3 ± 1.5 mV for P20, and 
from 52.5 ± 1.1 to 38.6 ± 1.2 mV for P200 TNEs (Figure 3.1). These results reveal an inversely 
proportional relationship between PEG surface density and the charge of TNEs. Varying PEG 
densities on the TNE interface also allowed an investigation into the in vitro release of a model-drug, 
DiI – a lipophilic carbocyanine dye.  
To investigate the capacity of TNEs to retain cargo over time (13 days), DiI was encapsulated within 
the oil core (Miglyol812) of AM1, P20 and P200 TNEs. DiI has been widely applied to label cell 
membranes (Schlessinger et al., 1977, Struck and Pagano, 1980) and is only weakly fluorescent in 
aqueous solutions. Dilution curves of DiI in miglyol and water showed that DiI in water was more 
than 250 times less fluorescent than DiI in oil (Figure 3.2A). Therefore, cargo retention was evaluated 
by dispersing the TNEs in an aqueous buffer solution to enable any decline in the fluorescence to be 
observed and indicate leakage of DiI from the TNEs over time (Figure 3.2B). The results showed that 
P20 and P200 TNEs retained about 99% of their cargo for five days. However, naked AM1 emulsions 
showed a 10% release of DiI into the medium after only one hour, and an almost 80% loss of cargo 
from the oil core into the aqueous medium after 48 hours. Thus, even the low ratio of DAMP4-PEG 
on the TNE interface (P20 TNEs) enabled cargo retention for at least 120 hours, showing a remarkable 
difference from the unmodified TNEs (Figure 3.2B).  
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Figure 3.1. Size and charge characterisation of TNEs prepared with different PEG densities. It 
demonstrates the Z-average size and ζ-potential of AM1, P20 and P200 TNEs. The results are 
shown as average of triplicates (± standard deviation).    
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Figure 3.2. Effect of PEG density on the DiI retention profile of TNEs. (A) Shows the 
difference in DiI fluorescence between the hydrophilic and hydrophobic media (for measuring 
the percentage of dye retained within the oil core). (B) Shows the percentage of DiI retained 
within the oil core of the AM1, P20 and P200 TNEs, the results are shown as an average of 
triplicates (+ standard deviation). 
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These results suggested that by investigating the effect of changing the PEG densities on TNEs, the 
minimum amount of DAMP4-PEG required to maintain the physical stability of TNEs and cargo 
retention could be determined. Therefore, the cargo retention of lower DAMP4-PEG densities (P0, 
P1, P2, P5, P10, P20 and P200 TNEs) were analysed over 13 days. Results revealed that the amount 
of cargo retained over time increased with an increase in PEG densities on the TNE interface. For 
example, the P2 TNEs showed greatly improved cargo retention when compared to the P0 TNEs. 
Moreover, the P10, P20 and P200 TNEs retained over 90% of the encapsulated cargo for 13 days 
(Figure 3.3A).  
The hydrodynamic size measurements at the first and last day of DiI-labelled TNEs have also 
reflected the effect of PEG density on stability and dye retention with the higher PEG densities 
producing more stable TNE droplets with better in vitro release profiles. For example, P0 and P1 
emulsions showed an increase in size from approximately 170 nm to over 1000 nm. The observed 
size increase (instability) may account for the relatively high dye release from these TNEs over the 
first few hours. In contrast, P20 and P200 TNEs have retained their hydrodynamic stability over time 
(Figure 3.3B). Varying PEG density also affected the stability of TNEs under different storage 
conditions. TNEs with different PEG densities were stable at room temperature and 4 °C. In contrast, 
only P200 TNEs were stable at all freezing conditions, while P100 TNE were stable only at -80 °C. 
(Figure 3.4). TNEs with lower PEG densities (P0, P5 and P50) were unstable at -20 °C and -80 °C. 
This is probably due to  the fact that storage conditions below 0 °C  result in the formation of fat 
crystals within the oil phase, which reduce the stability of O/W emulsions (van Boekel and Walstra, 
1981). These fat crystals protrude into the aqueous phase penetrating the film between adjacent oil 
droplets and causing partial coalescence (Harada and Yokomizo, 2000, Vanapalli et al., 2002, 
McClements, 2004). The slow freezing (-20 °) condition produces large fat crystals when compared 
to fast-cooling (-80 °) that results in smaller crystals formation. Consequently, the slow cooling 
process led to lower stability of TNEs at even high PEG densities (P100 TNEs). Therefore, tuning 
the integration of DAMP4-PEG density onto the TNE interface is an important factor in TNEs 
stability and their use in drug delivery, ultimately determining their structural and functional 
properties. 
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Figure 3.3. Size characterisation and DiI retention within the oil core of TNEs prepared with 
different PEG densities over time. (A) Retention of DiI over time by different TNEs 
formulations including: P0 (red), P1 (grey), P2 (orange), P5 (purple), P10 (green), P20 (blue) 
and P200 (black) shown as average of triplicates (± standard deviation). (B) Results reveal the 
size of TNEs based on their interfacial PEG density when loaded with a lipophilic tracer, DiI. 
Size was measured using dynamic light scattering and performed in aqueous solutions. The 
results are shown as an average of triplicates (± standard deviation). 
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Figure 3.4. Size of TNEs in different storage conditions. The results show the effect of storage 
conditions, including room temperature (25ºC), 4ºC, -20ºC and -80 ºC, on TNE size (measured 
using dynamic light scattering). 
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3.3.2 Exploring the surface properties of TNEs toward topical (skin) applications  
NEs are heterogeneous systems composed of dispersed and continuous phases that can be stabilised 
using emulsifiers or surface-active molecules (Mason et al., 2006). NEs are biodegradable, easily 
produced and show good safety profiles in food (Silva et al., 2012), pharmaceuticals (Singh et al., 
2017) and cosmetics (Sonneville-Aubrun et al., 2004). They have been administered through different 
routes including parenteral (Araújo et al., 2011), ocular (Hagigit et al., 2012), nasal (Hosny and 
Banjar, 2013), oral (Beauchesne et al., 2007) and topical (skin) (Kelmann et al., 2016). These delivery 
routes were discussed in greater detail in chapters 1 and 2. The use of NEs to deliver hydrophobic 
compounds via the skin shows great potential. Topical administration is non-invasive and does not 
require highly trained medical professionals (Barry, 2004). However, topical delivery can be also 
challenging considering the different biological and physical barriers of the dermal layers (Paudel et 
al., 2010).  
Controlling the surface charge of TNEs can be useful in several applications. In collaboration with 
Professor Tarl Prow’s group in the University of Queensland’s School of Medicine, we investigated 
the possibility of exploiting the tailorable surface charge of TNEs for topical drug delivery in humans. 
DiI-loaded TNEs were used to coat the negatively charged EMPs that were recently developed to 
enhance topical delivery (Raphael et al., 2013) and show remarkable penetration into the epidermis 
and dermis layers of pig skin. DiI was used as a model drug to demonstrate that TNEs could be used 
as a carrier for hydrophobic molecules on EMPs. The efficiency of the coating was investigated using 
TNEs with different surface charges achieved by varying the PEG-DAMP4 densities.  
A variety of methods were used to coat the EMPs with TNEs including freeze-dry coating, wet 
coating, alginate cross-linking and alginate cross-linking with freeze-dry coating. Particle size 
analysis was performed to detect any change to the unbound TNEs after each coating method. The 
results showed almost no TNE size change associated with the wet and freeze dried coatings, whilst 
coating methods that involved alginate, a cross-linker, showed larger hydrodynamic radii (Figure 
3.5A). This could explain why the total fluorescence of resuspended TNE-coated EMPs decreased 
after alginate cross-linking, suggesting some TNEs might be disrupted (Figure 3.5C). However, the 
alginate-coating methods using P20 TNEs had much higher percentages of coated EMPs compared 
to wet and freeze dried coatings. Interestingly, the PEG density of TNEs had a considerable impact 
on EMP coating efficiency with P20 TNEs producing less supernatant fluorescence and indicating 
more efficient coating (Figure 3.5C). The ability of EMPs to adhere better to P20 TNEs rather than 
P200 TNEs, is possibly due to a higher surface charge associated with P20 TNEs leading to stronger 
electrostatic interactions (Figure 3.5B).  
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The successful application of P20-TNEs as a drug carrier onto EMP surfaces suggests that this 
combined drug delivery system is promising for human use. To facilitate clinical translation, the 
release profile of a clinically relevant lipophilic fluorescent dye, CFC, was investigated after being 
encapsulated within the of TNEs oil core. The encapsulation efficiency of CFC was estimated at 75% 
with 48% of the dye released from the oil core of P20-TNEs after incubation in an aqueous solution 
for 24 hours (Figure 3.6). CFC-labelled P20 TNEs coated onto EMPs were applied to frozen human 
skin as well as human subjects in collaboration with Dr Miko Yamada and Professor Tarl Prow at the 
School of Medicine in TRI. The excised human skin from abdominoplasty was obtained from the 
Greenslopes hospital, Brisbane Australia, and approved by the University of Queensland Human 
Research Ethics Committee (Ethics approval number HREC_12_QPAH217). The excised human 
skin was also sourced from Massachusetts General Hospital, Boston, USA, with protocol number 
2014P001345, and approval was provided by Harvard University Human Research Ethics committee. 
The patients involved in the study were healthy with no skin health problems, and this study was 
conducted in compliance with the National Health and Medical Research Council of Australia. The 
results show that the TNE formulation was well tolerated by the skin delivery route, and that TNEs 
have improved the delivery to the epidermis skin layer when compared to hydrophobic compounds 
alone (Miko Yamada, pers comm, 21 April 2018). These results suggest that TNEs have a promising 
future in pharmaceutical applications via the skin route.               
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Figure 3.5. Coating efficiency of EMPs by TNEs. (A) Shows the hydrodynamic radius (nm) of 
unbound TNEs released from EMPs following coating (± standard deviation). (B) Illustration of the 
electrostatic interactions between TNEs and EMPs. (C) DiI fluorescence was measured from 
resuspended TNE-coated EMPs and from the supernatant following gravitational separation of 
EMPs. The coating methods used were wet coating (W), freeze-dried coating (F), alginate cross-
linking plus freeze-dried coating (AF), and alginate cross-linking (A). Low supernatant values 
relative to total values indicate efficient coating. 
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Figure 3.6. CFC release from the oil core of P20-TNEs. The increase in fluorescence of 
released CFC is presented as an average of triplicates (± standard deviation) in percentages 
(%) over 72 hours. 
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3.3.3 Tailorable nanocarrier emulsions toward intravenous applications 
The delivery of hydrophobic drugs via the IV route is a major challenge for nanocarriers. Nanocarrier 
design should incorporate strategies that minimise phagocytosis and off-targeting (Gustafson et al., 
2015). However, it is unknown to what degree these obstacles can be overcome, considering the wide 
spectrum of complexity encountered by nanocarrier design to meet the needs of each biological 
barrier in different delivery routes (Peer et al., 2007). Only a few in vivo studies involving targeted 
nanocarriers have shown improvements in the efficacy of their encapsulated drugs (Zhang et al., 2010, 
Xu et al., 2010) and provide evidence that targeted nanocarriers may become important treatment 
regimens for various diseases (Peer, 2014). 
To investigate TNEs as a diagnostic tool and drug delivery vehicle via the IV route, experiments were 
designed to explore how TNEs can actively target cancer cells. To achieve active targeting a scFv 
antibody, specific to EGFR, was fused to the N-terminus of DAMP4 (DAMP4-VECT) via a short 
linker (Figure 3.7A). An isotype antibody against RSV was similarly linked to DAMP4 as a negative 
control (DAMP4-RSV). These experiments were performed to compare the targeting specificity of 
these DAMP4-antibody fusions to EGFR (that were measured using ELISA). The ELISA results were 
as expected for the EGFR-specific DAMP4 fusion and showed high binding specificity to EGFR, 
whereas the RSV-DAMP4 fusion only showed low non-specific binding to the receptor (Figure 3.7B).  
DiI-labelled TNEs were functionalised with 1 µM DAMP4-VECT, and RSV-DAMP4 fusions 
resulting in VECT-1 and RSV-1 TNE formulations with droplet sizes 172.4 ± 0.4 and 186.4 ± 2.8 nm 
respectively (Figure 3.9A). Both formulations were compared to control TNEs (P200 TNEs) to 
investigate their binding specificity to EGFR-coated plate wells. The results demonstrate that the anti-
EGFR labelled TNEs (VECT-1) have much higher binding specificity for the EGFR receptor 
compared to the negative controls, suggesting that DAMP4-VECT is accessible and presented on the 
TNE interface (Figure 3.7.C).  
In the next step, flow cytometry was utilised to examine the functionality of VECT-1 compared to 
P200 TNEs and TNEs displaying the isotype antibody (RSV) with respect to receptor-specific 
targeting of EGFR-expressing cancer cells (MDA-MB-468). At the optimal dilution, fluorescence 
showed that while the negative TNE controls showed some DiI signal, there was a clear positive shift 
for VECT-1 TNEs. These results demonstrated that the targeted TNEs specifically bound to the 
EGFR-expressing cells and therefore had a higher median fluorescence than the controls (Figure 
3.8A).  
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Figure 3.7. Functionalisation of peptide-stabilised TNEs with DAMP4 ScFv fusions. (A) Shows 
functionalisation of the peptide-stabilised TNEs with an anti-EGFR (DAMP4-ScFv fusion, 
VECT-1) targeting ligand to actively target MDA-MB-468 breast cancer cell lines. (B) ELISA 
results of EGFR-DAMP4, RSV-DAMP4 (an isotype antibody labelled TNEs) and PBS (control) 
shown as average of triplicates (± standard deviation) (against EGFR-immobilised plate). (C) 
Binding assay of P200, EGFR-DAMP4 and RSV-DAMP4 TNEs (0.05% oil concentration) to 
EGFR-coated plate shown as average of triplicates (± standard deviation). 
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Figure 3.8. Binding of TNEs to MDA-MB-468 cells using flow cytometry. (A) An overlay 
histogram of DiI-loaded VECT-1, RSV-1 and P200 (untargeted) TNEs that were applied to 
MDA-MB-468 cells and analysed using a flow cytometry software. (B) Comparisons of 
dialysed (light colour) and undialysed (dark colour) TNE samples. DiI-loaded P200 (pink 
and light pink) (i), RSV-1 (green and light green) (ii) and VECT-1 (blue and light blue) (iii) 
TNEs were applied to MDA-MB-468 cells. 
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Dialysed and undialysed TNEs were compared to confirm that TNEs were stable during incubation 
with the cells, helping to validate the comparison between targeted and untargeted TNEs by ruling 
out the presence of free dye in their preparations. Both dialysed and undialysed TNEs showed similar 
results, suggesting no leakage occurred (Figure 3.8B).  
A pilot in vivo study was conducted to evaluate the feasibility of using TNEs in the active targeting 
of breast cancer cells via the IV route. Tail vein injection with VECT-1 TNEs (targeted) and P200 
TNEs (control), at 0.25% oil produced fluorescence in the tail and urinary tract areas, particularly in 
the bladder, five hours post-injection. The injected TNE volume was approximately 10% of mouse 
blood volume, resulting in 0.025% final blood oil concentration. As shown in Figure 3.9B, active 
targeting was not successful using injected TNEs as they were excreted in urine within 2 - 4 hours 
post-injection as evidenced by fluorescence in the legs and feet. However, the potential rapid 
clearance and biocompatibility of TNE formulations could possibly contribute to a satisfactory safety 
profile.  
TNEs with different PEG densities were then tested for stability as a carrier of hydrophobic drugs 
within simulated plasma fluids. The results shown in Figure 3.10A illustrate how the P200 TNEs 
(control) retained their cargo for at least 48 hours. Size measurements were also used to evaluate the 
stability of TNE droplets before and after incubation in the simulated body fluids. The control P200 
TNEs remained stable during the incubation period with no change to the hydrodynamic radius of the 
emulsions, however all other TNEs increased in size following the incubation (Figure 3.10B). These 
findings prompted investigations into the biodistribution of P200 TNEs over 24 hours, although due 
to the fast clearance profile of TNEs demonstrated in the pilot study, the biodistribution study also 
included short time intervals post-injection.    
To explore the biodistribution profile of TNEs across short time intervals, 12 mice were injected with 
DiI-loaded P200 TNEs (control) before organ, blood and urine samples were taken every 30 minutes 
for the first two hours. Final measurements were then taken 24 hours post-injection. The results 
showed very low fluorescence in the liver from DiI-labelled TNEs after only 2 hours post-injection, 
suggesting that the hepatic path was not the main excretion route (Figure 3.11). Fluorescence was 
also detected in the gut that was possibly caused by food-related substances. Serum fluorescence 
revealed that TNEs remained in circulation for at least 120 minutes (Figure 3.12A). Urine 
fluorescence showed that renal excretion of TNEs was detectable from 60 to 120 minutes post-
injection (Figure 3.12B). The fluorescence of DiI in the urine strongly suggested that the TNEs were 
intact as the DiI remained in the oil (based on the weak fluorescence in hydrophilic media).   
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Figure 3.9. In vivo evaluation of TNEs targeting cancer cells. (A) Size measurement of AM1, 
untargeted (control) and targeted TNEs (VEC1-1) shown as average (± standard deviation). (B) 
Mouse back images 4 hours post-injection of targeted TNEs. (C) Mouse back images 4 hours post-
injection of untargeted TNEs. 
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Figure 3.10. Evaluation of DiI retention in TNEs in simulated serum fluid. (A) Evaluation of DiI 
retention in TNEs with different PEG densities (P0, P5, P10, P20 and P200) in the simulated serum 
fluid over time. (B) Shows the size of TNEs loaded with DiI, based on their surface PEG density, 
measured before and after 48 hours incubation in the simulated body fluid (using dynamic light 
scattering). Results are expressed as an average of triplicate measurements (± standard deviation). 
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Figure 3.11. Ex-vivo analysis of TNE biodistribution. (A) Shows organs collected organs 
from the ex-vivo analysis with the liver highlighted by red circles. (B) The data (fluorescence 
of DiI-labelled TNEs) obtained from the liver in each petri-dish over different time points. 
The control mice were not injected with TNEs (n= 2). The number of mice for each time point 
was 2. The results are shown as average of duplicates (± standard deviation). 
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Figure 3.12. Biodistribution of TNEs in mouse sera and urine. (A) DiI signal in collected mice 
sera over time. The control sample is a non-injected mouse. (B) DiI signal in collected urine 
from two mice at each time point. The results are shown as average of duplicates (± standard 
deviation). 
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The immunotoxicity potential of nanomaterials following IV injection is an important aspect and 
requires attention because of the adverse reactions that could occur. Here, the immunotoxicity profile 
of TNEs was evaluated by measuring the serum levels of six cytokines (IFN-γ, IL-2, IL-4, IL-6, IL-
10, TNF-α) at each time point post-injection. IFN-γ and IL-4 could not be detected at any time point 
following TNE injection, or in the control. IL-2 was not detected above control levels and was close 
to the assay limit of detection at any time point. Proinflammatory TNF-α and IL-6, as well as the anti-
inflammatory cytokine IL-10, showed a spike in concentration at 60 minutes followed by an 
immediate decrease and return to control levels. The decrease was more intense for IL-6 compared 
to TNF-α and IL-10. The decline in cytokine production suggests these cytokines were produced as 
a non-specific stress response rather than an immune response (Figure 3.13).  
The mice used in this study were athymic, therefore macrophages and endothelial cells were the main 
sources of cytokine production in the initial responses. The very low fluorescence from DiI-labelled 
TNEs in the liver post-injection, that was not observed in the control mice, suggests this organ, which 
is a major site of IL-6 production, was not involved in the immune response.  If TNEs stimulated 
inflammatory cytokines beyond the immediate stress caused by the injection, then the prolonged 
circulation and persistent, low level accumulation in the liver, would cause at least IL-6 to continually 
increase. Therefore, the low cytokine levels and sudden decline could suggest there were no adverse 
reactions. Possibly the response was inflammatory provoked by the formulation components. 
Although TNEs show short circulation times and no active targeting following IV administration, the 
safety profile substantiates their use in other drug delivery applications through IV injection and 
possibly different routes of administration. 
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Figure 3.13. Release of cytokines over time from mice post-TNE injection. The results are shown 
as an average of duplicates (± standard deviation). 
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3.4  Discussion 
Nanomaterials are being developed in different sizes, shapes, and surface designs to improve the 
therapeutic and diagnostic outcomes of hydrophobic compounds. However, there are currently no 
guidelines that specify the use of an appropriate NPs design for a specific application or route of 
administration. Therefore, the present comparative screening methods are just considered speculative 
and investigating the use of a specific NP design is still needed to obtain a promising drug delivery 
application. NEs possess various advantages including biocompatibility, payload protection and high 
loading capacity, making them promising drug carriers in food production, skin care and 
pharmaceutical applications. TNEs are promising peptide-stabilised NEs developed by Professor 
Anton Middelberg’s group and have been administered subcutaneously for targeting dendritic cells 
to obtain specific immune responses (Zeng et al., 2013). In this chapter, TNEs were investigated as a 
topical and IV drug delivery system.  
Controlling the surface properties is an important factor for applying TNEs as a drug delivery system. 
To study the capacity of TNEs to encapsulate hydrophobic compounds and to tune the TNE surface 
charge, PEG density on the TNE interface was varied. This led to promising results for combining 
TNEs with EMPs via electrostatic interactions toward topical drug delivery, where PEG density was 
found to be indirectly related to surface charge. These interesting results suggest that TNEs can be 
promising drug carriers for topical administration. 
Cargo retention within the oil core of the TNEs was also found to be related to TNE surface properties, 
specifically PEG density. Varying the PEG density on the TNE surface directly affected the stability 
of DiI-labelled TNEs and subsequently, DiI retention.  
The solubility of compounds within the oil core of TNEs is an important factor that determines 
retention/release of cargo. The high log P (partition coefficient) value of DiI (+20), that represents 
lipophilicity of compounds, explains the high retention by stable TNEs. Conversely, CFC was 
released from the oil core of the TNEs at a linear rate where a lower log P value may have contributed 
to faster dye partitioning from the oil to the water phase. 
Another possible explanation for the different leakage profiles of DiI and CFC may have been the 
different testing methods used to assess the amount of cargo retained with the oil core of TNEs over 
time. That is, the amount of DiI retained within the oil core was measured by exploiting the 
fluorescent signal of DiI in oil, compared to a negligible signal in aqueous solutions. In contrast, the 
amount of released CFC was measured using dialysis. It is possible that the linear release profile of 
CFC was indicative of diffusion across a consistent surface area into a non-saturating solution, 
whereas the exponential release of DiI in the presence of lower PEG densities may have been due to 
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coalescence. Reorganisation of surfactants (desorption/adsorption) during coalescence of oil droplets 
might have also contributed to leakage of DiI-labelled TNEs with lower stability (lower PEG 
densities).  
FRET (Förster resonance energy transfer) is a common tool in biochemistry, biophysics and 
molecular biology (Jares-Erijman and Jovin, 2003), and it is applied to measure intra-molecular 
distances or to study co-localisation at a nanometer scale. FRET can occur between two different or 
identical donor and acceptor fluorophores (Homo-FRET) (Bader et al., 2011). It has been shown 
previously that the release of hydrophobic probes, such as DiI, from their carrier can be monitored 
via FRET effects (Chen et al., 2008). Thus, Homo-FRET might be another possible technique for 
characterising the release of hydrophobic fluorophores from the oil core of emulsions.          
PEG density also affected the stability of TNEs under different storage conditions. TNEs with 
different PEG densities were stable at 4 °C and room temperature, however, P200 only was stable at 
all freezing conditions, and P100 showed stability only at -80 °C. TNEs with lower PEG densities 
(P0, P5 and P50) showed instability at -20 °C and -80 °C. This is because storage below 0 °C 
temperatures produces fat crystals within the oil phase (crystallisation) that reduce the stability of 
O/W emulsions (van Boekel and Walstra, 1981). The fat crystals can protrude into the water phase 
penetrating the film between adjacent oil droplets and causing partial coalescence (Harada and 
Yokomizo, 2000, Vanapalli et al., 2002, McClements, 2004). A slow freezing (- 20°C) process results 
in the formation of larger fat crystals when compared to fast-cooling (- 80°C) that produces smaller 
fat crystals. Subsequently, slow-cooling led to lower stability of TNEs at even high PEG densities 
(P100) as shown in Figure 3.4.  
Polymer surface coatings are commonly used to improve the in vitro and in vivo performance of 
nanomaterials. Polymers such as PEG can reduce non-specific binding and provide stability for 
nanomaterials during incubation with surrounding biological environments. Even though in vitro 
binding assays involving P200 TNEs (PEG-decorated emulsions) showed non-specific binding 
possibly caused by ionic interactions with cells, PEG display on nanomaterial surfaces can help to 
minimise these ionic interactions. It is also well known that surface coating nanomaterials with PEG 
can provide hydrodynamic stability and help emulsions evade phagocytosis potentially extending 
their blood circulation. However, the complexity of biological barriers, including plasma proteins 
(protein corona), can adsorb onto nanomaterial surfaces and affect the in vivo fate of nanomaterials 
inferring that the short circulation time observed in this study may have been due to the interaction 
of TNE surfaces with plasma proteins following IV injections.  
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The biodistribution study of P200 TNEs suggested clearance through urination, however the droplet 
size of TNEs (170 nm) is bigger than the pore size (10 nm) of kidney filters. In contrast, TNE droplets 
are soft contractible materials with mechanical properties that allow them to shrink and relax back to 
normal shape without affecting their stability (Zeng et al., 2013). The other explanation for renal 
clearance may be cargo (DiI) partitioning from the oil phase, however this is less likely because DiI 
is weakly fluorescent in aqueous solutions, therefore partitioning and clearance through urine should 
not produce a high signal. Consequently, the results from this study demonstrated urine fluorescence 
indicating TNEs (oil droplets-containing DiI) were cleared as intact droplets. The likely interactions 
between TNEs and biological systems strongly suggest that a deeper understanding of TNE interfaces 
and their interactions with surrounding environment is needed. This exploration can be facilitated by 
the tuneable interfacial properties of TNEs. 
To conclude, TNEs were successfully directed toward in vitro receptor-specific targeting of cancer 
cells. However, the in vivo application of TNEs through the IV route for active targeting was not 
successful due to short circulation times, subsequently these findings present opportunities for further 
research. Distribution studies of un-targeted TNEs at short time intervals suggests TNEs were mostly 
cleared via the renal route, and to some extent, through the hepatic path within 24 hours. These results, 
combined with the absence of enduring cytokines levels and the biocompatible design, all contribute 
to an acceptable safety profile for TNEs as a drug carrier of lipophilic drugs. However, the rapid 
clearance of TNEs, due either to bound serum proteins or phagocytosis, suggests that their surface 
decoration, that encodes TNEs functionalities, requires better understanding (and will be discussed 
in further detail in chapter 4). 
 
 
  
101 
 
4 Chapter 4: Insights into the Interfacial Structure–Function of Poly(ethylene 
glycol)-Decorated Peptide-Stabilised Nanoscale Emulsions 
The entire chapter 4 is composed of a journal article published as following: 
Hossam H. Tayeb, Stefania Piantavigna, Christopher B. Howard, Amanda Nouwens, Stephen M. 
Mahler, Anton P. J. Middelberg, Lizhong He, Stephen A. Holt and Frank Sainsbury (2017). Insights 
into the interfacial structure–function of poly(ethylene glycol)-decorated peptide-stabilised nanoscale 
emulsions. Soft Matter, 13 43: 7953-7961. doi:10.1039/c7sm01614j 
The rapid clearance of TNEs that minimised the success rate of active targeting, due either to bound 
serum proteins or phagocytosis, suggests that their surface decoration, encoding TNEs functionalities, 
requires better understanding. the following chapter addresses this. The physio-chemical properties 
of a tuneable model interface are related to ligand accessibility and receptor-binding performance of 
nanoscale emulsions. Polyethylene glycol (PEG)-mediated surface shielding is commonly applied to 
impart anti-fouling and immune-evading characteristics on interfaces and NPs. Using precise control 
over the surface decoration of peptide-stabilised emulsions the interfacial properties of a PEG-
modified oil-water interface were investigated. In particular, how the physical parameters of the PEG 
layer impact the accessibility of a co-decorated single-chain fragment antibody were determined. The 
interfacial properties of soft nanomaterials are fundamental determinants of their performance and 
the structure-function findings presented in this chapter also provide a general understanding of 
interfaces. By defining a trade-off window in molecular design space, this work paves the way for 
the rational design of sophisticated nanomaterials that interact with their environment in controlled 
and predictable ways.  
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4.1 Abstract 
The interfacial properties of nanoscale materials have profound influence on biodistribution and 
stability as well as the effectiveness of sophisticated surface-encoded properties such as active 
targeting to cell surface receptors. Tailorable nanocarrier emulsions (TNEs) are a novel class of oil-
in-water emulsions stabilised by molecularly-engineered biosurfactants that permit single-pot 
stepwise surface modification with related polypeptides that may be chemically conjugated or 
genetically fused to biofunctional moieties. We have probed the structure and function of 
poly(ethylene glycol) (PEG) used to decorate TNEs in this way. The molecular weight of PEG 
decorating TNEs has considerable impact on the ζ-potential of the emulsion particles, related to 
differential interfacial thickness of the PEG layer as determined by X-ray reflectometry. By co-
modifying TNEs with an antibody fragment, we show that the molecular weight and density of PEG 
governs the competing parameters of accessibility of the targeting moiety and of shielding the 
interface from non-specific interactions with the environment. The fundamental understanding of the 
molecular details of the PEG layer that we present provides valuable insights into the structure–
function relationship for soft nanomaterial interfaces. This work therefore paves the way for further 
rational design of TNEs and other nanocarriers that must interact with their environment in controlled 
and predictable ways. 
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4.2 Introduction 
Soft nanomaterials, such as emulsions, are attractive for various biomedical applications such as drug 
delivery (Hörmann and Zimmer, 2016), molecular imaging (Rosenblum et al., 2010) and engineered 
vaccines (Leleux and Roy, 2013). Nanoscale emulsions have evolved as robust carriers for a broad 
range of hydrophobic drugs, although until recently they have been at the lower end of the design 
sophistication spectrum. Emulsions offer several advantages over other NPs such as ease of 
fabrication, high loading capacity and colloidal stability (Koo et al., 2005, Solans et al., 2005, Tadros 
et al., 2004). However, approaches to engineering the surface of emulsions have been limited to 
bottom-up integration of functional moieties during emulsification or to deposition by electrostatic 
interactions (Sainsbury et al., 2014). The potential to overcome this limitation exists with peptide-
stabilised emulsions (Dexter et al., 2006) where emulsification is decoupled from subsequent 
controlled functionalisation via the spontaneous integration of a designer protein anchor-surfactant 
onto the interface of kinetically stable emulsions (Sainsbury et al., 2014, Zeng et al., 2013). This top-
down approach to nanoscale emulsion engineering imparts remarkable flexibility on the range and 
number of surface modifications now possible. 
Surface modification of NPs for therapeutic and diagnostic use is commonly performed to optimise 
formulation stability and in vivo performance. PEG is an FDA-approved nonionic and hydrophilic 
polymer commonly used to modify liposomal and NP surfaces to improve their pharmacokinetics. 
PEG provides steric stabilisation during storage and application and may also reduce the adsorption 
of serum proteins (Harris and Chess, 2003), potentially prolonging circulation time in the blood 
stream via immune shielding (Pasut and Veronese, 2007, Knop et al., 2010). A recent report shows 
that PEG also affects the com position of the protein corona surrounding nanocarriers and in doing 
so decreases their non-specific cellular uptake, highlighting the importance of understanding the 
physical properties of NP surfaces (Schöttler et al., 2016). 
The influence of PEG on protein adsorption, as well as the storage and serum stability of PEGylated 
NPs is affected by the molar mass, density and conformation of the PEG moiety (Vonarbourg et al., 
2006, Georgiev et al., 2007). Furthermore, in the case of sophisticated particles possessing one or 
more functional moieties in addition to PEG, the physical characteristics of the PEG layer impact the 
density, accessibility and conformation of additional molecules, such as targeting ligands (Wang and 
Thanou, 2010). The effect of PEG modification on biodistribution, active targeting, and in vivo 
stability are important questions in soft matter engineering that still require fundamental research into 
the physical basis for interpreting the role of PEG. 
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Understanding how the structure–function of nanomaterial interfaces governs their interactions with 
the environment would enable rational design from first principles. Here we seek to understand the 
interfacial structure of a unique tailorable nanocarrier emulsion (TNE), thereby gaining insights into 
the remarkable interfacial self-assembly process of a poly(ethylene glycol)-decorated protein. The 
amphiphilic surface active peptide, AM1 (Malcolm et al., 2006) can be used to stabilise nanoscale 
O/W emulsions (Chuan et al., 2012). Surface modification is enabled by the subsequent spontaneous 
integration of a protein anchor-surfactant, DAMP4 (Middelberg and Dimitrijev-Dwyer, 2011), onto 
pre-adsorbed AM1 interfaces (Zeng et al., 2013, Dwyer et al., 2013). Genetic fusion or chemical 
conjugation of functional molecules to DAMP4 thereby facilitates their display on the aqueous phase 
of the emulsion. Thus, the TNE surface is tuneable in a sequential step-wise fashion, offering great 
flexibility to control the characteristics of the oil–water interface. Following the detailed 
characterisation of PEGylated DAMP4, we confirm the sequential addition of functionalised 
biosurfactants onto the interface. The effects of varying PEG length and density on TNE size, surface 
charge and interfacial thickness were evaluated to systematically assess their influence on the 
accessibility of co-displayed functional moieties. 
4.3 Experimental section 
4.3.1 DAMP4 expression, purification and quantification 
DAMP4, a protein surfactant, sequence (MD(PSMKQLADSLHQLARQ VSRLEHAD)4) was 
expressed and purified as previously described (Middelberg and Dimitrijev-Dwyer, 2011). Briefly, 
DAMP4 was purified in three sequential chromatographic steps; immobilised metal affinity 
chromatography taking advantage of the eight histidine residues, ion exchange chromatography at 
pH 7.0 and reversed-phase (RP)HPLC. RP-HPLC fractions were lyophilised, quantified using 
analytical HPLC against a DAMP4 standard curve and stored at ˗80 °C. 
4.3.2 DAMP4 PEGylation 
DAMP4 was rehydrated with 25 mM HEPES, pH 7.0 and PEGylated using NHS-functionalised 
polyethylene glycol mPEG–NHS; (www.nanocs.com). PEGylation of DAMP4 using 5000 Da 
mPEG:NHS, was carried out at two different molar ratios of PEG : DAMP4 (20 : 1 and 50 : 1) and 
incubated for approximately 16 hours at 4 °C with continuous stirring. 
DAMP4 was also PEGylated with the 10 000 Da mPEG–NHS at a 20 : 1 molar ratio under the same 
conditions. DAMP4 mixtures were analysed by SDS-PAGE using the Any-kD TGX Precast Protein 
Gels (www.bio-rad.com). Samples (3.55 µg of DAMP4) were loaded in triplicate and stained using 
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Coomassie brilliant blue R-250 and densitometric analysis was performed using Image J software 
following destaining to determine the mean percentage contribution of each band in the sample. 
4.3.3 Matrix-assisted laser desorption/deionisation 
5000 Da PEG-labelled DAMP4 was separated from free DAMP4 using size exclusion 
chromatography on a S75 column (www.gelifesciences.com) in 25 mM HEPES, pH 7 at 0.5 mL 
min˗1. Collected fractions were desalted with a C4 ziptip (www.merckmillipore.com.au), where the 
ziptip was first wet with 80% acetonitrile (ACN)/0.1% formic acid (FA), equilibrated with 1% 
ACN/0.1% FA, the sample loaded, washed with 1% ACN/0.1% FA, and eluted first with 80% 
ACN/0.1% FA followed by 100% ACN. Eluted material was dried in a speed vac, and resuspended 
in 3 mL 1% ACN/0.1% FA. An aliquot (0.5 mL) was spotted to a polished steel MALDI target plate 
along with 0.5 mL DHB matrix (7 mg mL˗1) in 50% ACN) and allowed to dry. MS data was acquired 
on an Autoflex III MALDI-TOF/TOF mass spectrometer (www.bruker.com) in positive linear mode. 
MS data were externally calibrated using a mix of cytochrome C and myoglobin. 
4.3.4 Interfacial tension analysis 
The IFT kinetics for PEGylated DAMP4 mixtures were measured using a DSA-10 droplet-shape 
analysis unit (www.kruss.de). Each sample of DAMP4 solution was loaded onto an 8 mL quartz 
cuvette (www.hellma-analytics.com) at 10 mM. A known diameter U-shaped stainless steel capillary 
fed by a glass syringe was used manually to form droplet of Miglyol® 812 (www.axoindustries.be) 
of approximately 9 mL. Interfacial tension was derived by the Young-Laplace equation using images 
of the droplet collected by a connected camera at a rate of about 1 measurement per second. 
4.3.5 Quartz crystal microbalance 
Quartz crystal microbalance with dissipation monitoring (QCM-D) experiments were performed 
using the E4 system with flow cells (Q-Sense, Västra Frölunda, Sweden). The QCM-D instrument 
measures the relative changes to the resonance frequency (f) and energy dissipation (D) of the sensor 
over the course of the experiment. ∆f and ∆D were measured simultaneously at the fundamental 
frequency and the 3rd, 5th, 7th and 9th harmonics. The original data was processed in QTools 
(www.biolinscientific.com) before being exported for further analysis in OriginPro 8 
(www.originlab.com). All experiments were conducted at a temperature of 24 ± 0.05 °C and repeated 
at least twice. In a typical experiment, firstly, a solution of AM1 0.1 mg mL˗1 was flushed, flow rate 
50 mL min ˗1, over the surface of a silicon dioxide sensor chip surface modified with a layer of 
trichloro(octadecyl)silane (OTS; www.sigma-aldrich.com). After the flow was stopped, the peptide 
solution was left to incubate for 30 minutes and the chamber rinsed with HEPES buffer 25 mM pH 7 
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to remove any unbound material. After a stable baseline was reached, a solution of 0.1 mg mL ˗1 10K-
PEG DAMP4 was flushed through the chamber at the same flow rate and left to incubate for 30 
minutes. The experiment concluded with the rinse of the chamber with HEPES buffer. 
4.3.6 Preparation of the tailorable nanosized emulsions (TNEs) 
Lyophilised AM1 (molar mass 2473 Da, ≥ 95% purity) was custom synthesised by Genscript 
(www.genscript.com) and dissolved using 25 mM HEPES containing 800 mM of ZnCl2, to reach a 
final concentration of 400 mM. 1,1'-Dioctadecyl-3,3,3',3' tetramethylindocarbocyanine perchlorate 
(DiI; www.thermofisher.com) stock was prepared by dissolving the DiI powder in 100% ethanol at 
10 mg mL ˗1. DiI stock was diluted in Miglyol to a final concentration of 1 mg mL ˗1. Miglyol was 
added to the AM1 solution to a final oil composition of 2 v/v%. The mixture was sonicated four times 
at 45 seconds using the Branson Sonifier 450 Ultrasonicator (www.emersonindustrial.com). Only 
emulsions with a polydispersity index below 0.2 were accepted for surface modification. The 
integration of PEGylated DAMP4 products onto emulsion surfaces was achieved by drop-by-drop 
addition of AM1-stabilised emulsions to vigorously stirring PEG–DAMP4 at a 1 : 1 volumetric ratio. 
To prepare untargeted TNEs, PEG–DAMP4 was used at a DAMP4 concentration of 400 mM. 
Targeted TNEs were prepared by sequential addition using the same technique. First, PEG–DAMP4 
was used at 40 mM, followed by scFv-DAMP4 fusion at 2 mM and a final addition of PEG–DAMP4 
at 400 mM. Hydrodynamic radii with associated polydispersity indices and ζ-potentials were 
measured using a Zetasizer ZS (www.malvern.com). All samples were diluted to 1 : 100 in Milli-Q 
water and ζ-potential measurements were made using an electrophoretic cell (www.malvern.com). 
4.3.7 Interfacial thickness 
The thickness of the air–liquid interface was obtained through X-ray reflectometry measurements 
done with the Panalytical X’Pert Pro reflectometer (Cu-Kα X-rays, λ = 1.5418 Å) at the Australian 
Centre for Neutron Scattering (Sydney, Australia). The intensity of monochromatic X-rays reflected 
from the smooth air–liquid interface was measured as a function of momentum transfer, Q [Q = 
(4π/λ)sin θ, where θ is the incidence angle].  
The samples used for these measurements were 0.05 mg mL-1 DAMP4, 0.1 mg mL-1  5 kDa or 10 
kDa mPEG–NHS, and 0.05 mg mL-1  PEGylated DAMP4 (5K-PEG DAMP4 and 10K-PEG 
DAMP4). Each of these samples was dissolved in 25 mM HEPES pH 7 buffer. Thirteen mL of this 
solution was poured into a teflon trough, 8 ˣ 5 cm ˣ 0.2 cm deep and left to equilibrate for at least 10 
minutes before commencing the measurements. After alignment, measurements were performed by 
scanning from an angle of incidence of 0.007 to 0.56 in 0.001 Å-1
 
steps for a total time period of 45 
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minutes. In order to ensure complete equilibration scans were repeated at least twice. The data fitting 
was carried out using Motofit macros (Nelson, 2006) operating in the Igor Pro environment where 
the interface is described as a series of layers parallel to the interface. Each layer is described by three 
parameters its thickness, scattering length density (SLD), and a Gaussian interfacial roughness. The 
SLD is related to the electron density as follows;  
SLD	 = 	 &''(	r0 ρe 
where λ is the wavelength, r0 the classical electron radius and ρe the electron density. Data were then 
fitted to a single layer using a least-squares genetic algorithm routine by varying the layer parameters 
within physically reasonable bounds.  
4.3.8 scFv-DAMP4 expression and purification 
A synthetic gene encoding an scFv based on panitumumab34, preceded by an immunoglobulin κ light 
chain signal peptide and fused to DAMP4 via a Gly4Ser linker was codon optimised for expression 
in Chinese hamster ovary (CHO) cells. The gene was transferred into the pcDNA 3.1 (+) mammalian 
expression plasmid (www.thermofisher.com) for transient expression. Plasmid DNA was transfected 
using 2 mg of DNA per mL of cells at a concentration of 3 x 106 cells per mL. DNA was complexed 
with polyethylenimine-Pro (www.polyplus-transfection.com) in Opti-Pro serum free medium 
(www.thermofisher.com) at a DNA (µg) to PEI (µL) ration of 1: 4 (w: v) for 15 minutes prior to 
transfecting suspension-adapted CHO cells. The transfected cells were cultured in chemically defined 
CHO medium (CD-CHO; www.thermofisher.com) at 37 oC, 7.5% CO2, 70% humidity with shaking 
at 130 rpm for 6 hours, before feeding with 7.5% CD CHO Efficient Feed A 
(www.thermofisher.com), 7.5% CD-CHO Efficient Feed B (www.thermofisher.com) and 0.4% anti-
clumping agent (www.thermofisher.com). Viability of the cells was evaluated by trypan blue staining 
from day 7 and culturing was stopped when viability ≤ 50%.  
Following transfection, the cells were pelleted by centrifugation and the supernatant was filtered 
through a 0.22 µm membrane (www.sartorius.com). The scFv-DAMP4 was purified from the 
supernatant utilising a 5 mL Protein-L column (www. gehealthcare.com.au), eluting the protein with 
100 mM glycine pH 3.0. Elution fractions were buffer exchanged into PBS pH 7.4 using the HiPrep 
26/10 column (www.gehealthcare.com.au). The final product was filtered through a 0.22 µm 
membrane and the concentration was determined by measuring absorbance at 280 nm. The fusion 
was further analysed by SDS PAGE and size exclusion HPLC using a TSK gel G3000SW column 
(www.tosoh.com).  
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4.3.9 Biolayer interferometry 
Biolayer interferometry was used to determine the binding affinity constants of the scFv-DAMP4 
fusion protein for recombinant EFGR (rEGFR)-Fc targets. The Octet-Red (www.fortebio.com) 
platform was used to evaluate binding using 96 well black plates (www. greinerbioone.com). Each 
well was prepared with 200 µL of sample, the reactions were conducted at 30 oC and 1000 rpm 
agitation was used for each step. Biosensors were hydrated in 200 µL of PBS for 10 minutes prior to 
the start of the binding assay. Anti-human Fc-specific biosensors (www.fortebio.com) were 
immobilised with 100 µg mL-1 rEGFR-hFc (www.sinobiological.com). The assay conditions included 
an initial baseline step in PBS for 5 minutes, followed by loading 100 µg mL-1 rEGFR-Fc for 10 
minutes, PBS baseline for 5 minutes and then an association step with scFv-DAMP4 for 10 minutes 
followed immediately by a 10 minutes dissociation step in PBS. The scFv-DAMP4 was titrated from 
500–6.25 nM to measure the binding kinetics for EGFR using a 1: 1 binding kinetic model.  
4.3.10 Solid state EGFR binding 
The human epidermal growth factor receptor (5 µg mL-1) in PBS (www.sinobiological.com) was 
immobilised onto 96-well black polystyrene plates (www.corning.com) at room temperature for 4 h. 
Then, the immobilised EGFR was blocked using 2% milk PBS for 1 hour. Diluted TNEs (0.05 oil%) 
formulations were applied and incubated for 30 minutes at room temperature. Unbound TNEs were 
removed with two washes of PBS, containing 0.05% Tween-20, and a final wash using PBS, before 
re-filling the wells with PBS. Fluorescence intensity was measured using an M200Pro TECAN plate 
reader (www.lifesciences.tecan. com) with emission and excitation wavelengths of 535 nm and 570 
nm, respectively. 
4.3.11 Flow cytometry 
Targeted and un-targeted TNEs prepared using each DAMP4–PEG species were diluted (0.025–
0.015 oil%) and applied at 1 : 1 volumetric ratio to the MDA-MB-468 cell suspension (1.5  ˣ 106 cells 
per mL) in PBS containing 10% Foetal Calf Serum (FCS). Cells were then incubated 1 hour for 
binding at 4 oC, followed by three washing steps to remove weakly bound TNEs. FACS 
measurements were limited to 20 000 events, cells gating and a full analysis were performed using 
flowing software v2.5.1. 
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4.4 Results and discussion  
4.4.1 Characterisation of protein co-surfactant PEGylation  
The protein co-surfactant DAMP4, is a tetrameric repeat of the peptide surfactant AM1 joined by 
designed fold-permissive linkers. In solution it is a hyper-stable 4-helix bundle formed by 
hydrophobic interaction of the amphipathic helical AM1 units. PEGylation by NHS-coupling is used 
to bioconjugate to the free amines of the four lysine residues plus the amino terminus and this generic 
approach results in mixed species of DAMP4 with varying numbers of conjugated PEG (Figure 4.1). 
SDS-PAGE was used to separate the PEGylated species from un-conjugated DAMP4, which, 
although it could not be used to determine molecular weight of each species (Zheng et al., 2007), did 
allow quantification by densitometry. Matrix assisted laser desorption/ionisation time of flight 
(MALDI TOF) mass spectrometry (Supplementary Figure 4.1) showed that the four species including 
the free DAMP4 (11116 m/z) (Dimitrijev Dwyer et al., 2014) resulting from the conjugation of 5 kDa 
PEG correspond to DAMP4 + 1PEG (16551 m/z), DAMP4 + 2PEG (21537 m/z) and DAMP4 + 3PEG 
(27378 m/z).  
Enriching the DAMP4–PEG conjugate yield could be achieved by increasing the PEG: DAMP4 ratio 
and also by using longer length polymers. The low PEG: DAMP4 ratio (20:1) reaction yields 
approximately 50% PEGylated DAMP4 species (5K-PEG-Lo). However, increasing the PEG: 
DAMP4 ratio (50 : 1) shows a significant increase in the yield of the PEGylated forms to 
approximately 90% (5K-PEG-Hi). The use of 10 kDa NHS–PEG results in more than 90% PEGylated 
DAMP4 at the same 20:1 molar ratio as 5K-PEG-Lo. We suspect that this is due to different reactivity 
of the functional groups of the two NHS–PEG reagents. Due to the presence of multiple free amines 
on DAMP4, the NHS–coupling performed here results in a mixture of products. Although we find 
that the relative abundance of species is consistently obtained, further engineering of DAMP4 could 
permit site-specific and potentially, with the use of click chemistry, stoichiometric bioconjugation 
(Salmaso et al., 2009, Sato, 2002, Kolb et al., 2001, Fee and Van Alstine, 2006)  
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Figure 4.1. Bioconjugation of NHS-mPEG to DAMP4. (A) Cartoon of DAMP4 showing the 
position of the four lysine residues. (B) Densitometric analysis of DAMP4–PEG mixtures 
including DAMP4 conjugated to 5000 Da NHS– PEG using the low (5K-PEG-Lo) and high 
(5K-PEG-Hi) ratio reaction, and DAMP4 conjugated to 10 000 Da NHS–PEG (10K-PEG). 
Values represent the mean percentage composition of the different reaction products from 3 
independent reactions, which each varied by no more than 10% between conjugation 
reactions. 
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4.4.2 Interfacial tension of PEGylated DAMP4  
Due to the kinetic mass transfer limitations of large surfactant molecules on interfacial activity we 
analysed the IFT of the PEGylated DAMP4 species to determine the impact of the bioconjugate. The 
oil–water IFT kinetics of DAMP4 and the various PEGylated ensembles are shown in (Figure 4.2). 
A drop in surface tension from 31 mN m˗1, that of a pristine oil droplet, indicates adsorption of the 
biosurfctant. While an increase in average size due to DAMP4 conjugation results in lower mass 
velocity and migration to the interface, all PEGylated DAMP4 mixtures are interfacially active. The 
increase in PEG length from DAMP4 to 5K-PEG to 10K-PEG reduces the adsorption as would be 
expected due to the decrease in diffusion coefficient (Cussler, 2009). The increasing density of 
conjugated PEG does result in slightly lower interfacial activity, although the different DAMP4 
samples give similar final reductions in surface tension, (Figure 4.2). The IFT is lowest for DAMP4 
at 13.8 mN m˗1 whereas for the 5K-PEG-Lo PEGylated DAMP4 mixture it is 15.5 mN m-1. The 5K-
PEG-Hi and 10K-PEG preparations, which have similar PEGylation reaction yields, also have similar 
IFT measurements of 17.3 and 17.8 mN m-1, respectively. Interestingly, therefore, steady state IFT 
values appear to depend more on the number of conjugated PEG moieties per DAMP4 than the MW 
of the conjugate, indicating an impact of the bioconjugated state of individual residues on interfacial 
activity. 
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Figure 4.2. Interfacial tension analysis of the DAMP4:PEG conjugates. Measurement of the 
interfacial tension (mN m˗1) against time (s) was performed for DAMP4 (black squares), 5K-
PEG-Lo (green triangles), 5K-PEG-Hi (blue circles) and 10K-PEG (red diamonds) at 10 mM. 
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4.4.3 Sequential addition of DAMP4 conjugates  
Previous work has shown that AM1-stabilised O/W emulsions can be modified by the spontaneous 
integration of PEGylated DAMP4 onto the interface (Zeng et al., 2013). Here we investigated the 
interaction of PEGylated DAMP4 with a pre-formed AM1 layer by monitoring the mass variation on 
a hydrophobic interface using QCM-D (Figure 4.3). A decrease in frequency, corresponding to mass 
addition, from ˗6 Hz to ˗37 Hz shows that 10K-PEG–DAMP4 adsorbs at the AM1 layer. This 
interaction is stable and irreversible as the signal is unchanged after initial adsorption during the 
incubation time (Figure 4.3; step c), with only a small amount of material removed by the buffer wash 
(Figure 4.3; step d), which was continued until the signal was stable for two minutes. The response 
of the three harmonics is very similar suggesting that the DAMP4 penetrates the AM1 layer rather 
simply adsorbing on top. The observed stable increase in dissipation (ΔD) may be due to the PEG 
tails protruding in the bulk solution.  
To relate the addition to AM1-stabilised nanoscale emulsions we sought to confirm the stable 
adsorption of PEGylated DAMP4 by quantifying the amount of free AM1 and DAMP4 following 
sequential assembly. Modification with increasing amounts of PEG–DAMP4 showed that up to 
approximately 40 pmol cm−2 DAMP4 can be integrated onto a 1% (v/v) AM1-stabilised Miglyol 
emulsion (Supplementary Figure 4.2). At 57 pmol cm−2 some AM1 is displaced from the interface 
and this increases with higher density of DAMP4. However, even a low amount of PEG–DAMP4 
can confer hydrodynamic stability on the emulsions; preventing coalescence in PBS where 
electrostatic repellent effects are negated, or in the presence of EDTA (Supplementary Figure 4.3), 
which disrupts the cohesive interfacial peptide network (Malcolm et al., 2006). This indicates that 
PEG is functionally displayed on the interface, creating a steric barrier to coalescence. Therefore, 
PEG–DAMP4 is stably integrated onto AM1-stabilised TNEs, presumably with PEG oriented into 
the bulk phase. 
  
114 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.3. Typical ∆f and ∆D versus time plots of 10K-PEG–DAMP4 interacting with AM1 
peptide. The dashed lines mark the end of each phase. Phase a corresponds to the flow and 
incubation of AM1 solution, whereas c denotes the flow and incubation of PEG–DAMP4. 
The rinse with HEPES buffer solution corresponds to phase b and d. The 5th (red), 7th 
(green) and 9th (blue) harmonics are displayed. 
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4.4.4 Impact of DAMP4 PEGylation on the size and ζ-potential of TNEs 
To investigate the influence of variable DAMP4 PEGylation on the surface properties of TNEs we 
modified the interface of AM1-stabilised emulsions with the DAMP4 mixtures. Application of the 
DAMP4–PEG conjugates results in predictable changes to the size and ζ-potential values of TNEs 
(Figure 4.4). While there is no change in size following the addition of 5K-PEG-Lo DAMP4, from 
165 ± 2 to 166 ± 3 nm, there is a variable size increase following the addition of 5K-PEG-Hi DAMP4 
to 171 ± 7 nm and a considerable and consistent increase with 10K-PEG DAMP4 to 178 ± 2 nm. 
Emulsion preparations remain monodisperse (polydispersity index ≤0.2) following the integration of 
DAMP4–PEG indicating that colloidal stability of the emulsions is maintained. The increase in size 
corresponds to the amount and size of PEG moieties displayed on the surface of each TNE 
preparation. However, recent estimations of the density and linear dimension of anchored PEGs in 
the extended brush format (Damodaran et al., 2010, Meng et al., 2004), suggest that the PEG 
molecules here are displayed in a compressed conformation or even oriented parallel to the TNE oil–
water interface. 
The addition of 5K-PEG (Lo or Hi) also changes the electrophoretic mobility of TNEs (Figure 4.4) 
by masking the positive charge carried by surface-exposed residues of the hydrophilic face of 
AM1/DAMP4 helices (Dexter et al., 2006). Integration of PEGylated DAMP4 reduces the ζ-potential 
of AM1 emulsions from 62.7 to 38 and 39.6 mV for the 5K-PEG-Lo and 5K-PEG-Hi formulations, 
respectively. The integration of the 10K-PEG onto TNEs further reduces the ζ-potential to 24.3 mV, 
indicating that 10K-PEG better shields AM1 and DAMP4 helices at the oil–water interface. Since the 
two 5K-PEG preparations result in the same ζ-potential despite presumed differences in PEG density, 
the effect on apparent surface charge could be due to expansion of the surface double layer such that 
less charge is able to ‘‘shine through’’ from the 10K-PEG TNEs relative to 5K-PEG-Hi TNEs (Pasche 
et al., 2005), as opposed to simply an effect of overall PEG mass. Reducing the ζ-potential of NPs is 
a significant factor for minimising non-specific interactions with serum proteins and cells (Lane et 
al., 2015), thus it is imperative to understand the physical basis for control of this parameter. 
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Figure 4.4. Dynamic light scattering and ζ-potential measurements of TNEs prepared with 
DAMP4-PEG conjugates. (A) Schematic representation of the spontaneous integration of 
DAMP4 conjugates onto the surface of AM1-stabilised emulsions. (B) Z-averaged size and 
ζ-potential of the AM1-stabilised emulsion, as well as the 5K-PEG-Lo, 5K-PEG-Hi and 10K-
PEG TNEs. Values represent the mean of three emulsions ± SD. 
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4.4.5 Interfacial thickness of the PEG layer 
Using an air–water interface as a model that closely mimics the oil–water interface, we have applied 
X-ray reflectometry to probe the thickness and relative density of the PEG layer in the aqueous phase. 
This was compared to interfaces with DAMP4 or PEG only. Figure 4.5 shows the layer fit (see Table 
4.1 for parameters) and the scattering length density (SLD) profile, which is effectively a scaled 
electron density perpendicular to the interface as a function of distance where ‘‘0’’ represents the 
interface and positive values are moving into the bulk solution. The data were fitted simultaneously 
where the upper layer (layer one) was constrained to have the identical thickness across the three 
datasets. As DAMP4 consists of four AM1 units it is not possible to distinguish between them by 
XRR. This modelled density profile showed that for DAMP4, there is a surface excess layer about 11 
Å thick with a higher electron density than pure water, as has been previously observed (Dwyer et 
al., 2013, Li et al., 2016). For a solution containing 5K-PEG-Hi PEGylated DAMP4 there is a surface 
layer with a slight reduced electron density suggesting that the surface packing of the DAMP4 may 
be disrupted. With the 10K-PEG DAMP4 an initial layer similar to that from DAMP4 is observed but 
with a second layer of material and corresponding density gradient extending into solution over a 
distance of about 50 Å. This ‘tail’ is attributed to the 10 kDa PEG molecules extending into the bulk 
solution and is not observed for the 5 kDa PEG. It should be noted that the scattering from this second 
layer is very weak and its inclusion imparts a marginal improvement to the data fitting. 
This intriguing difference in the interfacial structure resulting from PEGs of different molecular 
weight may explain the observed differential influence on physical properties of TNEs. The extension 
of 10 kDa PEG into the aqueous phase is consistent with the marked increase in hydrodynamic radius 
of TNEs modified with 10K-PEG DAMP4. In addition, substantially decreased ζ-potential following 
the addition of 10K-PEG DAMP4 is consistent with expansion of the electrical double layer due to 
the extended density profile of the neutral polymer. On the other hand, negligible or variable size 
changes of TNEs modified with 5 kDa PEG together with density-independent impact on ζ-potential 
and a potential influence on DAMP4 packing, suggest that the 5 kDa PEG is indeed oriented parallel 
to the TNE oil–water interface or remains in an otherwise compressed state. If this were the case, 
then an effect on PEG spacing of DAMP4, as suggested by the SLD profile, would be expected to 
lower the average charge density at the interface. Knowledge of the biophysical properties of the PEG 
layer is fundamental to molecular understanding of the TNE interface and, therefore, the potential for 
rational design of functional interfaces. 
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Figure 4.5. X-Ray reflectivity data and the real space fit to the datasets. (A) Reflectivity data 
multiplied by Q4 for DAMP4, 5K-PEG-DAMP4 and 10K-PEG–DAMP4 where the points 
represent the data and the lines the fit to the data, error bars not shown where they are smaller 
than the symbol. (B) The real space SLD profile according to the data fits presented in (A). 
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Table 4.1. Parameters from the fit to the XRR data sets. Where there are two layers layer one is 
against the air and layer two against the subphase. 
 
  
Parameter DAMP4 5K-PEG DAMP4 10K-PEG DAMP4 
Layer 1 thickness (Å) 11 11 11 
Layer 1 SLD (Å-2) 11.9 11.0 12.6 
Layer 1 roughness (Å) 3.3 3.5 3.8 
Layer 2 thickness (Å) - - 49 
Layer 2 SLD (Å-2) - - 10.3 
Layer 2 roughness (Å) - - 6.5 
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4.4.6 Presentation and accessibility of functional moieties on TNEs 
As we have verified herein, surface modification of TNEs is as simple as adding DAMP4 conjugates 
to a single reaction pot. This approach was used to sequentially introduce cell-specific targeting to 
TNEs, in addition to PEG-mediated shielding from non-specific uptake (Zeng et al., 2013). To 
generate a simple model for surface presentation of functional moieties on TNEs we constructed a 
single-chain variable fragment-DAMP4 fusion as a ligand- binding reporter. As designed, the fusion 
is competent for epidermal growth factor receptor (EGFR) binding, with a 1 nM dissociation constant 
measured by biolayer interferometry (Supplementary Figure 4.4). Following the integration of a low 
density PEG layer to confer hydrodynamic stability on the emulsions, the surface was further 
modified with the scFv-DAMP4, followed by backfilling with PEGylated DAMP4 as previously 
described (Zeng et al., 2013). 
The integration of the 38 kDa scFv fusion onto the TNEs results in an increase in size and while the 
ζ-potential of 5K-PEG-Hi and 10K-PEG TNEs is slightly reduced by the presence of the scFv, there 
is a marked impact on the variability of the 5K-PEG- Lo TNE ζ-potential (Supplementary Figure 4.4). 
Although all preparations again remained monodisperse, this size change suggests some impact on 
the colloidal stability of 5K-PEG-Lo TNE. 
To show that the targeting moiety was functionally presented at the oil–water interface and assess the 
impact of PEG length and density on accessibility of the scFv we devised a solid state binding assay 
to the ligand. The 5K-PEG-Lo TNE shows no specificity in ligand binding (Figure 4.6B). In contrast, 
both the 5K-PEG-Hi and 10K-PEG TNEs display scFv-dependent binding to the receptor in this 
controlled environment. However, the more complex surface of the cell imparts a more stringent test 
for specificity and the coverage of the TNE surface by PEG. Using EGFR-positive breast cancer cells 
and a high emulsion concentration (32.7 droplets per cell) to assess both specific and non- specific 
binding, no difference in median fluorescence can be seen between 5K-PEG-Lo formulations with 
and without the targeting moiety (Figure 4.6C). While the 5K-PEG-Hi targeted formulation only 
improves binding 1.8-fold, the use of 10K-PEG is substantially more effective at preventing non-
specific binding and the display of the scFv on 10K-PEG TNEs results in a 2.6-fold increase in median 
fluorescence. These results show that the scFv was functionally displayed on the surface of TNEs and 
that the specificity of binding can be controlled by the density of PEG at the surface. 
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Figure 4.6. Functionalising TNEs with a ligand-binding reporter. (A) Schematic 
representation of the spontaneous integration of the scFv-DAMP4 fusion protein onto the 
surface pre-PEGylated TNEs. (B) Solid-state binding assay of the functionalised TNEs. 
Depicts the binding of fluorescent TNEs assembled using the 5K-PEG-Lo, 5K-PEG-Hi and 
10K-PEG DAMP4 mixtures both with and without the scFv displayed on their surface, 
applied to EGFR-coated wells. (C) Flow cytometry showing the binding to EGFR-positive 
MDA-MB-468 cells of targeted (black) and control (grey) TNEs assembled using the 
different DAMP4 mixtures. The values shown are median fluorescence values (from 20000 
events). Values represent the mean of three emulsions ± SD. 
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4.5 Conclusions 
The interfacial properties of NPs comprise a set of key determinants for how they interact with their 
environment. For multifunctional particles, the complexity of this interaction is compounded by the 
impact of the functional moieties on one another, defining a competition trade-off window in 
molecular design space. Here we have used a unique model system that permits the controlled 
assembly of multifunctional NPs to probe the structure-function relationship of an interface modified 
with the competing influences of PEG and a targeting moiety. TNEs have been shown to be a 
potentially powerful in vivo delivery system (Zeng et al., 2013) and here we present a detailed analysis 
of their building blocks, preliminary verification of their assembly mechanism and determination of 
the molecular characteristics of the aqueous phase. Despite the expected differences in thickness of 
their respective PEG layers demonstrated by X-ray reflectometry, a solid state binding assay suggests 
that the scFv is equally accessible at the surface of 5K-PEG-Hi TNEs and 10K-PEG TNEs. However, 
the PEG layer proved vital in reducing non-specific interactions. Summarising these results in a 
simplistic model (Figure 4.7) allows us to entertain the possible future rational interfacial design of 
multifunctional TNEs. Continuing work on exploring the assembly and display capacity of TNEs, as 
well as controlled functionality and performance in vivo, is on-going. 
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Figure 4.7. Schematic model of the competing influences on EGFR binding of PEG and an 
anti-EGFR scFv at the oil-in-water interface of TNEs. 
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4.7 Supplementary materials  
Supplementary Figure 4.1 
Matrix assisted laser desorption/deionisation. The figure represents the mass spectrometry traces 
and mass-to-charge ratio (m/z) of DAMP4, DAMP4+1PEG, DAMP4+2PEG and DAMP4+3PEG. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
126 
 
 
Concentrations of free AM1 and DAMP4 following the adsorption of PEG-DAMP4 onto AM1-
stabilised emulsions. Triplicate emulsions, dispersed in the presence of 400 µM AM1 were mixed 
with PEG-DAMP4 at the indicated µM concentrations. Taking the surface area corresponding to the 
subsequent 1% O/W emulsion, the DAMP4 surface densities were as follows: P50 = 14 pmol/cm2, 
P100 = 28 pmol/cm2, P200 = 57 pmol/cm2, P400 = 113 pmol/cm2.  
A sample of the continuous phase was isolated using a centrifugal ultrafiltration device (100 MWCO) 
and peptide concentrations determined by HPLC. Values represent the mean of three emulsions ± 
SD. 
 
  
Supplementary Figure 4.2 
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Stability of TNEs following the addition of DAMP4-PEG. Emulsions containing DiI, dispersed in 
the presence of 400 µM, were mixed with DAMP4-PEG to obtain the indicated final µM 
concentrations (5 µM and 10 µM). Each emulsion prepared with DAMP4, 5K-PEG-Lo, 5K-PEG-Hi 
and 10K-PEG was mixed 1:1 with 100 mM EDTA. The unPEGylated DAMP4 addition at both 
concentrations shows clear aggregation. The addition of the different DAMP4-PEG preparations at 
10 µM stabilises the emulsions, making them resistant to the aggregation in the presence of EDTA. 
While the addition of 10K-PEG also stabilises the emulsion at 5 µM, 5K-PEG-Lo and 5K-PEG-Hi 
did not, resulting in reduction in the colouration of the solution due to aggregation of the droplets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 4.3 
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(A) Schematic representation of the spontaneous integration of the scFv-DAMP4 fusion protein onto 
the surface pre-PEGylated TNEs. (B) Biolayer interferometry sensogram showing the association and 
dissociation of the scFv-DAMP4 fusion to EGFR. (C) Z-averaged size and ζ-potential of the 5K-
PEG-Lo, 5K-PEG-Hi and 10K-PEG versions of scFv-functionalised TNEs. Values represent the 
mean of three emulsions ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 4.4 
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5 Chapter 5: Site-Specific Bioconjugation with Poly(Ethylene Glycol): Impact 
on the Interfacial Activity of a Protein Biosurfactant 
The entire chapter 5 is composed of a journal article submitted 12/01/18 as following: 
Hossam H. Tayeba, Marina Stieneckera, Anton P. J. Middelberga1 and Frank Sainsburya* (2018) Site-
specific bioconjugation with poly(ethylene glycol): impact on the interfacial activity of a protein 
biosurfactant. Submitted to Colloids and Surfaces B: Biointerfaces Manuscript ID: COLSUB-D-18-
00076. 
 
a The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St 
Lucia, QLD 4072, Australia. 
 
1 Present address: Faculty of Engineering Computer & Math Sciences, The University of Adelaide, 
Adelaide, SA 5005, Australia. 
In the previous chapter it became apparent that the precise bioconjugation of functional moieties to 
DAMP4 is necessary for effective design of sophisticated interfaces as well as for the more controlled 
determination of their biophysical properties. This chapter describes the creation of a second 
generation of DAMP4. Rationally designed cysteine variants by amino acid substitution or addition 
were generated to enable specific and efficient bioconjugation of maleimide-functionalised PEG. 
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5.1 Abstract 
Biosurfactants are surface active molecules that can be produced by renewable, industrially scalable 
biological processes. DAMP4, a novel designer biosurfactant, enables the modification of interfaces 
via genetic or chemical conjugation to functional moieties. However, inconsistent bioconjugation 
introduces heterogeneity that limits the precision of functionalisation and the resolution of interfacial 
characterisation. In this work, we successfully designed DAMP4 variants with cysteine point 
mutations to allow for site-specific bioconjugation. These designed DAMP4 variants were shown to 
retain the structural stability and interfacial activity of the parent molecule, while permitting efficient 
and specific conjugation of polyethylene glycol (PEG). PEGylation results in a considerable reduction 
on the interfacial activity of the single and double mutants. Comparison of conjugates with one or 
two conjugation sites shows that both the number of conjugates as well as the mass of conjugated 
material impacts the interfacial activity of DAMP4. As a result, the ability of DAMP4 variants with 
multiple PEG conjugates to impart colloidal stability on peptide-stabilised emulsions is reduced. We 
suggest that this is due to constraints on the structure of amphiphilic helices at the interface. Specific 
and efficient bioconjugation permits the exploration and investigation of the interfacial properties of 
designer protein biosurfactants with molecular precision. Our findings should therefore inform the 
design and modification of biosurfactants for their increasing use in industrial processes, and 
nutritional and pharmaceutical formulations.   
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5.2 Introduction 
Self-assembling biosurfactants have been extensively applied in different areas including food 
science (McClements, 2015, McClements and Rao, 2011), pharmaceuticals (Brokx et al., 2002, 
Gudiña et al., 2013, Rodrigues et al., 2006), cosmetics (Vecino et al., 2017, Varvaresou and Iakovou, 
2015) and the petroleum industry (Perfumo et al., 2010). Biosurfactants offer many advantages when 
compared to chemically-synthesised equivalents such as biocompatibility, biodegradability, and 
sustainable manufacture (Marchant and Banat, 2012, Pacwa-Płociniczak et al., 2011). The interfacial 
activity of biosurfactants is defined by intermolecular and intramolecular electrostatic and 
hydrophobic interactions, as well as hydrogen bonds and van der Waals forces. These interactions, 
that the drive the assembly of protein biosurfactants into supramolecular interfacial arrays, are 
determined by the primary sequence that dictates their fold into α-helices or β-sheets. Genetic or 
chemical modifications provide an opportunity to expand the functional repertoire of protein 
biosurfactants, but they must also consider the possibility of structural alteration and resulting 
biophysical implications on function.    
DAMP4 is an 11.1 kDa protein biosurfactant that was generated by linking four copies of a designer 
amphiphilic peptide into an anti-parallel four-helix bundle (Middelberg and Dimitrijev-Dwyer, 2011). 
It is extraordinarily stable in bulk solution (Schaller et al., 2015) and amenable to industrially relevant 
purification procedures (Dimitrijev Dwyer et al., 2014). Yet it is a highly functional surface-active 
molecule that has the ability to mediate switchable foaming under variable solution conditions 
(Dimitrijev-Dwyer et al., 2012). Highly expressed in Escherichia coli, DAMP4 can be functionalised 
via genetic fusion or chemical conjugation and possesses the unique ability to integrate into interfacial 
films pre-stabilised by the helical monomers that constitute DAMP4 (Dimitrijev Dwyer et al., 2014). 
These features have seen DAMP4 used to modify O/W emulsions providing functionality for 
inorganic shell deposition (Wibowo et al., 2015), immune-shielding (Zeng et al., 2013) and cell-
receptor targeting (Zeng et al., 2013, Tayeb et al., 2017). The extent of non-specific interactions 
between the emulsion interface and the surrounding environment can be controlled by the mass and 
density of decorating polyethylene glycol (PEG) molecules (Tayeb et al., 2017).  
PEGylation is widely applied to improve the performance biopharmaceuticals and NPs by reducing 
immunogenicity, and increasing serum half-life and stability (Mateo et al., 2000, Herman et al., 1995, 
Jokerst et al., 2011). However, PEGylation of proteins has many challenges including polydispersity 
of PEG during chemical synthesis or inefficient reaction yield (Fee and Van Alstine, 2006). We 
recently showed that modification of DAMP4 using NHS-functionalised PEG yields heterogeneous 
reactions products resulting in limitations on the physico-chemical characterisation of DAMP4-
132 
 
populated interfaces as well as on the precision of surface modification (Tayeb et al., 2017). However, 
bioconjugation chemistries offer a range of possible modifications dependent on the accessibility of 
suitable amino acid side chains (Stephanopoulos and Francis, 2011). For example, conjugates can be 
coupled to proteins through functional groups including hydroxyl, carboxyl, and thiol-reactive 
compounds. thiol-maleimide chemistry is widely applied to obtain site-specific bioconjugation (Nair 
et al., 2014) due to the less frequent occurrence of solvent-exposed cysteine residues allowing for 
their rational insertion by site-specific mutagenesis.  
Bioconjugation should impart the desired modification on a biomolecule whilst preserving its 
activity. In the case of biosurfactants, function is achieved via adsorption at an interface between two 
phases. This generally occurs in two steps; (A) transfer or transportation of the protein molecule to 
the interface; (B) protein unfolding and rearrangement at the interface (Tcholakova et al., 2006). 
TNEs are peptide-stabilised O/W emulsions that can be functionalised by the spontaneous integration 
of genetically or chemically modified versions of DAMP4 (Zeng et al., 2013, Sainsbury et al., 2014). 
During the assembly of TNEs with multifunctional interfaces, DAMP4 conjugated to polyethylene 
glycol (PEG) is used to provide steric stability during additional functionalisation steps. Here we 
genetically engineered DAMP4 to improve the accuracy with which it can be used to impart 
functionality to the surface of peptide-stabilised emulsions. The rational introduction of cysteine 
residues at select positions designed to retain structure and function of DAMP4 resulted in highly 
efficient site-specific bioconjugation using the maleimide-thiol reaction. We report the impact of 
single and double cysteine insertions on interfacial activity and are able to address whether the 
number of conjugates or the total mass of conjugated polymer affect this parameter. This work shows 
how genetic and chemical modification of amphiphilic structural features relates to the design of 
functional interfaces stabilised by biosurfactants using the TNE model.  
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5.3 Materials and methods 
5.3.1 Molecular cloning 
DAMP4-encoding sequences were ordered from Integrated DNA Technologies (www.idtdna.com) 
with extensions homologous to the flanking insertion site of the E.coli expression vector pET48b+ 
(Novagen; www.merckmillipore.com). Coding sequences were amplified with upstream (5`-
ACTTTAAGAAGGAGATATACAT-3`) and downstream (5`-TGTACAGAATTCGGATCC-3`) 
oligonucleotides corresponding to the extensions and the vector was amplified with their reverse 
complements. Expression constructs were assembled using the NEBuilder HiFi DNA assembly 
master mix (New England Biolabs; www.neb.com) and clones were verified by Sanger sequencing.  
5.3.2 Expression and purification of DAMP4 variants 
DAMP4 variants were expressed and purified in E.coli as previously described except where 
indicated (Dimitrijev Dwyer et al., 2014). Briefly, each variant was purified using sequential 
chromatography steps; immobilised metal affinity chromatography by taking advantage of the 
presence of eight histidine residues in each protein sequence, ion exchange chromatography at pH 
7.0 and reversed-phase (RP) HPLC. Purified proteins were lyophilised and analyzed for purity and 
concentration using analytical HPLC against DAMP4 standard curve. Accurate concentrations were 
determined by amino acid analysis conducted by the Australian Proteome Analysis Facility (APAF). 
5.3.3 PEGylation of DAMP4 variants 
DAMP4 variants were resuspended with 25 mM HEPES (pH 7.0), 2 mM tris(2-
carboxyethyl)phosphine (TCEP) and PEGylated using 5 kDa maleimide-functionalised methoxy 
polyethylene glycol (www.sigmaaldrich.com). PEGylation of DAMP4 variants was carried out at 4 
°C for approximately 16 hours. The PEGylation reaction for all DAMP4 variants was evaluated by 
SDS-PAGE using the Any-kD TGX Precast Protein Gels (www.bio-rad.com). 
5.3.4 Interfacial tension analysis 
The IFT kinetics for the DAMP4 variants were measured using a DSA-10 droplet-shape analysis unit 
(www.kruss.de). The sample volume of each protein (10 µM) is 8 ml in 25 mM HEPES (pH 7.0) 
loaded onto a quartz cuvette (www.hellma-analytics.com). Approximately 10 µl Miglyol® 812 
(www.axoindustries.be) droplets were manually formed using a known-diameter U-shaped stainless 
steel capillary fed by a glass syringe. The obtained interfacial tension was based on the Young-
Laplace equation through images captured by a connected camera for each oil droplet at an 
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approximate rate of 1 measurement/second. The surface tension of a mature pristine oil droplet was 
31 mN/m and IFT values were derived by averaging the final 100 seconds of measurement.  
5.3.5 Circular dichroism (CD) spectroscopy 
To analyze the secondary structure (Helicity level) of each DAMP4 variant, at 0.25 mg/ml in 2.8 mM 
HEPES (pH 7.0), 2 mM TCEP, we determined the CD spectra using (http://www.jascoinc.com) at 
190-260 nm. CD spectra measurements (300 s) were conducted in a 1 mm path length glass cuvette 
(www.starnacells.com) at 20 and 90 °C to evaluate the stability against high temperature for all 
DAMP4 variants. Molar ellipticity was derived from collected data of each variant.    
5.3.6 Differential scanning calorimetry (DSC) 
DSC analysis was performed to evaluate the thermal stability of the DAMP4 mutants before and after 
PEGylation. The experiment was conducted using the MicroCal VP- DSC Microcalorimeter 
(http://www3.gehealthcare.com) and the VPViewer 2000 DSC software. The test and reference 
samples were treated using the ThermoVac degassing station at 25 °C for 5 minutes to eliminate air 
bubbles. The molar ratio of DAMP4 mutant samples (0.75 mg/ml) to TCEP was maintained at 1:10. 
DSC measurements were conducted at scan rate ranging from 25 °C to 125 °C. The collected data 
were analyzed using the MicroCal-enabled Origin data analysis package.  
5.3.7 Preparation and characterisation of TNEs 
Lyophilised AM1 (molar mass 2473 Da, ³  95% purity) was custom synthesised by Genscript 
(www.genscript.com) and dissolved using 25 mM HEPES (pH 7.0) containing 800 µM of ZnCl2, to 
reach a final concentration of 400 µM. Miglyol was added to the AM1 solution to a final oil 
composition of 2% v/v. The mixture was sonicated four times at 45 seconds using the Branson 
Sonifier 450 Ultrasonicator (www.emersonindustrial.com). AM1-stabilised emulsions were added 
drop-by-drop onto to each PEGylated DAMP4 variant (100 µM) while vigorously stirring in a 1:1 
volumetric ratio. Prepared TNEs were analyzed using dynamic light scattering and ζ-potential 
(www.malvern.com). 
For stability analysis the concentration used of each PEGylated DAMP4 variant was 10 µM. TNEs 
modified by PEG-S28C and PEG-D4C2 were diluted in 25 mM HEPES (pH 7.0) or 0.1 M EDTA in 
the same buffer at 1:1. Emulsions were labelled with 1,1′-dioctadecyl- 3,3,3 0 3 0 -
tetramethylindocarbocyanine perchlorate (DiI; www. thermofisher.com) and monitored over time to 
evaluate TNEs stability.  
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5.4 Results and discussion 
5.4.1 DAMP4 variants 
The protein biosurfactant, DAMP4 (11.1 kDa), is composed of four repeats of the helical amphiphilic 
peptide AM1 (Figure 5.1A). Each repeat is linked by a short sequence designed to break the helix and 
provide the conformational flexibility that allows the overall 4-helix bundle structure of the protein 
(Middelberg and Dimitrijev-Dwyer, 2011). In order to insert unique sites for efficient bioconjugation, 
cysteine mutations were generated by replacing serine residues within the linkers. Selecting this 
location should not affect the structure and interfacial activity of DAMP4 given the similarity between 
the substituted side chains. In addition, the C99 variant was created by adding a cysteine residue to 
the carboxy (C)-terminus of DAMP4 (Figure 5.1B). All variants were successfully expressed and 
purified (Supplementary Figure 5.1).  
5.4.2  Structure, stability and activity of cysteine mutants  
DAMP4 is an extremely stable four-helix bundle in solution (Dimitrijev Dwyer et al., 2014) and its 
helicity is preserved at high temperature (Schaller et al., 2015). However, it is possible that even 
rational modifications to the sequence might interfere with the structure or function of DAMP4. 
Therefore, to investigate the structure and stability of the cysteine variants we performed CD 
spectroscopy. At 20 °C, all single cysteine mutants showed similar CD spectra to DAMP4, 
characterised by the double absorption minima at 222 nm and 208 nm (Supplementary Figure 5.2). 
This indicates that all variants show a similar level of helicity. Thermal stability was also performed 
by CD spectroscopy for each protein at 90 °C, which showed that the variants retained the remarkable 
stability of DAMP4 (Figure 5.2A). To evaluate the impact of these changes to the primary structure 
on interfacial activity of each DAMP4 variant, we determined interfacial tension of an O/W bubble 
in the presence of the biosurfactants. Interfacial tension in the presence of DAMP4 shows an 
immediate drop, levelling off to 11.32 Nm/m consistent with the adsorption of the protein at the 
interface (Tayeb et al., 2017). The variants all resulted in a similar surface tension drop indicating 
that all DAMP4 variants possess similar interfacial activity at the oil-water interface (Figure 5.2B). 
This is expected as the interfacial activity of DAMP4 is governed by the designed helical structuring 
present in both the four-helix bundle in bulk and of the repeated helices of the unfolded protein at the 
interface (Middelberg and Dimitrijev-Dwyer, 2011, Dwyer et al., 2013). This shows that the genetic 
modification/substitution with cysteine residues at rationally chosen positions does not have an effect 
on the overall interfacial activity at the oil-water interface. Preserving the interfacial activity for 
DAMP4 variants allows their further use in the stabilisation and functionalisation of TNEs.  
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Figure 5.1. Sequence design for DAMP4 cysteine variants. End (A) and side (B) views 
of a molecular model of the four-helix bundle DAMP4 protein with mutated serine 
residues indicated. (C) The sequence variation between single cysteine mutants 
developed in this study. Dots represent conserved residues. 
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Figure 5.2. Thermal stability and interfacial activity of DAMP4 single cysteine variants. (A) 
CD spectra of DAMP4 variants at 90 °C. (B) Interfacial tension analysis of DAMP4 variants. 
138 
 
5.4.3 Functional bioconjugation to DAMP4 variants 
The single cysteine mutants were genetically engineered through the substitution/addition of cysteine 
residues to obtain site-specific bioconjugation.  In previous work we showed that the density and 
mass of PEG molecules presented on the surface of nanoscale emulsions was central to the properties 
of the interface and accessibility of co-presented functional moieties (Tayeb et al., 2017). Here we 
PEGylated each DAMP4 variant using maleimide-functionalised methoxy PEG (5 kDa). The 
efficiency of the PEGylation reaction was evaluated using SDS-PAGE and showed successful 
PEGylation at a yield approaching 100% (Supplementary Figure 5.3). The precise and efficient 
modification of DAMP4-derived biosurfactants with maleimide-thiol chemistry is a significant 
improvement on the variable amine labelling previously employed. Such defined conjugates will 
enable controlled evaluation of the structure and function of DAMP4-modified interfaces. 
DAMP4 facilitates the presentation of a wide range of biomolecules via the spontaneous integration 
onto an AM1-stabilised interface (Figure 5.3A). To test the interfacial activity of PEG conjugates of 
the DAMP4 variants, we assessed their ability to impart colloidal stability on AM1-stabilised 
emulsions. The positive surface charge of individual droplets results in a net repulsion effect that 
prevents coalescence on the timescale of days. However, dilution of the peptide-stabilised emulsion 
into a high salt solution negates the positive charge leading to rapid coalescence in the absence of a 
stabilising modification. The adsorption of PEGylated DAMP4 onto the TNE interface was thus 
confirmed by comparing them to the AM1 stabilised emulsion in PBS. While AM1-emulsions rapidly 
coalesce, TNEs stabilised with PEGylated DAMP4 mutants remain stable (Supplementary Table 5.1). 
PEGylated DAMP4 variants were used at a final surface density of 14 pmol/cm2, which is well below 
the capacity for DAMP4 integration (Tayeb et al., 2017). The presentation of each PEGylated 
DAMP4 variant resulted in a slight increase in the droplet size when compared to AM1-emulsions 
(Figure 5.3B) attributed to an increased hydrodynamic diameter of TNEs with PEG presented into 
the aqueous phase (Tayeb et al., 2017). Furthermore, PEG presentation decreased the ζ-potential of 
TNEs following the integration of each PEGylated DAMP4 variant (Figure 5.3B) due to the effect of 
PEG shielding surface charge. Interestingly, the drop in ζ-potential was variable even though each 
protein carries a single PEG. This suggests that the orientation and/or conformation of the PEG is 
affected by its position, probably due to the orientation of the cysteine insertions within the DAMP4 
sequence. For example, brush-like or mushroom-like orientation of PEG can affect the electrophoretic 
mobility of NPs (Jokerst et al., 2011). Future studies involving PEG orientation and architecture when 
presented on TNE interfaces are required and are enabled by the specifically modifiable 
biosurfactants reported herein.     
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Figure 5.3. Functionalisation of TNEs by PEGylated DAMP4 variants. (A) Schematic 
representation of the spontaneous integration of DAMP4 onto the surface of an AM1-
stabilised Miglyol emulsion. (B) DLS and ζ-potential measurements of the TNEs modified 
with PEGylated DAMP4 cysteine mutants. TNEs size and ζ-potential measurements are 
presented as black circles and grey squares respectively and values represent the average of 
three independent assembly steps. 
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5.4.4 Stability, interfacial activity and bioconjugation to a double cysteine variant 
Devising an emulsion platform with controlled variability in PEG density gives maximum flexibility 
in interface design and will lead to greater understanding of the interactions between soft matter 
interfaces and the surrounding environment. Therefore we designed a DAMP4 variant that combines 
two of the cysteine insertions to enable the comparison of TNE formulations with varied PEG 
densities. Combining the S28C and S76C mutations created D4C2, with cysteines positioned at one 
end of the four-helix bundle (Figure 5.1A). We also cloned a variant that combined the S28C and 
S52C mutations (at opposing ends of the four-helix bundle), but did not pursue this variant due to 
low level expression and a strong propensity to aggregate, even in the presence of high concentrations 
of reducing agents. 
D4C2 is also predominantly helical although it was shown to have less pronounced 222 nm and 208 
nm CD spectroscopy minima compared to DAMP4 (Figure 5.4A). Nevertheless, the helicity is 
preserved at 90 °C indicating that the double variant maintains high thermal Stability. Despite the 
small difference in the helical structure of D4C2, the interfacial activity at the oil-water interface is 
similar to the constituent single mutants and DAMP4 (Figure 5.4B). It is possible that the interaction 
of hydrophobic side chains aligned on one side of the four helices with the oil phase imposes a 
constraint on helical conformation, reinforcing the same structural feature that imparts interfacial 
activity. In any case, the IFT results of D4C2 shows that the slight changes in the level of helicity did 
not interfere with its spontaneous integration onto an oil-water interface, which also suggests that it 
could also be used to modify an AM1-stabilised emulsion. SDS-PAGE separation of PEGylation 
reactions showed that bioconjugation via maleimide-thiol chemistry also efficiently reacts with the 
thiols of both inserted cysteines of D4C2 (Figure 5.5A). We have previously shown by mass 
spectrometry that the additional molecular weight of the conjugates conferred by PEG appears to be 
2-fold higher than expected on a PAGE gel (Tayeb et al., 2017). Thus, the single and double cysteine 
mutants are conjugated to 1 and 2 PEGs, respectively. We investigated the size and charge of TNEs 
stabilised with PEGylated D4C2, S28C and S76C to evaluate the influence of different PEG densities 
on the interface. Again, the adsorption of each PEGylated variant of S28C, S76C and D4C2 was 
confirmed by TNE stability in PBS, which showed that while PEGylated D4C2 was able to stabilise 
TNEs there was a slight increase in hydrodynamic radius (Supplementary Table 5.2). This was 
mirrored in the size variability among replicate emulsions stabilised by this conjugate (Figure 5.5B). 
Despite the two-fold increase in PEG at the interface, there are no significant surface charge 
differences between the TNEs formulated with the single and double PEGylated DAMP4 variants 
(Figure 5.5B). Together this suggested that interfacial activity of DAMP4 variant could be 
differentially altered by PEGylation.  
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Figure 5.4. Thermal stability and interfacial activity of D4C2, a double cysteine variant of 
DAMP4. (A) CD spectra of DAMP4 and D4C2 recorded at both 20 °C and 90 °C. (B) 
Interfacial tension analysis of D4C2 and variants possessing its constituent single mutations 
compared to DAMP4. 
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Figure 5.5. PEGylation and TNE functionalisation by D4C2. (A) SDS-PAGE analysis of 
PEGylated D4C2 and its constituent single mutations. (B) DLS and ζ-potential of TNEs 
formulated with these variants. 
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5.4.5 Interfacial activity is affected by both the mass and number of conjugates 
Conjugation of the relatively large PEG molecules to DAMP4 is expected to have a significant impact 
on the kinetic mass transfer and, therefore, adsorption rate of DAMP4. However, how the mass and 
position of the conjugate impacts steady-state interfacial activity is unknown and highly relevant to 
the design and deployment of tailored interfaces. Comparing the single (S28C) and double (D4C2) 
cysteine variants with either 5 kDa (5K) or 10 kDa (10K) conjugated PEG, revealed that not only 
does the mass of the conjugate impact interfacial activity, so too does the number of conjugates 
(Figure 5.6). While S28C-5K-PEG reduces IFT from the 31 mN/m of a pristine oil droplet to 15.8 
mN/m, S28C-10K-PEG only reduces IFT to 17.2 mN/m. In comparison, the unconjugated protein 
reduces IFT to 11.1 mN/m. PEGylated D4C2 reduced IFT to 19.3 and 21.9 mN/m when conjugated 
to 5K and 10K PEG, respectively. This additional insight enables us to refine our previous 
interpretation using heterogeneous conjugate mixtures (Tayeb et al., 2017), here we show that the 
mass of the conjugate has a considerable impact on IFT in addition to the number of conjugates. The 
efficient, site-specific bioconjugation now achievable allows us to compare the D4C2-5K PEG (19.3 
mN/m) with S28C-10K-PEG (17.2 mN/m), which possess the same theoretical mass of polymer and 
show that the number of PEGs has a considerable impact on IFT. These results highlight the utility 
of the DAMP4 variants and their precise conjugation in enabling the fundamental study of 
biosurfactants and their interfacial properties. To rule out an effect of PEG on the unfolding of 
DAMP4, which is necessary for its adsorption onto the interface, we subjected the PEGylated variants 
to differential scanning calorimetry.  
The transition temperature of both S28C and D4C2 were found to be unaffected by the conjugated 
PEG (Supplementary Figure 5.4), indicating that the polymer has negligible impact on the stability 
of the proteins and, therefore, its capacity to unfold at the interface. Furthermore, although we have 
not enumerated the initial rate of the reduction in IFT, the drop is similar for D4C2-5K PEG and 
S28C-10K-PEG, indicating that as with protein unfolding, transit to the interface is dependent on 
mass and is not affected by the number of conjugates. To examine the functional impact of the 
interference with interfacial activity due to PEG conjugation, we assembled TNEs with a low (1.4 
pmol/cm2) density of PEG-DAMP4. Incubation with 0.1 M EDTA disrupts the cohesive interfacial 
peptide film by chelating the Zn2+ that acts to cross-link histidine-bearing AM1 peptides, resulting in 
susceptibility to coalescence (Tayeb et al., 2017, Malcolm et al., 2009). Using a low density of PEG-
DAMP4 variant ensures that TNEs will coalesce within a reasonable timeframe. TNEs decorated with 
PEGylated S28C remained stable at least for 1 hour (Figure 5.7).  
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Figure 5.6. Interfacial activity of double and single PEGylated DAMP4. Analysis was performed 
on D4C2 and the single cysteine variant S28C conjugated to 5K and 10K PEG compared to 
DAMP4. 
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In contrast, and despite the two-fold increase in PEG density, phase separation of the PEGylated 
D4C2 stabilised TNEs was detectable at approximately 2 minutes, similar to the undecorated AM1 
emulsion (Figure 5.7). Thus, the differences in the interfacial activity of PEGylated S28C and D4C2 
result in a functional impact on their ability to stably decorate TNEs. As the conjugate does not appear 
to affect the unfolding of DAMP4, these results suggest rather that the PEG conjugate can affect the 
conformation of DAMP4 at the interface. This has implications on the effect of conjugates on the 
function of surfactants and, more broadly, the impact that PEGylation potentially has on 
pharmaceutical protein activity. It could be expected that a greater mass of PEG attached to a single 
conjugate could compensate for the reduced activity of the double conjugate, however, TNEs 
modified by S28C-10K-PEG are similarly unstable (data not shown). This leads us to an alternative 
explanation; that the increase in PEG density presents a steric constraint on the permissible density 
of DAMP4 at the interface, effectively preventing adsorption. Although we have previously found 
evidence to suggest the presence of PEG directly at the interface (Tayeb et al., 2017), the low density 
of DAMP4 used here means that this is unlikely to explain the reduced stabilisation of TNEs by 
preventing PEG-DAMP4 adsorption. Nor can we rule out the possibility that electrostatic interactions 
between the AM1 interface and DAMP4 are important for the integration of DAMP4 and that such 
interactions could be masked by the increased mass of PEG, thereby reducing the adsorption of the 
more highly PEGylated variant. 
  
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.7. Stability of TNEs modified with PEGylated DAMP4 variants in the presence of 
EDTA. AM1 emulsions labelled with DiI, and those subsequently modified with PEG-S28C and 
PEG-D4C2 were diluted 1:1 in 25 mM HEPES (pH 7.0) as a control (C) or the same buffer with a 
final EDTA concentration of 50 mM, and monitored for stability over time. 
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5.5 Conclusion 
Controlling the interfacial properties of nanomaterials is essential for understanding their interactions 
with the surrounding environment. Here we used a bioengineering approach to obtain biosurfactants 
amenable to site-specific bioconjugation. Rational design of cysteine mutants of the designer protein 
surfactant, DAMP4, yielded variants with preserved structure, stability and interfacial activity that 
could be specifically PEGylated with almost 100% yield. The biologically produced DAMP4 has 
potential as a renewable surfactant in industrial processes and as a co-surfactant useful in the top-
down functionalisation of sophisticated interfaces for high-end applications. The present work 
demonstrates that the primary sequence can be tailored for specific applications requiring chemical 
modification and will, for example, allow more precise functionalisation of TNEs than was previously 
possible. Furthermore, controlled modification of these versatile biosurfactants will provide tools to 
investigate the fundamental relationship between structure and function of polypeptides at an 
interface. As an example, we showed that the number of conjugates as well as the mass of a 
conjugated polymer, PEG, influences interfacial activity, likely via perturbation of secondary 
structure of the biosurfactant at the interface. We expect that the outcomes of this study will provide 
the tools to further explore the design of functional interfaces and increase understanding of the 
relationship between the genetic and chemical modification of polypeptides and their function.  
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5.7 Supplementary materials  
 
 
SDS-PAGE analysis of the expression and purification of DAMP4 single cysteine variants. L = 
soluble fraction of cell lysate, P = purified DAMP4 variant. 
 
 
 
 
 
  
Supplementary Figure 5.1 
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Structural characterisation of DAMP4 single cysteine variants. CD spectra of DAMP4 variants at 20 
°C. 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 5.2 
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SDS-PAGE analysis of the PEGylation of DAMP4 single cysteine variants. Each cysteine mutant is 
shown before and after incubation with and without maleimide-PEG. 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 5.3 
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Supplementary Table  5.1. Stability of TNEs formulated with the PEGylated single cysteine variants 
following dilution in PBS. 
 
 
 
 
 
  
TNEs (P50) Size (d.nm) 
AM1 1370.2 ± 1.6 
S4C 168.3 ± 4.4 
S28C 169.5 ± 4.2 
S52C 165.4 ± 0.1 
S76C 166.3 ± 2.6 
C99 170.4 ± 2.0 
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Supplementary Table  5.2. Stability of TNEs formulated with the PEGylated single and double 
cysteine variants following dilution in PBS. 
 
 
  TNEs (P50) Size (d.nm) 
AM1 1299.3 ± 85.4 
S28C 163.7 ± 1.1 
S76C 165.6 ± 1.8 
D4C2 172.5 ± 2.7 
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Differential scanning calorimetry of PEGylated DAMP4 variants. The single cysteine variant 
(S28C) and double cysteine variant (D4C2) were analysed with and without PEGylation. 
 
 
 
 
 
 
 
  
Supplementary Figure 5.4 
155 
 
6 Chapter 6: Conclusion and Future Directions 
Nanoparticle-mediated drug delivery involves the development of nanosized materials loaded with 
pharmaceutical compounds for specific therapeutic and diagnostic applications. Although 
nanomaterials are considered promising, they must overcome a series of complex physical and 
biological barriers encountered through different routes of administration. These barriers lead to 
instability during circulation, non-specific biodistribution, and cytotoxicity to healthy cells (Xin et 
al., 2017).  
Recent studies involving mice report that less than 1% of injected NPs reach their target site (Wilhelm 
et al., 2016) clearly showing how active targeting of NPs is still unrealistic in living organisms. 
Therefore, a deeper understanding of the biophysical properties of a particular NP design, including 
the size, surface charge, and presentation of functional moieties, is required. The biological 
complexity encountered in delivery routes and the type and stage of disease are other aspects that 
must be considered in the design of NPs to enhance the effectiveness of nanomaterials in drug 
delivery. Exploring the potential of a particular drug delivery design through different applications 
or routes of administration can help reveal possible limitations. By addressing these limitations, the 
clinical translation of nanomaterials can be more realistic. 
Despite all the challenges facing nanomaterials in drug delivery, there are few nanomaterials that 
have gained approval for clinical use against diseases such as cancer. For example, the liposomal 
formulation, Doxil®, was approved by the FDA for the treatment of Kaposi’s sarcoma (Barenholz, 
2012b). Lipid-based nanomaterials, including liposomes (Bulbake et al., 2017) and NEs (Singh et al., 
2017), are considered promising vehicles for hydrophobic drugs. Emulsions offer a broad range of 
advantages including high solubilisation and loading capabilities, biocompatibility and ease of 
production, and have been applied with safe profiles in cosmetic, nutritional (Intralipid®) and 
pharmaceutical applications (Liple®).     
The aim of my research project was to refine the use of TNEs toward pharmaceutical applications. 
TNEs were invented recently by the Middelberg group at the AIBN and have shown promising results 
in the targeted, subcutaneous delivery of antigens (Zeng et al., 2013). TNEs are easily formulated by 
the assembly of protein-based surfactants at the oil-water interface in a bottom-up fashion via the top-
down sequential addition of reagents. The TNE core is made from a pharmaceutical-grade oil 
(Miglyol 812) that is generally recognised as safe (GRAS) and approved by the FDA.  
In this project, the properties of TNEs were investigated as well as their administration through topical 
(skin) and IV routes. Specifically, PEGylation was used to alter the surface design of the TNEs and 
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determine the effect of PEG density on the interfacial properties furthering the refining of TNEs for 
drug delivery. PEGylation is a common technique that improves the stability and pharmacodynamics 
of drugs and is one of the most important aspects in drug delivery research. Controlling the surface 
charge of TNEs via PEG density enabled the successful coating of EMPs through electrostatic 
interactions. The combined system showed promising results as a carrier of hydrophobic drugs for 
human skin applications. IV administration of TNEs was also explored showing an acceptable safety 
profile, however circulation time was short and showed that the TNEs were mostly cleared via the 
renal route.   
The research outcomes from my PhD project were divided into three chapters. The aim of the first 
experimental chapter (Chapter 3) was to broadly explore the use of TNEs as a vehicle of hydrophobic 
drugs for topical and IV administration. Exploring the use of TNEs via the IV route provided the basis 
of the second experimental chapter (Chapter 4) that delivered insights into the interfacial structure-
function of poly(ethylene glycol)-decorated peptide-stabilised nanoscale emulsions. With a deeper 
understanding of the TNE interface provided by Chapter 4, the final experimental chapter (Chapter 
5) aimed at gaining better control over the TNE interface through genetic engineering of DAMP4 for 
precise bioconjugation whilst maintaining interfacial activities. A summary of the key findings from 
each chapter will be discussed in the following sections.  
6.1 Exploring the suitability of TNEs in diagnostic and therapeutic applications by 
employing different routes of administration. 
Nanomaterials are being continuously developed into drug delivery systems with various surface 
designs to improve the therapeutic efficacy of lipophilic drugs. However, there are still no specific 
guidelines that help facilitate the fabrication of NP designs capable of overcoming most drug delivery 
challenges. These challenges include the biological barriers encountered within each route of 
administration, as well as the complexity of NPs designs. Subsequently, the feasibility of TNEs in 
diagnostic and therapeutic applications was considered through both topical and IV delivery routes. 
Firstly, by varying the PEG-DAMP4 density on the TNE interface, the surface properties of TNEs 
could be explored revealing that surface charge was inversely proportional to the integrated PEG 
density on the TNE interface. 
To investigate the capacity of cargo retention, a hydrophobic dye was encapsulated within the oil 
phase of TNEs showing that over time the amount of retained dye was directly related to the DAMP4-
PEG density. A leakage profile of the encapsulated cargo also revealed that PEG density was directly 
related to the stability of DiI-labelled TNE droplets over time. By tuning the surface charge, TNEs 
were combined with EMPs via electrostatic interactions and showed promising human skin 
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applications. The coating efficiency of EMPs with TNEs was investigated through different methods 
with results suggesting that freeze drying of DiI-loaded P20-TNEs (positively-charged) droplets onto 
powdered EMPs (negatively-charged), in the presence of alginate as a cross-linker, gave better 
coating results. Having control over the surface charge by simply varying PEG densities is attributed 
to the remarkable and inherent spontaneous integration capability of DAMP4 at the interface of AM1-
pre-stabilised TNEs. These results suggest that TNEs have great potential in topical (skin) drug 
delivery applications. 
The delivery of hydrophobic drugs using active targeting via the IV route is a major obstacle for 
nanomaterials. TNEs were successfully functionalised with DAMP4-scFv fusion for targeting EGFR 
on cancer cells. The fusion complex alone had high binding specificity to EGFR (which was validated 
through ELISA). DAMP4-scFv fusion was also successfully presented on the TNE interface, 
resulting in a VECT-1 formulation that showed high binding specificity to EGFR-coated wells in a 
fluorescence-based plate assay. Binding to EGFR using VECT-1 formulations was also demonstrated 
in vitro using the breast cancer cell line, MDA-MB-468. However to some extent, non-specific 
binding was observed and may have been due to increased targeting complexity going from proteins 
bound to a plate, to surface proteins in a more diverse cellular environment. 
The potential of administering targeted TNE (VECT-1) formulations through the IV route was 
explored using an in vivo pilot study. This study showed that TNEs were mainly execrated via the 
renal route suggesting that TNEs only have a short circulation time that was insufficient to achieve 
active targeting. The rapid clearance of TNEs was then explored in more detail using a biodistribution 
study that involved serum, urine, and cytokines analyses. These analyses suggested that TNEs 
remained in circulation for at least two hours with renal excretion starting one-hour post-IV injection. 
TNEs were also detected in the liver two hours post-injection but at very low levels implying that the 
hepatic path was not the main clearance pathway. The very low cytokine levels, as well as their 
biocompatible design, suggested that TNEs did not cause adverse reactions and showed a safe profile 
during IV administration. However, given the instability of TNEs during circulation that might have 
been due to opsonisation or phagocytosis, it’s obvious that a deeper understanding of the TNE 
interface is required for optimising the surface design for drug delivery.  
6.2 Insight into the interfacial structure-function of the polyethylene glycol-decorated 
peptide-stabilised nanocarrier emulsions 
Interfacial properties of nanocarriers directly influence the biodistribution, stability and efficiency of 
nanomaterials in drug delivery. Chapter 4 aimed to understand the interfacial structure of TNEs and 
gain insights into the molecular interfacial assembly of a poly ethylene-decorated protein 
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biosurfactant (DAMP4). The surface modification of TNEs was facilitated by the remarkable 
spontaneous integration feature of DAMP4 onto the pre-adsorbed AM1 oil-water interface. Genetic 
fusion or chemical modification of DAMP4 with functional molecules facilitates their presentation 
on the aqueous phase of TNEs. TNEs formulated in a sequential step-wise fashion have tuneable 
surface properties that offer great potential to gain control over the oil-water interface. DAMP4 
PEGylation using different PEG lengths was characterised in detail and the sequential addition of 
functionalised DAMP4 molecules at the oil-water interface was confirmed. The influence of varying 
PEG density and length on TNE size, surface charge, and interfacial properties was evaluated by 
determining the accessibility of co-displayed targeting molecules.        
For multifunctional nanomaterials, the complexity of the surrounding environment is compounded 
by the impact of functional molecules on one another, defining a competition-trade off window in 
molecular design space. As a unique model system, TNEs allow controlled assembly and were used 
to probe the structure-function relationship of the interface designed with the competing effects of 
two functional biomolecules: PEG and a targeting ligand. In this research, the building units of TNEs 
were analysed in detail along with verification of the assembly mechanism and determination of the 
molecular characteristics of the TNE aqueous phase. Regardless of the predicted differences in 
interfacial thicknesses with respect to the PEG layer, that were demonstrated using x-ray 
reflectometry, the solid state binding assay indicated that the targeting moieties presented on TNEs 
surfaces were equally accessible to their receptors. In contrast, the difference in PEG layer proved to 
have an essential role in minimising non-specific targeting. These findings validated the concept of 
designing multifunctional TNE interfaces. The next chapter continued to explore TNE assembly and 
presentation capacity of biomolecules at the interface. The use of a homogeneous population of 
DAMP4 conjugates should give better control over interfacial properties. Controlled functionalisation 
of the TNE interfaces using the protein biosurfactant, DAMP4, is discussed in the next section. 
6.3  Site-specific bioconjugation with poly(ethylene glycol): impact on the interfacial activity 
of a protein biosurfactant   
Controlling the interfacial properties of nanomaterials is vital for understanding their interactions 
with surrounding environments. Biosurfactants are amphiphilic surface active molecules that can be 
synthesised using industrially scalable, renewable biological processes. Biosurfactants also offer 
several advantages including biocompatibility, biodegradability, and sustainability. A novel designer 
protein biosurfactant, DAMP4, allows surface modifications through genetic engineering or chemical 
conjugation to functional molecules. However, inconsistent and unpredictable chemical conjugation 
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results in heterogeneous products that restrict precise functionalisation and the resolution of physio-
chemical characterisation of interfaces. 
In this research, we successfully bioengineered DAMP4 variants with single/double cysteine point 
mutations to obtain biosurfactants capable of site-specific bioconjugation. Rational point mutations 
of the designer protein surfactant, DAMP4, with cysteine residues produced variants with conserved 
structure and stability, and surface activity that can specifically conjugate to PEG with nearly 100% 
yield. Bio-synthesised DAMP4 holds great potential as a renewable biosurfactant in industrial 
applications, and as a valuable co-surfactant in the top-down modifications of interfaces for 
sophisticated applications. This work demonstrated that the primary sequence of DAMP4 could be 
tailored toward specific applications that require chemical modifications. For example, it allowed 
precise functionalisation of the TNE interface.  
Controlled functionalisation of DAMP4 provided means to study the fundamentals of the structure-
function relationship of polypeptides at the interface. For example, the number, as well as the mass 
of PEG conjugates, were found to influence the interfacial activity of the biosurfactant probably 
because the secondary structure at the interface was perturbed. Therefore, the capability of DAMP4 
variants with multiple PEG conjugates to impart colloidal stability on peptide-stabilised emulsions 
decreased. This observation was made based on the possible constraints on the amphiphilic helices 
of DAMP4 at the interface that resulted from the attachment of multiple PEG conjugates. 
Specific and efficient chemical modifications enable investigation of the interfacial properties of 
designer protein biosurfactants with molecular precision. The outcomes of this work are expected to 
contribute to further exploring the design of functional interfaces, and help understand more about 
the relationship between the genetic and chemical modifications of protein biosurfactants and their 
function. This research may help to inform the design and modification of biosurfactants for 
increasing their applications in industrial processes, and nutritional and pharmaceutical formulations. 
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6.4 Future directions 
It is well known that the administration of APIs via different routes has various effects on therapeutic 
efficacy. Administered API can be affected by the harsh conditions encountered within biological 
systems including enzymatic secretions and pH changes. To help overcome the challenges of 
administered API, in particular hydrophobic compounds, nanomaterials like polymer-based NPs 
(Chan et al., 2010, Crucho and Barros, 2017), inorganic materials-based platforms (Giner-Casares et 
al., 2016, Ojea-Jimenez et al., 2013), and lipid-based NPs (Qi et al., 2017) have emerged as delivery 
vehicles to improve therapeutic outcomes.  
These vehicles have improved the overall pharmacokinetics of drugs such as water-solubility and 
extended circulation times. However, these improvements, that fall under the umbrella of patient 
safety and lower morbidity rate, and have led to the successful clinical translation of nanomaterials 
like Doxil®, are still considered minimal. The main reason being that once nanomaterials are 
administered through different routes, they face complex environments involving various physical 
and biological barriers that limit their therapeutic efficacy. This evidence therefore suggests that the 
“magic bullet” hype surrounding nanomaterials remains unrealistic to date and that far more 
knowledge of the fundamentals of nanomaterial interfaces and how they relate to specific biological 
applications is still required. 
Tailoring the surface properties of drug carriers is an important aspect of drug delivery and helps to 
contribute fundamental knowledge of the interface and possible solutions for overcoming the 
complexity of biological systems. One of the main obstacles that limits the study of, and precise 
control over, the surface design of nanomaterials is ensuring physical stability that limits the ability 
to functionalise surfaces with biomolecules. TNEs are O/W peptide-stabilised emulsions that are 
easily formulated, biodegradable and allow the decoupling of physical stability imparted during 
emulsification from subsequent functionalisation (Sainsbury et al., 2014). 
AM1, a surface active peptide with rapid adsorption rate, is used to stabilise O/W droplets during 
emulsification (Dexter et al., 2006). AM1 also provides mechanical stability at the oil-water interface 
in the presence of metal ions via histidine residues (Malcolm et al., 2009). DAMP4, a protein 
biosurfactant, is made of four repeats of AM1 joined by linkers that permit folding in solution. 
DAMP4 spontaneously unfolds and integrates at the pre-adsorbed AM1 oil-water interface, allowing 
surface functionalisation via either genetic fusion or chemical conjugation. These remarkable features 
of the surface-active designer molecules (AM1 and DAMP4) provide TNEs with amenability to step-
wise surface modification, independent of droplet formation.   
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Decoupling the biological functionalisation of TNEs from the emulsification process enabled PEG 
density to be varied at the TNE interface. This allowed the surface properties of TNEs to be 
controlled, which directly affected the stability of DiI-labelled TNEs and, concomitantly, cargo 
retention within the oil core. Other factors that may influence cargo retention include the solubility 
level of drugs within the oil phase. Controlling the surface properties of TNEs played an important 
role in coating EMPs with TNEs via electrostatic interactions. The TNE-coated EMPs that 
encapsulated a clinically relevant imaging agent, were explored in human skin applications. Future 
research could be aimed at investigating therapeutic applications of TNE-coated EMPs. For example, 
encapsulating therapeutic agents such as antifungal drugs targeted to specific skin layers for the 
treatment of fungal infections.     
TNEs were successfully directed toward in vitro active targeting using the scFv-DAMP4 fusion that 
was synthesised by genetic engineering, however the accessibility of the scFv-DAMP4 fusion was 
affected by the display of PEG. Therefore, future studies are needed to investigate the accessibility 
of presented functional moieties on the TNE interface. The precise and site-specific bioconjugation 
of PEG to DAMP4 variants, such as S28C, allows greater control of bioconjugation to the protein 
biosurfactant. This should enable characterisation of the accessibility of functional moieties displayed 
at the TNE oil-water interface with greater precision. Improved accessibility might be achieved in the 
future through one of the following proposals: 
1- Chemical modifications of the biosurfactant: the presentation of functional moieties using 
bifunctional PEG molecules where the targeting molecule is conjugated to the opposite end 
of PEG (e.g. via an NHS ester), and displayed on the TNE interface using a DAMP4 cysteine 
variant that can be conjugated to PEG using maleimide chemistry (Figure 6.1A). 
a. Advantages: 
i. It should eliminate the masking of functional molecules by the PEG, leading 
to better accessibility. 
b. Disadvantages: 
i. The need for extra purification steps to remove unconjugated bi-functional 
PEG molecules from DAMP4. 
ii. The interfacial activity of the biosurfactant might be affected.   
2- Optimising the genetic fusion of the scFv to DAMP4 variants by increasing the linker length. 
The previously synthesised scFv-DAMP4 fusion has a single G4S linker and it may help to 
extend this with more copies (Figure 6.1B).  
a. Advantages: 
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i. Increasing the linker length might lead to better accessibility of the presented 
functional moiety by reducing the interference of presented PEG on the 
interface.   
b. Disadvantages: 
i. Folding and stability of the protein fusion might be affected. 
ii. Changing the linker length might introduce challenges for the production of 
the fusion protein within mammalian cells.  
iii. The additional flexibility may prove to be a disadvantage during sequential 
addition if it allows interaction of the targeting moiety with the interface. 
3- Studying the interfacial properties of TNEs with shorter PEG length. Previously applied PEG 
masses on TNEs were 5 kDa and 10 kDa, whereas 2 kDa or 3.4 kDa PEG may be sufficient 
to impart stability (Figure 6.1C).  
a. Advantages:  
i. Less interference with other presented functional molecules. 
ii. Possibly better interfacial activity when compared to DAMP4 variants 
conjugated to PEG with larger mass.   
b. Disadvantages: 
i. Possible increase in non-specific interactions with the surrounding 
environment due to changes in the surface properties, such as surface charge.  
ii. Shorter PEG lengths might not impart sufficient colloidal stability to prevent 
coalescence or aggregation.  
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Figure 6.1. Accessibility of functional moieties displayed at the TNE interface. (A) 
Presentation of functional moiety with bifunctional PEG. (B) Illustrates the display of the 
functional moiety (scFv) genetically fused to DAMP4 by increasing the linker length. (C) 
Presentation of functional moieties fused to DAMP4 at the interface of TNEs functionalised 
with shorter PEG length. 
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The combined outcomes from this research show that TNEs have great potential in topical 
formulations for human skin applications. TNEs are also considered safe IV formulations for further 
biodistribution studies. Specific and non-specific TNE interactions are directly affected by their 
surface decoration. Site-specific bioconjugation of a biocompatible, renewable, and industrially-
scalable protein biosurfactant, DAMP4, was obtained and permitted the investigation and tailoring of 
the TNE interface for specific applications with precision. The remarkable characteristics of these 
designer protein surfactants make TNE interfaces amenable to a wide range of genetic or chemical 
modifications ensuring that TNEs have a promising future in drug delivery. Based on the combined 
outcomes of my PhD project, further physiochemical and biophysical studies would contribute to 
better understanding of the TNE system and, potential of biosurfactants.  
Physical chemistry, employs techniques to study and monitor the behaviour of a particular matter on 
a molecular and atomic level. Therefore, to reach this level of detail a precise understanding of a 
particular material or system is required. The Controlled site-specific bioconjugation of DAMP4 
variants should facilitate precise fundamental interface studies. These include X-ray reflectometry to 
study interfacial thickness, which may help to elucidate the interaction of TNE surface design with 
the surrounding environment. Also, neutron reflectometry can be applied to determine the precise 
composition at the interface, the density of DAMP4 integration and whether DAMP4 integration 
results in AM1 displacement. Quartz crystal microbalance (QCM) can be used to monitor mass 
changes at the interface, which can provide insights into the molecular assembly of surfactants at air-
fluid or fluid-fluid interfaces. These studies are currently ongoing in collaboration with colleagues at 
ANSTO and Monash University. 
Harnessing the metal-binding properties of surface designer surfactants is another important property 
for the formulation of NEs with PET/MRI imaging agents. Based on the formation of a cohesive 
interfacial network via the coordination of metal ions, the possibility of incorporating additional 
functionality using the radioisotope, Cu64, was investigated (data not shown). Perfluorocarbon 
emulsions are commonly applied as MRI agents but do not easily permit further surface modifications 
in a controlled way. Comparatively, TNEs enable spontaneous integration of a wide range of 
biomolecules in a step-wise fashion via DAMP4, that allows further surface modifications with 
functional moieties, such as PEG, to improve formulation stability and performance within a living 
organism. AM1 stabilises O/W droplets during emulsification and enables the incorporation of 
positron emitting isotopes (Cu64) at the interface via the metal-binding residues (histidine). 
Employing the oil core of AM1-stabilised TNEs by incorporating MRI agents (perfluorocarbons), 
can potentially direct TNEs toward promising bimodal imaging applications. The idea of this work 
was aimed at paving the way for further applications of TNEs as bimodal imaging agents administered 
165 
 
through different routes. This research was conducted in collaboration with the research group of 
Professor Andrew Whittaker at the AIBN and the Centre of Advanced Imaging (CAI).      
The potential of TNEs in both localised and systemic delivery can be explored by investigating 
alternative administration routes in the future. The local administration of hydrophobic drugs using 
emulsions offers strategies that can help avoiding biological and physical barriers by modulating their 
surface properties. For example, tailoring surface charge can permit penetration of biological 
membranes via electrostatic interactions in ocular or topical applications. The administration of 
nanomaterials via alternative routes for systemic delivery also offers various advantages including 
self-administration, being non-invasive (Sun et al., 2017), exploitation of high absorption surface 
areas such as the lung, and avoidance of first path-metabolism and enzymatic degradation (Mathias 
and Sridharan, 2017).   
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6.5 Concluding remarks 
NEs have a safe history in food, cosmetic, and pharmaceutical applications.  However, NE surface 
functionalisation is limited by the stabilisation process that takes place during emulsification. In this 
project, the use of novel TNEs was explored in both topical and IV delivery routes that allowed 
decoupling of physical stabilisation and functionalisation. TNEs showed promise as a platform for 
carrying hydrophobic drugs combined with the EMPs, that helped to overcome the physical barrier 
of skin. In contrast, the IV delivery of TNEs resulted in a short circulation time but an acceptable 
safety profile. These findings highlight the need for further research into the interfacial properties of 
TNEs to better understand molecular assembly. The spontaneous integration of DAMP4, that can be 
easily functionalised via genetic engineering or chemical modifications, at the interface enabled PEG 
in different masses and densities to coat the interface. These experiments revealed important 
information about the assembly and stability of TNEs, as well as the accessibility of targeting 
moieties. 
Variants of DAMP4 were genetically engineered using rational design that allowed site-specific 
bioconjugation of a wide range of molecules with almost 100% yield of DAMP4-PEG products. This 
allowed a controlled number of biomolecules to be displayed on the TNE interface and showed how 
the interfacial activities of biosurfactants can be affected by the number and mass of their conjugates. 
Further investigations into how interfacial properties of TNEs relate to the different biological 
environments encountered in various routes of administration, are required to advance the use of 
TNEs in future drug delivery systems.  
The potential of NPs in targeted drug delivery is yet to be realised, subsequently clinical translation 
of drug carrier candidates requires further research to better understand the surface design of 
nanomaterials, the physiology of different diseases, the biological complexity associated with each 
route of administration as well as the safety and biocompatibility of nanomaterials. Keeping the 
design of nanomaterial surfaces simple can improve the understanding of nanomaterial interactions 
with surrounding environments, and by addressing all of the considerations discussed above, better 
functional, affordable, safe, and biocompatible drug delivery candidates will be synthesised.  
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7 Appendix A 
Animal Ethics Approval Certificate: 
The targeting and biodistribution studies (Chapter 3) were performed in compliance with the 
Australian National Health and Medical Research Council guidelines for the care and use of 
laboratory animals, and with the approval of the EnGeneIC Animal Ethics Committee under ethics 
application number: AIBN/400/13/ARC/NHMRC (certificate attached in the following page).  
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